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QUILL ON SCALPEL This section
provides a medium through which Canadian 
surgeons can declare themselves, briefly and in­
formally, on the day-to-day affairs of surgery.
MULTIPLE TRAUMA*
Multiple trauma is a particularly com­
plex and lethal problem. The injuries may 
involve several systems with extensive 
blood loss and circulatory collapse; brain, 
heart and kidney anoxia can lead to irre­
versible changes. The patient is in mortal 
danger and his survival is strongly depen­
dent on the facilities, energy, organization 
and attitudes of the staff in the hospital to 
which he is transported.
Emergency D epartment
The problem presents itself to the sur­
geon, usually a resident, with the un­
announced arrival of an ambulance at the 
door of the Emergency Department. This 
is a place devoted to resuscitation of the 
patient, not to the reduction of his frac­
tures, not to suturing his scalp wound and 
not to determining whether he has in­
surance or wishes a private room. The de­
sign of an emergency department must 
facilitate those measures which are critical 
to resuscitation. Everything must be close 
at hand; endotracheal intubation, supply­
ing of oxygen, starting I.V.’s and splinting 
of fractures must be carried out quickly 
without having to send the nurse down 
the corridor looking for the pieces.
The detailed care of the traumatized pa­
tient need not be discussed here, but one 
point deserves comment, even though it 
has been learned and re-learned over and 
over again it tends to be forgotten. Every 
patient with significant multiple injuries is 
in shock, and a normal blood pressure 
reading does not change the situation. 
Fracture of the femoral shaft means a loss 
of one to two units of blood into the sur-
4Adapted from a paper delivered at the Royal 
Alexandra Hospital Clinic Day, Edmonton, Alta., 
March 13, 1970.
rounding tissues and several injuries may 
deprive the cardiovascular system of one- 
third of its circulating volume, without 
one drop of blood appearing on the emer­
gency room floor. The immediate treat­
ment consists of intravenous electrolyte 
solutions with cross-matched blood ad­
ministered at the earliest possible moment. 
Some patients may need as much as 10 to 
12 units and 30 units have been used on 
occasion. The late Campbell Gardner, 
when lecturing to McGill University stu­
dents about surgical shock, was known to 
conceal a bottle of outdated Red Cross 
blood under his white coat. At an auspi­
cious moment during the lecture, he 
whipped the bottle out and smashed it to 
the floor. This seemed to impress even the 
most obtuse student. Nevertheless, some­
one would inevitably ask: “How much do 
you give, sir?” His answer was brief: “All 
you’ve got.” “How fast do you give it, sir?” 
As fast as you can.” Never confused by 
scientific minutia, he made his point. The 
treatment is blood (elapsed time for his 
lecture, 10 minutes).
The patient should not leave the emer­
gency room until he has a relatively secure 
grip on life, with airway and circulation 
re-established and with a written record 
of his vital functions. We must resist the 
temptation to begin definitive therapy 
when the patient’s life is still in danger. 
There is an almost insurmountable urge to 
push the patient about, to apply casts, take 
radiographs and otherwise traumatize this 
very sick individual. Skull films in the 
head-injured patient can wait, and at any 
rate they cannot replace a careful physical 
examination and a detailed history ob­
tained from the patient or his companion. 
There must be no interference with re­
suscitation.
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Intensive C are Unit
Admission to hospital is a risky experi­
ence for the multiple traumatized patient.
A thousand hurdles stand between the 
Emergency Department and a hospital 
ward. He is moved, perhaps to a stretcher 
and then to a bed, and his I.V. is certain 
to infiltrate. A great deal of attention is 
given to the management of his valuables 
and to recording his date of birth and next- 
of-kin. He is transferred to the care of a 
new group of people who have never seen 
him before, and cannot read the hand­
writing on the chart. He arrives on a 30- 
bed ward, and is pushed into a private 
room—“out of sight, out of mind” . The in- 
service intern is called to do a history and 
physical, which must precede all else, but 
he is unfortunately incommunicado in the 
operating room and the patient, waiting 
with indifferent supervision, may slip back 
into danger.
The seriously injured emergency room 
patient must never be admitted to the hos­
pital ward. If he does not go directly to 
the operating room, he should be trans­
ferred to an Intensive Care Unit, some­
thing which every hospital should have. 
Contrary to popular opinion, it is not a 
mysterious or complicated place. It is 
simply a large room with six to 12 beds 
(privacy is not a major consideration), a 
few intelligent nurses with no special 
training, ample needles, dressings and 
other supplies, and some monitoring and 
respiratory control equipment which any 
of us can leam to use. The unit should be 
centrally located so that the patient is 
easily accessible to the many people who 
must see him. Proximity to the Anesthesia 
Department is an advantage and the most 
frequent plan is to build the Unit on the 
operating room floor. Well-run Intensive 
Care Units can be found not only in uni­
versity and large city hospitals but also in 
community and small-town hospitals, and 
here they function successfully without 
residents. One of the best I have ever seen 
is in the Belleville (Ontario) General Hos­
pital, staffed by a group of cool, calm 
nurses with an average of 3% years of ex­
perience in their Unit.
The multiple trauma patient who has 
incurred life-threatening injuries should
remain in the Intensive Care Unit until he 
is self-stabilizing, until he can maintain his 
own blood pressure, ventilate his own 
lungs, pace his own heart and perfuse his 
own brain and kidneys—in summary, until 
he can be moved to an ordinary hospital 
room and left alone for an hour or two 
without the risk of sudden collapse or 
departure.
W ho Treats the Patient?
The answer to this complex and sensitive 
problem varies from community to com­
munity, and hospital to hospital. A good 
deal of personal and departmental jealousy 
can develop, and the competition regard­
ing the treatment of injured parts some­
times becomes so strenuous that the com­
plete patient can be forgotten. The very 
nature of the multiple traumatized patient 
demands that more than one specialty and 
more than one doctor be involved, and 
they must be involved in such a way that 
their skills and knowledge complement 
one another. In small hospitals, only a 
single surgeon may be on call and he uses 
his discretion in seeking help from others. 
In large multispecialty institutions, any 
state of affairs may exist varying from a 
highly structured plan to no plan at all.
Perhaps the best way to describe the 
options is to narrate the history of my 
own institution, the Montreal General 
Hospital. For many years, multiple trauma 
was managed by what I choose to call 
“catch-as-catch-can” ; in effect, a race in 
which the first service to get to the emer­
gency room claimed the patient, and all 
other services were obliged to fidget 
around awaiting an invitation to help. This 
worked moderately well for most patients, 
but periodically the attending surgeon was 
embarrassed to discover, at some late date, 
a concealed and untreated injury related 
to another specialty.
Twelve years ago a formal Trauma 
Service was established. In this new system 
the general surgeons were charged with 
the care of chest and abdominal trauma, 
the orthopedic surgeons with fractures, 
plastic surgeons dealt with faces, hands 
and problems of skin loss, and the neuro­
surgeons with their traditional field. The 
advantages of this organization were many;
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the various specialists became aware of 
one another’s problems, co-operation was 
the keynote and a weekly Trauma Con­
ference was established and continues to 
meet, even to the present (proceedings of 
this Conference are now published in each 
issue of the Canadian M edical Association 
Journal). Teaching and research all profited 
and above all, the patient received superb 
care. The passage of time revealed two 
defects: first, the patient occasionally
seemed to reside in limbo, with all services 
consulting but no one service assuming 
prime responsibility. Second, the concept 
of the “traumatic” surgeon emerged. Dur­
ing the day, patient care was by defined 
specialties, but at night a resident on rota­
tion from one of the specialty services was 
responsible for the entire Trauma Service. 
The hope was that each of these young 
men, as a result of broad exposure, would 
develop into a traumatic surgeon—a mythi­
cal fellow who could deal expertly with 
all aspects of the injured patient. In prac­
tice the orthopedic resident would occa­
sionally find himself dealing with a gun­
shot wound of the abdomen, and the 
plastic surgeon usually felt fainthearted at 
the prospect of a craniotomy. Eventually, 
the residents made a quiet deal among 
themselves to call in one another at night 
so that each could manage the problems 
most relevant to his specialty.
The formal Trauma Service concept 
slowly evolved to the current “common- 
sense” approach. When a multiple trauma 
patient arrives in the emergency room the 
interns, in addition to initiating resuscita- 
tive measures, call the surgical chief resi­
dent. This individual delegates prime re­
sponsibility and seeks consultation from 
other specialties as the need becomes ap­
parent. The prime responsibility for the 
care of the patient may stay with general 
surgery, or may be assigned to neuro­
surgery, orthopedic surgery or any other 
service, depending on the combination of 
injuries and circumstances of each case. 
The patient is then admitted, usually to 
the Intensive Care Unit, where all inter­
ested specialties continue to care for him. 
Prime responsibility is handed from one 
service to another as the patient progresses; 
for example, several weeks ago a victim of
a highway accident arrived with multiple 
fractures, facial injuries, a suspected head 
injury and a rupture of the aorta. Prime 
responsibility was assigned to the cardio­
vascular team, while other specialties con­
sulted and dealt with the injuries in a 
logical sequence. Ten days later he was 
recovering well from his thoracotomy and 
no longer required intensive care. Respon­
sibility was then transferred to the Ortho­
pedic Service, with cardiovascular surgery, 
plastic surgery and neurosurgery continu­
ing to consult. This approach depends very 
largely on common sense and gentlemanly 
co-operation and an awareness of each 
other’s problems. I can recall only one 
occasion where the residents vigorously 
disagreed on priorities. On investigation, 
this turned out to be a clash of personali­
ties and with a little firm encouragement 
did not recur.
In a recent review1 of 100 severely in­
jured patients who most clearly profited 
from their stay in the Intensive Care Unit 
of the Montreal General Hospital, 41 were 
admitted under the prime responsibility of 
general surgery, 38 to the care of ortho­
pedic surgery, 10 to neurosurgery, six to 
cardiovascular and thoracic surgery, four 
to plastic surgery and one to urology. 
Twenty-four hospital services contributed 
to the care of these 100 patients, an aver­
age of almost four services per patient.
In summary, there is no magic formula 
for the treatment of the multiple trauma 
patient. The formation of a trauma service 
or unit does not provide an easy or com­
plete answer. The care of the patient with 
life-threatening injuries requires a good 
emergency department devoted to resusci­
tation, an Intensive Care Unit devoted to 
stabilization and, most important of all, a 
state of mind which is difficult to acquire 
but worthy of the effort, that is, a sense 
of unpretentious and common sense co­
operation among the members of many 
specialty services.—Jo M il l e r .
The Montreal General Hospital,
Montreal, Que.
R e f e r e n c e
1. R oddick DW, M acL ea n  AE, G urd FN : Un­
published data, 1969
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THE BRUCE LECTURE
The work of surgeons and physicians 
may be regarded as inefficient in the sense 
that we often strive to prolong life in weak 
and unproductive individuals. We need 
not, however, be apologetic about indi­
vidual patient care, since the willingness 
of society to support its unproductive 
members is a measure of its civilization. In 
any event, displays of concern and ener­
getic participation in community life by 
physicians reassures society that the pro­
fession is aware of its dual role—those of 
practitioner and citizen.
The late Honourable Dr. Herbert A. 
Bruce exemplified the concern of the good 
doctor for the welfare of both patient and 
community. A distinguished clinical sur­
geon, he founded the Wellesley Hospital 
in Toronto, was a member of the Parlia­
ment of Canada, and a Lieutenant- 
Governor of Ontario. After many years as 
one of the busiest surgical practitioners in 
Ontario, Dr. Bruce devoted the latter half 
of his long and productive life to the 
affairs of community and state. In his 
memory, his widow, Mrs. Angela Bruce, 
has endowed a lectureship and the first 
Bruce Lecture, by Professor A. P. M. For­
rest, appears on page 19 of this issue.
As inaugural lecturer, Dr. Forrest added 
an interesting and generous feature to the 
lectureship. He presented the Wellesley 
Hospital with a silver tray to carry the 
names of future Bruce Lecturers, and 
directed that part of his honorarium be 
used to send a Surgical Fellow from the 
Wellesley Hospital to visit the Bruce Lec­
turer at his home university. This arrange­
ment, if continued over the years, will 
forge valuable links between a series of 
young Canadian surgeons and distin­
guished surgeons in other parts of the 
world. His many friends will be pleased to 
learn that “Pat” Forrest has recently been 
appointed Regius Professor of Surgery in 
the University of Edinburgh.
Dr. Forrest’s gesture will remind many 
local surgeons that, in 1922, Harvey Cush­
ing contributed the cash award that 
accompanied his Charles Mickle Fellow­
ship to send a Toronto surgeon to Boston 
for training in neurosurgery. The late 
Kenneth G. McKenzie persuaded Clar­
ence Starr to give him the chance and, as 
a result of “seed-money” from a distin­
guished guest and the fortitude and per­
sistence of a pioneer, Canadian surgery 
received lasting benefit.—Neil  A. W atters.
The Wellesley Hospital,
Toronto, Ont.
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R E V I E W  A R T I C L E
HETEROLOGOUS ANTILYMPHOCYTE SERUM: A REVIEW
H. F . JEEJEEBH O Y, M.B., B.S., F.R.C.S., Ph.D .,° M ontreal, Que.
Antilym phocyte serum (ALS), a potent 
and effective immunosuppressive agent, is 
widely used in clinical transplantation. 
This review will consider the salient fea­
tures relating to the preparation, standard­
ization, use and mode of action of ALS. 
Space does not permit comprehensive 
coverage, and the references given cover 
only a portion of the present literature 
pertaining to ALS.
ALS is one of the most potent immuno­
suppressive agents available at the present 
time, at least in the laboratory animal. It 
is prepared by immunizing animals with 
xenogeneic lymphoid cells. The antiserum 
obtained will, under appropriate condi­
tions, effectively depress immune responses 
when given to animals of the same species 
as the donors of lymphoid cells used for 
immunization. ALS should be distinguished 
from isoantiserum which is prepared by 
immunizing animals with allogeneic lym­
phoid cells. Isoantiserum is a much less 
potent immunosuppressive agent than ALS 
and probably has quite a different mode 
of action.
To avoid ambiguity, definitions are of­
fered for a few of the terms commonly 
used in transplantation biology. “Syn­
geneic” refers to animals that are genetic­
ally identical to each other as, for example, 
highly inbred animals or identical twins. 
“Allogeneic” individuals are genetically 
unrelated to each other but are members 
of the same species—this term would there­
fore cover most of the human race. “Allo­
grafts” are grafts exchanged between allo­
geneic individuals. The words “xeno­
geneic” or “heterologous” indicate species 
differences between donor and recipient. 
It is an axiom of transplantation biology 
that allografts or xenografts on unmodified 
recipients are always rejected.
“Associate Professor, Department of Surgery 
(Division of Surgical Research), McGill Univer­
sity, Montreal, Que.
Rejection is mainly effected by lympho­
cytes that are sensitized as the result of an 
immune reaction induced by the presence 
of a genetically dissimilar graft. Circulat­
ing (humoral) antibody plays, if anything, 
a minor role in the rejection of allografts 
and reactions of this type are therefore 
referred to as “cell-mediated” immune 
responses. The intensity of graft rejection 
depends on a number of factors: the 
degree of genetic or antigenic difference 
between host and donor, the effectiveness 
of immunosuppression of the recipient, and 
previous sensitization by an antigenically 
similar graft. This last factor will result in 
accelerated rejection of the second graft.
Immunization with most other antigens— 
bacterial, cellular or chemical—results in 
an immune reaction that is mainly 
humoral. Such a reaction is characterized 
by the presence in the serum of free circu­
lating antibody produced by plasma cells. 
This type of antibody is also produced in 
response to allografting and xenografting: 
in the latter situation such antibody is 
probably the main effector of rejection; in 
the former it plays a subsidiary role, bind­
ing itself to the vascular endothelium of 
the graft and causing platelet aggregation, 
endothelial proliferation and occasionally 
vascular occlusion.
H istorical Notes
The idea of using heterologous antisera 
to inactivate leukocytes dates back to 1899 
when Metchnikoff1 induced leukotoxic sera 
by injecting emulsions of guinea-pig lymph 
nodes and spleen into rabbits. Over the 
next half century, several workers de­
scribed the ability of such heterologous 
antisera to inactivate lymphocytes in vitro 
and to depress white cell counts when 
parenterally administered.2'10 The ability 
of ALS to depress immune responses was 
first described in two papers published in 
1958. Inderbitzin,11 using serum from rab-
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bits immunized with guinea-pig mono­
nuclear cells, was able to inhibit the 
tuberculin reaction in guinea pigs. Simul­
taneously, Wilhelm, Fisher and Cooke12 
reduced contact sensitivity to 2:4 dinitro- 
chlorobenzene in guinea pigs by treating 
the animals with rabbit anti-guinea-pig 
ALS. Subsequently, Waksman, Arbouys 
and Arnason13 showed that rabbit anti­
guinea-pig ALS could also prolong skin 
allograft survival times when given to 
guinea pigs. However, the degree of pro­
longation obtained was modest and there 
was little interest in the use of ALS until 
Woodruff and Anderson14’ 15 and Gray, 
Monaco and Russell16 demonstrated im­
pressive increases in graft survival ob­
tained by ALS treatment. These initial 
observations on the immunosuppressive 
properties of ALS were soon confirmed 
and many workers showed that, in the 
laboratory animal, ALS was a most potent 
immunosuppressive agent. These findings 
were reported in the middle of a decade 
of intense interest in clinical transplanta­
tion and at a time when the deficiencies of 
conventional immunosuppressive therapy 
were beginning to be recognized. It was 
therefore only natural that ALS should be 
seriously considered as an adjunct to con­
ventional methods in clinical transplanta­
tion. It remained for Starzl et al.17>18 to 
show that it could be successfully used in 
human patients. The last five years have 
been characterized by an intensity of in­
terest in the use and mode of action of 
ALS which can have few parallels in the 
field of transplantation biology, and this 
review will attempt to correlate some of 
the numerous observations that have been 
made. Many of the findings reported are 
controversial and some contradict others. 
The author therefore apologizes if, in the 
interpretation of these findings, his per­
sonal biases intrude on what should other­
wise be an unbiased communication.
Preparation of ALS
Choice of Antigen
Different lymphoid cell types have been 
used to prepare ALS with immunosuppres­
sive properties, including cells from the 
thymus, lymph nodes, spleen, thoracic duct
and peripheral blood. In addition, cells 
from patients with lymphatic leukemia19 
and cultured human lymphoblasts20 have 
been used to prepare sera that appear to 
induce good immunosuppression. ALS can 
also be made by immunizing animals with 
cells that are morphologically unrelated to 
lymphocytes, e.g. epidermal cells and 
fibroblasts,21 and recently it has been 
shown that ALS, which is capable of de­
pressing immune responses, can be ob­
tained by immunizing animals with sub- 
cellular fractions of lymphoid cells22’ 23 or 
even their cell sap.23
It is difficult to be categorical about the 
best antigen to use for the preparation of 
ALS. Certain requirements must be met: 
First, it must have been shown that the 
antigen being used can produce ALS with 
good immunosuppressive properties and, if 
possible, that it is superior to, or at least 
the equal of, other antigens in this respect. 
However, when a panel of animals is im­
munized with cells from a single pool of 
antigen one usually obtains ALS prepara­
tions with a wide range of immunosup­
pressive properties, despite the use of 
identical immunizing and bleeding sched­
ules.24 Hence, it is extremely difficult to 
evaluate statistically the superiority of one 
antigen over another. It has been stated 
that, for the preparation of potent ALS, 
thymus cells are superior to other anti­
gens,25’ 26 but this has been disputed.27 
However, there is certainly no evidence 
that thymus cells are inferior to other anti­
gens or to thoracic duct cells14’ 15, 28 and 
cultured human lymphoblasts.20 Second, 
the antigen used should be readily avail­
able. In the laboratory thymus cells are 
easily obtained for the preparation of ALS 
to be used on experimental animals; this 
is not so in the human context. Here, cul­
tured lymphoblasts and thoracic duct cells 
have obvious advantages—they are readily 
available, especially if the transplant pro­
gram involves preliminary drainage of the 
thoracic ducts of prospective recipients. 
Third, the antigenic preparation, as far as 
possible, should be free of irrelevant con­
taminating antigens such as those present 
in plasma proteins, red cells and platelets. 
Antibodies to these antigens could produce 
undesirable side effects such as anaphy-
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laxis, anemia and thrombocytopenia. These 
antibodies can be removed by appropriate 
absorptions before the ALS is injected but, 
when large volumes of serum have to be 
processed, such absorptions can be logis- 
tically formidable procedures. Cultured 
lymphoblasts have considerable advan­
tages over other antigens because they are 
virtually free of contaminating red cells, 
platelets and serum proteins.20
M ethod o f Immunization
A large number of immunizing and 
bleeding schedules have been used for 
the preparation of ALS. None has been 
proved to be indisputably superior to 
others.
When rabbits are used to produce ALS, 
the method commonly used is that de­
scribed by Levey and Medawar.25 The ani­
mals are injected intravenously with 10° 
xenogeneic thymus cells on days 0 and 14, 
and bled out on day 21. A variation of this 
procedure, described by Manniclc et al. 
(personal communication), gives the first 
injection subcutaneously in the footpads 
after emulsifying the cell suspension in 
Freund’s complete adjuvant. In our hands 
this latter procedure has consistently re­
sulted in the production of potent ALS 
while the former procedure has given 
somewhat disappointing results.
Horses are usually used to produce anti­
human ALS and a large number of dif­
ferent immunization and bleeding proto­
cols have been used. Generally the best 
method is some variation of the procedure 
described by Monaco et al.29 to produce a 
potent horse antidog ALS. The horse is in­
jected subcutaneously with xenogeneic 
lymphoid cells in Freund’s adjuvant (the 
number of cells varies from investigator to 
investigator) and this injection is usually 
repeated two or three times at weekly in­
tervals. Subsequently the horse receives a 
short course of intravenously injected lym­
phoid cells and is then bled.
Two points about the preparation of 
ALS are noteworthy. The first relates to 
the superiority of a short course in im­
munization over chronic immunization. In 
the rabbit, repeated immunization results 
in a significant loss of immunosuppressive 
potency of the ALS obtained;21' 30 in these
animals a short course of injections is in­
disputably superior to long-term immuniza­
tion. In the horse the evidence on this point 
is not quite so clear-cut. Many workers re­
peatedly immunize and bleed their horses 
and claim that this does not result in any 
loss of potency of the ALS so ob­
tained.17’ 18' 20,28’ 29 However, as will be 
discussed later, the immunosuppressive 
potency of antihuman ALS is very difficult 
to assess. Hence, it is difficult to be certain 
that there is no loss of potency when horse 
antihuman ALS is made by long-term im­
munization, and this method of ALS 
preparation should therefore be avoided if 
at all possible.
The second point concerns the use of 
Freund’s adjuvant. Jooste et al.sl have 
stated that toxic antisera tend to be pro­
duced when Freund’s complete adjuvant 
is used during immunization. However, the 
consensus at the present time seems to 
be that this is not so and that ALS pre­
pared with adjuvant is more potent than 
that prepared without. These are views 
which agree with our own experience and 
with which we fully concur.
Purification of ALS
Most ALS preparations contain anti­
bodies to plasma proteins, red cells and 
platelets—antibodies that do not contribute 
to immunosuppression and, if injected, 
could produce serious side effects. Usually 
they should be removed by absorption be­
fore injection of the ALS. Red cell anti­
bodies can be removed by “decomplement­
ing” the ALS (heating at 56° C.) and 
then adding packed erythrocytes; after in­
cubation the mixture is centrifuged. This 
process is repeated until most, if not all, 
of the anti-erythrocyte antibodies have 
been removed. The use of red cell stroma 
rather than whole cells is probably pref­
erable because it avoids the hemolysis 
that frequently occurs with outdated 
human blood.
Antibodies to plasma proteins are re­
moved by some variation of the procedure 
described by Iwasaki et a l,17 One volume 
of inactivated serum is incubated with 10 
volumes of immune horse serum. After 12 
hours at 4° C., the mixture is centrifuged 
to remove insoluble antigen-antibody com-
8 THE CANADIAN JOURNAL OF SURGERY Vol. 14
plexes. Unfortunately this procedure leaves 
soluble complexes in solution and these 
complexes potentially can produce serious 
renal lesions when injected.
Finally, to avoid administering large 
amounts of potentially toxic, non-antibody 
protein, the ALS is fractionated so that 
only the active immunosuppressive moiety 
will be administered. The bulk of this 
moiety resides in the IgG fraction of 
ALS17’ 32 34 although some may also be 
present in other fractions.27 The IgG frac­
tion of ALS is commonly isolated by salt 
precipitation with ammonium sulfate17’36,36 
or sodium sulfate.37 The IgG preparations 
obtained by such precipitation are con­
taminated with other serum proteins. The 
IgG can be purified further by chromato­
graphic or electrophoretic procedures and 
some workers recommend these extra pro­
cedures.20, 34, 36
The ALS preparation eventually ob­
tained should be stored at —20° C. because 
marked structural changes may occur in 
IgG preparations stored at 4° C. or 
higher.37
Immunosuppressive E ffects of ALS in
E xperim en tal  A nim als
Effect on Cell-Mediated, Immune
Responses
Prolongation o f graft survival.—In a large 
number of animal species, ALS can de­
press the immune response to a variety of 
allografts and xenografts. Thus ALS treat­
ment prolongs skin allograft and xeno­
graft survival in mice,16, 21, 25,26,30, 38 
rats,14,15,39,40 guinea pigs,13 primates41 
and man.20,33 Allograft survival in pri­
mates can also be prolonged by antihuman 
ALS;42 this method is now used to test the 
immunosuppressive potency of antihuman 
ALS (see below). ALS treatment increases 
the survival of renal allografts in rats43 and 
of renal, hepatic and cardiac allografts in 
dogs.18, 44-49 In addition to prolonging the 
survival of first-set skin grafts, ALS can 
prolong graft survival on previously sensi­
tized mice.25, 39
The degree to which ALS can prolong 
graft survival depends on a number of 
factors: First, the effect is dose-dependent, 
but there is no evidence that its action is
strain-specific,21 that is, ALS is not more 
effective when given to the animal strain, 
which provided the lymphocytes used for 
immunization, than to another strain. 
Second, when injecting ALS the intra­
venous route is probably more effective 
than subcutaneous or intramuscular 
routes.50 Third, the timing of the ALS in­
jections is probably of considerable im­
portance. With skin grafts in mice, Levey 
and Medawar25 showed that ALS given 
before grafting is less effective than that 
given after grafting. This opinion agrees 
with our own observations, but Monaco 
et al.ss got better results when their re­
cipients were pretreated with ALS. How­
ever, with renal allografts in dogs, it has 
been convincingly shown that the maximal 
immunosuppressive effect occurs only if 
ALS treatment is started several days be- 
for grafting.18, 48 Fourth, a number of pro­
cedures potentiate the immunosuppressive 
properties of ALS, namely, thoracic duct 
drainage,14,15 thymectomy of the re­
cipient,39, 40,51 whole-body irradiation be­
fore injection of ALS21 and certain im­
munosuppressive drugs,52 notably 6-mer- 
captopurine63—the active principle of aza- 
thioprine, a drug routinely used in clinical 
transplantation. It has also been reported 
that the effects of ALS can be potentiated 
by corticosteroids21,52 but others dis­
agree.63 Finally, the immunosuppressive 
properties of ALS are significantly reduced 
if the recipient has been preimmunized 
with, or has antibodies directed against, its 
IgG component.54 Conversely, graft sur­
vival times are prolonged if the recipient 
has been rendered tolerant to the IgG 
present in the ALS being administered.65
Inhibition o f graft-versus-host reactions. 
—These reactions are produced when im- 
munologically competent allogeneic cells 
are injected into animals that are in­
capable of rejecting them, either because 
the recipients are genetically compatible 
with the injected cells, e.g. parental cells 
injected into F I  hybrids, or because they 
are newborn (immunologically immature) 
or because their immune responses have 
been depressed by drugs or irradiation. 
The injected cells mount an immune 
response against the recipient and, in the 
most severe cases, kill the animal. Graft-
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versus-host reactions can be significantly 
reduced by ALS treatment of the donor 
or the recipient, and also by in vitro in­
cubation of the cells in ALS before in­
jection.56-60 Particularly pertinent in the 
human context are observations of van 
Bekkum et a l,60 who have shown that ALS 
treatment of the recipient can suppress the 
graft-versus-host reaction (“secondary dis­
ease”) that follows the transfer of allogeneic 
marrow cells to x-irradiated monkeys.
Induction o f tolerance with ALS.—'“Tol­
erance” refers to a specific state of no re­
activity. Thus, a tolerant animal will not 
reject a graft of the genotype to which it 
is tolerant but will reject all other genet­
ically dissimilar grafts. The use of ALS to 
induce tolerance was first described by 
Monaco, Wood and Russell.81 They used 
a combination of ALS and thymectomy to 
render their mice tolerant, but subsequent 
investigations62"64 have shown that toler­
ance can be induced by ALS treatment 
alone. The best results are obtained when 
skin grafting is followed by ALS treatment 
and intravenous injection of cells, genetic­
ally identical to the graft, some four to five 
days after completion of the course of ALS.
Effect on Humoral Antibody Production
ALS suppresses the humoral antibody 
response to sheep red cells in a number of 
species,38'40, 65' 67 to bovine serum albumin 
in rats88 and to salmonella antigens in 
mice.38 Timing of ALS injections is espe­
cially important because there is practi­
cally no suppression of humoral antibody 
production if ALS is given after the injec­
tion of antigen.65 However, ALS treatment 
does not always suppress antibody produc­
tion; indeed, with some antigens, e.g. key­
hole limpet hemocyanin, antibody produc­
tion is enhanced.69 Another antigen against 
which antibody production is greater than 
normal is the IgG contained in the ALS 
administered, that is to say, ALS IgG is 
more immunogenic than normal IgG. 43' 70' 71 
This is particularly important from a prac­
tical point of view because the immuno­
suppressive potency of ALS is significantly 
reduced if the recipient’s serum contains 
antibodies to the ALS IgG .54
E ffect on Autoimmune Processes
ALS seems to be an effective suppressor 
of autoimmune disease processes. Thus, 
ALS treatment protects against the devel­
opment of experimental allergic encephalo­
myelitis,13, 72 autoimmune thyroid dis­
ease, 73 and adjuvant arthritis in rats. 70 It 
also suppresses the Coombs-positive hemo­
lytic anemia in NZB mice,74 although it 
does not modify the course of already 
established disease or prevent the onset of 
autoimmune renal disease in B/W mice. 75
E ffect on Bacterial and Viral Infections
We have more information on the effects 
of ALS in infections with viruses than in 
those with other micro-organisms. ALS 
mainly affects infections that are normally 
dealt with by cell-mediated rather than 
humoral antibody responses. Thus, ALS 
treatment hastens miliary spread and death 
from tuberculous infection in mice76 and 
promotes the development of tumours in 
mice infected with oncogenic viruses77"81 
but has no effect on influenza or rabies in­
fections. ALS can activate latent infections 
such as canine distemper32 and it can 
greatly alter the type of infection usually 
produced by a given virus. For example, 
it can lead to antigen-antibody-complex 
nephritis following infection with lympho­
cytic choriomeningitis virus.82 Unfortu­
nately, very little work has been done on 
the effects of ALS in infections with the 
common bacteria such as the coliforms and 
the cocci.
Pathologic Effects o f ALS Administration
Some of the adverse effects of ALS 
treatment are due to the administration of 
irrelevant antibodies; for example, anti­
bodies directed against red cells account 
for the anemia, marrow hyperplasia and 
extramedullary erythropoiesis that are 
often found. 18 , 29, 83 Other effects are due 
to antibodies directed against lymphoid 
cells and these include the depletion of 
cells in the “thymus-dependent” para- 
cortical areas of the lymph nodes and the 
periarteriolar areas of the spleen.83 85
A third group of pathologic lesions re­
sults from the foreign protein present in 
the ALS administered. The kidney is the
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organ primarily affected and the charac­
teristic lesions have been found in both 
mice83 and dogs18 receiving long-term ALS 
therapy. The lesions include thickening of 
the glomerular basement membrane, 
hypercellularity of the tufts, adhesions be­
tween tufts and capsule, and narrowing or 
obliteration of the capillary loops. Deposits 
of amorphous material can be found in the 
glomerular basement membranes, on the 
subepithelial aspects of the glomerular 
capillary basement membranes and in the 
mesangium. These deposits were found by 
Iwasaki et al.17 to contain horse gamma­
globulin and dog IgA and /31C globulin. 
The highest incidence of lesions was found 
in dogs given ALS for the greatest length 
of time. These renal lesions are potentially 
lethal and are probably caused by the 
deposition in the kidney of antigen-anti­
body complexes consisting of horse protein, 
dog antibodies to this protein and compo­
nents of dog complement, resulting in a 
Masugi or serum-sickness type of nephritis.
U se o f  ALS in  C lin ical
TRANSPLANTATION
Difficulty in Assessing Value in Clinical
T ransplantation
ALS, or rather its IgG component (ALG), 
is widely used in clinical transplantation 
at the present time. Administration of ALG 
alone can prolong the survival of skin 
grafts in humans20,34 and allow the suc­
cessful transfer of allogeneic marrow 
grafts.86 Despite this obvious ability of 
ALG to depress immune responses in 
humans, it is extremely difficult to deter­
mine whether ALG treatment can improve 
the results obtained at present with con­
ventional immunosuppressive measures in 
clinical renal, hepatic and cardiac trans­
plantation. The reasons are as follows: 
First, the immunosuppressive potency of 
ALS can vary significantly from batch to 
batch and, until very recently, there was 
no satisfactory assay of the immunosup­
pressive properties of ALS (see later). Most 
workers have used serum from a number 
of different batches on each of their pa­
tients and the results are therefore very 
difficult to assess. Second, ALG is usually 
given to human patients in conjunction
with other immunosuppressive agents. This 
often makes it difficult to determine 
whether improvement is due to the ALG, 
especially in situations where results are 
already very good, as in transplantation 
between living related individuals. Third, 
in the laboratory, the immunosuppressive 
effect of an ALS preparation is easy to 
assess because genetic differences between 
mice and rats have been determined and 
standardized. Because immunogenetic dif­
ferences between humans cannot be pre­
cisely determined at the present time, it 
is difficult to assess results in the individual 
because immunosuppressive agents pro­
duce longer graft survival times when 
genetic differences between host and donor 
are weak rather than strong.
Dosage Schedules of ALG Used in
Patients
The use of ALG in clinical transplanta­
tion was first reported by Starzl and his 
associates17,18,87•88 and by numerous 
others since then.20,28,35, 89’92 Most have 
commented favourably on the results ob­
tained. Thus, Starzl et al.27 reported that, 
with ALG therapy, the one-year survival 
after intrafamilial renal transplantation 
rose to 90% and that after cadaveric trans­
plantation to 83%. Traeger et al.28’ 93 
found that the number of rejection crises 
in the first three months after transplanta­
tion was significantly reduced by ALG 
treatment.
The dosage schedule of ALG given to 
patients has varied from centre to centre. 
Thus, Najarian et al.20 give a short three- 
week course of ALG, beginning a few days 
before transplantation. At the other ex­
treme, Traeger et al.28’ 93 begin ALG 
therapy 10 days before transplantation. 
They give one injection a day for the 
first month and one injection every two 
days during the second month. From the 
beginning of the third month, the patients 
receive three injections a week indefinitely. 
They are the only workers who give ALG 
for such long periods and their observa­
tions on the relative absence of renal 
lesions in their patients (see later) are 
therefore particularly relevant. The dose of 
ALG given has varied from group to group 
and has ranged from 4 to 20 mg./kg. of
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immunoglobulin per injection. All workers 
used the ALG in conjunction with other 
immunosuppressive agents and many noted 
that ALG treatment allowed them to re­
duce steroid dosage with a commensurate 
decrease in the morbidity associated with 
this type of therapy.
The Use o f ALG to Reverse Threatened
Rejection
A few patients have received ALG dur­
ing threatened rejection, usually because 
the azathioprine and steroid dosage could 
not be increased because of intercurrent 
infection or marrow depression. In some 
of these patients renal function was defi­
nitely improved.84 There is a good theoreti­
cal basis for this form of therapy. Starzl 
et al,27 described an experiment in which 
they left 10 canine recipients of renal 
transplants untreated until rejection had 
begun, as evidenced by a rising blood urea 
nitrogen. At this stage the dogs received 
ALG and, in three or four of the animals, 
there was a prompt reversal of rejection.
Effect o f ALG on Delayed Hypersensi­
tivity Reactions and Autoimmune Dis­
orders in Man
ALG can suppress and often completely 
abolish delayed hypersensitivity reactions 
to a number of antigens.18’ 34 Traeger 
et al.28’ 93 have used this property to assay 
the immunosuppressive potency of the 
ALG they give their patients. They find 
that when an effective immunosuppressive 
agent is being used the hypersensitivity 
skin reactions to P.P.D., candidin and 
toxoplasmin become negative five to 10 
days after treatment begins.
ALG has been used to treat patients 
with autoimmune diseases such as derma- 
tomyositis and to treat diseases such as 
multiple sclerosis which might possibly 
have an autoimmune basis. This has only 
been done for a short time and the results 
are therefore difficult to assess although 
Traeger et al.28 found that it had no effect 
on their patients.
Complications of ALG Therapy in Man
The following are some of the local and 
systemic complications of ALG therapy.
Local complications.—These include local 
pain and tenderness at the site of injec­
tions, erythema, induration and occasion­
ally abscess formation.18' 28’ 34' 95 These 
complications develop when ALG is given 
intramuscularly and hence many workers 
now administer ALG by intravenous in­
jection.
Systemic complications.—A number of 
systemic complications have been reported 
after ALG therapy. The following list is 
not comprehensive but mentions the more 
common ones.
(1) Fever is very common but is usually 
of low grade.18,28, 34’ 85
(2) Instances of hypotension and air 
hunger have been reported after ALG 
therapy.18’ 28’ 95
(3) Skin rashes and generalized pruritus 
may develop.18’ 95
(4) ALG treatment depresses peripheral 
lymphocyte counts in man,18’ 20- 28 and it 
also has a deleterious effect on marrow 
cells, at least in the laboratory animal.67’ 96 
These effects could have serious conse­
quences if the patient’s marrow and lym­
phocytes were already depressed by aza­
thioprine.
(5) One of the most serious and trouble­
some complications of ALG therapy in 
man is thrombocytopenia.18’ 95 This com­
plication, which is probably due to anti­
platelet antibodies in the ALG used, often 
makes it necessary to stop ALG therapy.27 
However, Traeger et al.28 find that anti- 
human ALG prepared by immunization 
with thoracic duct cells does not produce 
this complication to any significant degree, 
but still has immunosuppressive properties.
(6) Anaphylactic reactions are probably 
due to previous sensitization of the patient 
to horse serum proteins. Another acute 
reaction is a reverse anaphylaxis owing to 
the passive introduction of antibody 
directed against human serum proteins. 
Hence, one must skin test to determine 
hypersensitivity to horse protein before 
giving ALG and, before use, should re­
move antibody to human serum proteins 
by appropriate absorptions.
(7) Patients receiving ALG frequently 
develop antibodies to the injected foreign 
proteins.18’ 28> 93’ 95 Depositions of hetero-
12 TH E CANADIAN JOURNAL O F SURGERY Vol. 14
logous and autologous proteins, presum­
ably in a complexed form, have been 
demonstrated in the kidneys of human 
recipients of ALG. The incidence, how­
ever, is small and according to Starzl 
et al.,27 horse proteins were found only in 
one of 41 of his patients who received 
ALG and had their kidneys biopsied two 
years later. Hence, the chances of devel­
oping a Masugi or serum-sickness nephritis 
after ALG seem to be negligible—a con­
clusion confirmed by observations reported 
by Traeger et al. (personal communication). 
However, deposits can appear and various 
histologic changes have been described in 
the kidneys, including thickening of the 
subepithelial and subendothelial basement 
membranes and fusion of the epithelial 
foot processes.
(8) Another potential, but as yet un­
realized, complication of ALG therapy is 
the development of renal lesions owing to 
the presence in ALG of antibody directed 
against glomerular basement membranes. 
An ALG preparation of this type has been 
recently described by H. Taylor of the 
Medical Research Council of Canada (per­
sonal communication). It was not used on 
human patients but produced a rapidly 
developing and fatal renal disease when 
given to chimpanzees. Thiel et al.97 have 
recently demonstrated antiglomerular base­
ment membrane antibody in a number of 
horse antihuman ALS preparations. The 
incidence was lowest when cultured lym­
phocytes, thoracic duct cells or washed 
thymus cells were used for immunization, 
rather than homogenates of spleen or 
thymus. Fluorescent microscopy showed 
that the antiglomerular basement mem­
brane antibody was deposited in the kid­
neys. However, the autologous phase of 
nephritis did not develop in these patients. 
This was probably because they were 
receiving additional immunosuppressive 
therapy which, with the ALS, effectively 
suppressed the production of autologous 
antibody to the complex of basement mem­
brane and heterologous antibody.
(9) Several workers have reported tu­
mours developing in long-term survivors of 
renal transplants,98 in particular, the other­
wise uncommon reticulum cell sarcoma. 
There is no evidence that ALG therapy is
uniquely implicated;27 rather, these tu­
mours probably represent an inevitable 
result of long-term, effective immunosup­
pression.
Assay and M ode o f  Action of ALS
The mode of action of ALS is not yet 
known precisely and hence many of the 
available methods for assaying ALS in 
terms of immunosuppressive potency are 
empirical. The following are some of the 
more common hypotheses concerning the 
depression of immune responses by ALS.
The Cytotoxic Theory
This hypothesis proposes that immune 
responses are depressed by ALS because 
lymphocytes are destroyed by the aggluti­
nating and cytotoxic antilymphocyte anti­
bodies present in almost all ALS prepara­
tions.31, 38 There are serious objections to 
this hypothesis. First, the immunosuppres­
sive potency of ALS cannot be correlated 
with its content of agglutinating and cyto­
toxic antibodies directed against lympho­
cytes.24, 30,90 Second, ALS preparations 
which lack antilymphocyte agglutinating 
and cytotoxic antibodies can be immuno­
suppressive.99 Third, ALS is no less effec­
tive when given to animals that are 
genetically deficient in the fifth component 
of complement (C'5).100,101 In the absence 
of C'5, cytotoxic lysis of cells cannot occur.
A variation of the cytotoxic hypothesis 
is one which states that ALS depresses im­
mune responses because it contains an 
opsonizing antibody which promotes 
phagocytosis of affected lymphocytes.102,103 
There is a good correlation between the 
immunosuppressive potency of antimouse 
ALS and its opsonizing activity, but with 
antihuman ALS the correlation is poor.104
The Blindfolding and the Competitive
Antigen Theories
According to the blindfolding hypo­
thesis, ALS coats lymphocytes and thus 
prevents them from recognizing antigen.25 
If this hypothesis were valid there should 
be a good correlation between the im­
munosuppressive potency of ALS and its 
content of lymphocyte agglutinating anti­
bodies. This is not so and the same objec-
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tion applies to the competitive antigen 
theory. This hypothesis postulates that 
ALS antibody preferentially binds to lym­
phoid cells and “preoccupies” them with 
antibody production because the ALS anti­
body is antigenic to the recipient. These 
“preoccupied” cells are then unable to 
respond to other antigens.
A variation of the blindfolding hypo­
thesis is one which states that ALS anti­
body masks the antigen in the graft 
itself108 because renal homografts from 
ALS-treated rats survive longer than grafts 
from untreated donors. However, we have 
recently found101 that, while ALS does 
contain antibody which acts on the graft, 
this antibody decreases rather than pro­
longs graft survival. This graft-rejecting 
antibody is C'5-dependent whereas the 
antibody responsible for immunosuppres­
sion is not.
The Sterile Inactivation Theory
ALS antibody has a non-specific mito­
genic action on lymphocytes in tissue 
culture.106 It has been suggested that in 
vivo administration of ALS results in a 
non-specific and functionally sterile pro­
liferation of lymphocytes which pre-empts 
all their functions.21 However, it has not 
been possible to correlate the in vitro mito­
genic activity of ALS with its in vivo im­
munosuppressive potency.107
The Immunosuppressive Antibody
Hypothesis
In vitro incubation of spleen cells with 
ALS decreases their ability to produce 
antibody when they are subsequently 
mixed with antigen and injected into im- 
munologically incompetent recipients.108 
This property of ALS is directly propor­
tional to its immunosuppressive potency 
but not to its content of antilymphocyte 
agglutinating and cytotoxic antibodies. 
Hence, it has been suggested that immuno­
suppression by ALS depends on its con­
tent of a specific immunosuppressive anti­
body, which is directed against cells 
involved in antibody production and which 
is distinct and different from lymphocyte 
agglutinating and cytotoxic antibodies.
The test described by Saleh et al.100 for
assaying the immunosuppressive potency 
of ALS probably depends on the validity 
of this hypothesis. When mouse or human 
cells are injected under the kidney cap­
sules of cyclophosphamide-treated rats, 
there is an infiltrative and proliferative 
reaction of the grafted cells against the 
host. This reaction can be inhibited by in­
jection of the rat with ALS directed 
against the grafted cells. The degree of 
inhibition produced depends on the im­
munosuppressive potency of the ALS used 
but not on its content of antilymphocyte 
antibodies. So far, a good correlation has 
been obtained between the immunosup­
pressive potency of antimouse ALS and 
its ability to decrease this type of reaction. 
It remains to be shown that this promising 
test correlates with the immunosuppressive 
potency of antihuman ALS.
The Antigen Recognition H ypotheses
ALS treatment can significantly depress 
the immune response in mice to sheep 
erythrocytes if the ALS is given before 
the antigen; it has little effect if ALS is 
given after immunization.65 Hence, it has 
been suggested that ALS acts primarily on 
cells which are involved in antigen recog­
nition.
The rosette inhibition test described by 
Bach et al.110 to assay the immunosuppres­
sive potency of ALS probably depends on 
this mechanism. The peripheral blood and 
spleens of both mice and humans contain 
lymphoid cells which, when mixed with 
sheep red cells, form clusters or rosettes. 
Each rosette consists of a central lymphoid 
cell with sheep erythrocytes around it. 
The rosette-forming lymphoid cell is pos­
sibly secreting immunoglobulin specifically 
directed against the red cells and respon­
sible for the adhesion. The removal of 
these rosette-forming cells from a popula­
tion of spleen cells results in a loss of anti­
body-producing capacity;111 therefore the 
rosette-forming cell might initiate antibody 
production by recognizing antigen. In  vitro 
incubation of spleen or peripheral blood 
cells with ALS, before mixing with sheep 
red cells, reduces the number of cells cap­
able of forming rosettes.110 The reduction 
is directly proportional to the immuno-
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suppressive potency of the ALS used. An 
excellent correlation has been obtained be­
tween the immunosuppressive potency of 
antimouse ALS and its ability to decrease 
rosette formation.110
The ability of antihuman ALS to inhibit 
rosette formation by human peripheral 
lymphocytes correlates fairly well with its 
ability to prolong skin-graft survival in 
subhuman primates.112 This latter test, 
which is widely used to assay the im­
munosuppressive potency of antihuman 
ALS, is based on the assumption that an 
antihuman ALS that prolongs allograft 
survival in chimpanzees and lower mon­
keys42 will have the same effect on allo­
graft survival in humans. This assumption 
is probably valid but is by no means 
proved. Hence, it still remains to be shown 
that the rosette-inhibition test and the 
primate skin-graft test have a predictive 
value in assessing the immunosuppressive 
potency of antihuman ALS preparations.
Site of A ction of ALS and the
Principal Cell Types Affected
ALS penetrates the central lymphoid 
tissues to a slight degree113 and all the 
present evidence suggests that the princi­
pal site of action of ALS is the peripheral 
recirculating lymphocyte.59, U 3 ,114 The 
various cell types involved in antibody pro­
duction have not been precisely delineated 
—probably at least two different cell types 
are implicated, namely, cells of thymus 
and marrow origin. ALS treatment has 
been shown to inactivate both these cell 
types 39, 40, B1> 68, 87
Perspectives
ALS has been a potent immunosuppres­
sive agent in every species tested to date. 
Its value as an adjunct to conventional 
immunosuppressive therapy in clinical 
transplantation remains to be proved by 
controlled studies, but circumstantial evi­
dence suggests that ALS will be a valuable 
addition to the clinical transplanter’s arma­
mentarium. In this respect a legitimate 
question has been raised by Hume et al.,ns 
namely, whether ALS is really needed in 
addition to conventional immunosuppres­
sive measures. If one only considers trans­
plants from related living donors, the 
answer is probably “no”, because the 
results are so good already. If ALS is really 
effective in humans it will prove its worth 
in transplantation from cadavers where the 
results still leave much to be desired. Per­
haps, in the long run, the greatest value 
of ALS will be that it will allow steroid 
dosages to be reduced in both transplants 
from living related and cadaver donors 
(much of the morbidity and some of the 
mortality in clinical transplantation are due 
to the large doses of steroids often ad­
ministered).
Finally, Mathe, Amiel and Schwarzen- 
berg86 have shown that ALS treatment is 
an extremely effective method of obtain­
ing successful grafts of allogeneic marrow 
and that graft-versus-host reactions do not 
result in patients treated in this manner. It 
is therefore possible that in future, ALS 
will be used to obtain the successful hema­
tologic and immunologic reconstitution of 
patients who have received potentially 
lethal doses of irradiation or drugs for the 
treatment of malignant disease.
ALS is one of the most potent immuno­
suppressive agents described to date. Much 
work remains to be done, particularly in 
relation to its mode of action and on 
methods of effective biologic standardiza­
tion. However, one cannot but be optimis­
tic about its future usefulness in clinical 
medicine and surgery.
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R esu m e
Le serum antilymphocytaire ( SAL), dans les 
essais effectues sur toutes les especes, s’est revele 
comme un immunodepresseur extremement actif. 
II faudra encore, par des etudes approfondies, pre- 
ciser sa valeur comme adjuvant du traitement im­
munodepresseur classique dans les transplantations 
d’organes, mais les preuves circonstancielles ac- 
cumulees permettent d’esperer que le SAL consti- 
tuera une nouvelle arme precieuse dans l’arsenal 
therapeutique des transplantations. A cet egard, 
Hume et al. ont pose une question parfaitement 
legitime, a savoir si le SAL est reellement neces- 
saire en plus des moyens immunosuppresseurs 
courants. Si on envisage des greffes provenant de 
donneurs vivants apparentes aux receveurs, la 
reponse sera probablement negative, en raison de 
l’excellence des resultats obtenus. Si le SAL est 
reellement efficace chez l’homme, il ne manquera 
pas de prouver sa valeur dans les transplantations 
d’organes preleves sur des cadavres, les resultats 
de eette operation laissant encore tellement a 
desirer. II est possible qu’a la longue, l’atout prin­
cipal du SAL sera de pouvoir reduire la posologie 
des corticoi'des utilises au cours des transplanta­
tions d’organes en provenance des deux sources 
preeitees (on sait en effet qu’une partie de la 
morbidite et un certain taux de mortalite con­
states dans les greffes sont attribuables aux fortes 
posologies de corticoi'des auxquelles on a souvent 
recours).
Enfin, Mathe, Amiel et Schwarzenburg ont 
montre que le traitement au SAL est extremement 
efficace pour reussir des greffons de moelle hetero­
gene et que, chez les malades ainsi prepares, la 
reaction greffe-contre-hote ne se produit pas. II est 
done parfaitement possible que, dans l’avenir, 
grace au SAL, on parvienne a realiser le retablis- 
sement hematologique et immunologique de 
malades qui ont regu des doses d’irradiation 
potentiellement mortelles ou des medications 
destinees a traiter des affections malignes.
Le SAL est un des plus puissants immuno- 
depresseurs que l’on connaisse. Sans doute faudra- 
t-il encore l’etudier encore beaucoup plus a fond, 
particulierement en ce qui conceme son mode 
d’action et les methodes efficaces d’etalonnage 
biologique. On ne peut cependant qu’etre opti- 
miste quant a son utilite future en medecine 
clinique et en chirurgie.
KIDNEY C ELL AND LYMPHOCYTE 
TYPING BY IMMUNE ADHERENCE 
Our present knowledge regarding human 
transplantation antigens and their genetic 
control has been derived in great part from 
correlations established between graft survival 
and in vitro assays using lymphocyte targets.
The immune adherence technique was 
modified to permit a direct comparison be­
tween the reactivity of lymphocytes and kidney 
cells from the same person. These two cells 
were typed using 17 well characterized anti­
sera. There were 82 significant discrepancies 
from a total of 234 direct comparisons. Ab­
sorptions with the negatively reacting cell re­
sulted in diminished or absent serologic 
activity against the positive cell type.
It is stressed that the present studies pro­
vide no evidence suggesting that kidney cells
possess unique histocompatibility markers not 
present on lymphocytes. It is likely that 
kidney-cell-positive lymphocyte-negative reac­
tions may be caused by antibodies to antigens 
other than HL-A antigens. This concept is 
supported by hyperacute rejection reactions 
where pretransplantation lymphocytotoxicity 
cross-match between the donor and recipient 
was clearly negative while the identical serum 
sample was shown subsequently to contain 
antibodies to kidney cells cultured from the 
donor.
The results support the concept that sig­
nificant quantitative differences in the expres­
sion of isoantigens exist among different cell 
types.—dePlanque B, Williams GM, Siegel A, 
et al: Comparative typing of human kidney 
cells and lymphocytes by immune adherence. 
Transplantation 8: 852, 1969.
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H e r b e r t  Al e x a n d e r  B r u c e  (Fig. 1) was 
bom in Cartwright, Ontario, in 1868, one year 
after Canadian confederation. He spent his 
youth on his father’s farm in Port Perry and 
in 1888 entered medical school in the Univer­
sity of Toronto. He graduated at the top of his 
class in 1892 and the following year was 
awarded his M.D. with the Ferguson gold 
medal.
After spending two years at sea to earn 
sufficient supportive funds, he proceeded to 
London and, in 1896, became the second 
Canadian to become a Fellow of the Royal 
College of Surgeons of England. While still 
in London he accepted an offer of an associate 
professorship of surgery in his alma mater, an 
appointment he held until September 1930. 
These were pioneer days in Canadian surgery 
and Bruce, a resolute and rugged character, 
possibly because of his Scots ancestry, was a 
pioneer. He had many “firsts” in Canada: the 
use of rubber gloves, the performance of gas­
serian ganglionectomy, the operative reduc­
tion of intussusception, and the excision of a 
cortical scar in an epileptic. Small wonder 
that soon he had a large and flourishing prac­
tice; to support this he purchased, in 1910, 
a building in Wellesley Street which in 1911 
became his own Wellesley Hospital. The 
further history of this now-great institution is 
well known, and culminated with its integra­
tion, in 1942, with the Toronto General Hos­
pital as a teaching institution of the Univer­
sity.
Surgery alone was insufficient challenge to 
Bruce. In 1913 he was the only Canadian 
member of the original Board of Regents of 
the American College of Surgeons. In 1914 
he went, at his own expense, to view the ac­
tivities of the Canadian Medical Service in 
France, and returned to Canada to head a 
commission that reported adversely on the 
organization of the medical services. This re­
port led to considerable controversy and, from 
some, continued antagonism. He returned to 
France as surgeon to the British Army and it 
was there that he met his future wife, Angela 
Hall, whose generosity has inaugurated this 
lectureship.
It could have come as no surprise to those 
who then knew him that he could retire from
“Professor of Surgery, Welsh National School of 
Medicine, Cardiff, Wales.
Fig. 1.—Herbert Alexander Bruce (1868-1963).
active surgery only if another more demanding 
activity required his energy and vim. This 
was a call to be Lieutenant-Governor of the 
Province of Ontario in 1932—a position he 
held with distinction until 1937. In 1931 he 
had become also a governor of the University 
of Toronto, which in 1933 awarded him an 
LL.D.
Even on his resignation as Lieutenant- 
Governor he did not rest for long. With the 
outbreak of World War II, at the age of 72, 
he stood for election as member of the House 
of Commons. He served his country in this 
capacity for a further six years. Finally, he 
retired to his farm, only to emerge again at 
the age of 90 to publish his autobiography. 
He died in 1963 at the age of 94.
Throughout his life Bruce was deeply in­
terested in cancer. His last professional task 
in 1930 was to visit cancer clinics in Europe; 
as a result of this visit he constantly urged 
the government to develop facilities for the 
treatment of cancer in Ontario—even offering 
the use of the Wellesley Hospital for this pur­
pose. His promotion of the George V Jubilee
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Cancer Campaign in 1935 he described as “a 
cause near to my heart”. It was partly this 
interest that prompted me to choose as a title 
for this first Bruce lecture “The Surgeon and 
Cancer Research”.
No lecture of mine can match the man and 
it is with a deep sense of pride and modesty 
that I give it.
In discussing the responsibility of the 
surgeon for cancer research, I do not in­
tend to consider men such as Lister or 
Huggins, whose contributions to research— 
as Herbert A. Bruce’s were to surgery and 
politics—were at the extreme end of the 
spectrum of human endeavour. Such men 
were outstanding scientists, endowed not 
only with great intelligence but with the 
persistence and single-mindedness of the 
devoted investigator. Rather do I intend 
to consider the role of the practical 
surgeon.
Many consider that the main, if not only, 
priority of the surgeon in practice is the 
care of his patients. This is not the case, 
for he has an equal responsibility to ad­
vance knowledge. Acceptance of this 
responsibility- is not easy, for it requires 
patience and understanding and denial of 
the well-worn dictum that research is the 
antithesis of good clinical care.
The contribution of the surgeon is far 
from passive, for his role is that of an 
equal and full collaborator whose prime 
function is to maintain the relevance be­
tween investigation and patients. It is this 
relevance that underlies the purpose of 
clinical research. This can best be con­
sidered further under two headings: clini­
cal care and clinical investigation.
C lin ic a l  C a re
A worthwhile contribution to cancer re­
search is unlikely ever to be made by the 
surgeon whose only concern is the indi­
vidual patient. The insistence that “every 
patient is different”, or that “I am treating 
a patient, not a disease”, is often only an 
excuse for inactivity in clinical research 
and arises from a refusal to admit that one 
may be wrong in certain aspects of current 
practice. Yet we all do it. In certain dis­
eases where cause and cure are well de­
fined—the perforated peptic ulcer, the
acute urinary retention, the fractured tibia 
—this approach is justified. But this is not 
so with cancer, for neither premise is true. 
Yet many surgeons persist in refusing to 
practise methods of treatment other than 
those that they were first taught, and op­
pose vehemently any suggestion that by 
such refusal they may not be acting in the 
best interests of their patients. These men 
condemn outright any participation in a 
controlled randomized trial.
The controlled clinical trial has proved 
one of our most effective therapeutic 
weapons against cancer. Moreover, the 
“spin-off” is considerable—better assess­
ment of patients both before and after 
treatment, meticulous follow-up and rigid 
documentation, all factors that bring ad­
ditional safeguards to the management of 
the patient with cancer.
During the past years we have set up 
in Cardiff joint clinics for conducting con­
trolled trials of the treatment of primary 
and advanced cancer of the breast. Both 
are run in co-operation with our radio­
therapy colleagues, Drs. J. M. Henk, V. 
Jones and C. A. F. Joslin. As it is important 
to keep patients with primary and ad­
vanced disease apart, we hold the clinics in 
different hospitals. The design of the trials, 
their conduct and the assessment of results 
are complex and require expert statistical 
help. This we are fortunate to have 
through the co-operation of Professor Hu­
bert Campbell.
Controlled randomized trials are of par­
ticular value in the assessment of a new 
method of treatment. An example is abla­
tion of pituitary function in advanced 
breast cancer.
Yttrium-90 Implantation
In 1955, contemporaneously with Tal- 
lairach and Tournoux,1 we developed a 
method of pituitary ablation aimed at 
providing a simple alternative to surgical 
hypophysectomy in patients with meta­
static cancer of the breast.2 This alterna­
tive consisted of the implantation of radio­
active sources into the pituitary fossa by 
transnasal cannulation. Initially radon 
seeds were used but, owing to complica­
tions from gamma radiation, we substi­
tuted the beta-emitter, yttrium-90 (90Y),
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which could cause intense necrosis of the 
pituitary without irradiation of surround­
ing structures.3
Accurate placing of the sources was 
found to be essential if complications were 
to be avoided and if complete destruction 
of the gland was to be achieved regularly. 
Visual damage, cerebrospinal rhinorrhea 
and meningitis occurred if the sources were 
placed too high in the fossa; paralysis of 
nerves III, IV or VI occurred if the sources 
were too lateral.
To achieve accurate placing of the 
sources in an optimum position, we modi­
fied our original method. The 90Y rods 
were incorporated in a stainless-steel 
screw-threaded base which was screwed 
into the bony floor of the fossa.4 Twin 
cannulas were inserted, one through each 
nostril, and guided radiologically to the 
floor of the fossa. Bilateral holes were 
drilled in the floor of the fossa and the 
screw units, attached to a special screw­
driver, were introduced until the yttrium 
rod reached the desired position. The 
screwdriver was detached and the yttrium 
units were left permanently in the fossa 
(Fig. 2).
Fig. 2.—Yttrium-90 screw implantation of the 
pituitary.
To December 31, 1969, yttrium-screw 
implantation of the pituitary has been car­
ried out in 387 patients with advanced 
cancer of the breast. Since it is a simple 
procedure, taking only 20 to 30 minutes to 
perform, postoperative death was rare and 
occurred only in 3.1% of patients. All had 
terminal malignant disease.
The incidence of complications (Table I) 
also has proved acceptable. Nine patients 
(2.3%) died as a result of complications; 
seven from meningitis and one each from 
myxedema and adrenal failure.
The incidence of unequivocal remission 
of disease in 274 assessable patients was
15.2%. However, in the face of varying 
clinical states of the patients, this figure is 
meaningless. Accurate evaluation de­
manded a controlled trial against a recog­
nized method of treatment; that selected 
was adrenalectomy and oophorectomy.
TA BLE I .— Com plication s o f  90Y  I m pla n t  of 
t h e  P itu it a r y  in  387  P a t ie n t s
Complications %
Meningitis 4 .9
Rhinorrhea—total 5 .2
permanent 1.0
Visual defects 1.8
Extraocular palsy 4 .1
Yttrium-90 Implant Versus
Adrenalectomy and Oophorectomy
Seventy-seven patients with advanced 
breast cancer were included in this trial 
between 1958 and 1962. All were post­
menopausal or castrated, all previously 
had been treated by simpler methods of 
palliation and all were considered fit for 
adrenalectomy. They were allocated ran­
domly for treatment either by 90Y implan­
tation or by adrenalectomy and oophorec­
tomy. Although these patients were not 
matched before selection, the similarity of 
certain factors in the two groups (age at 
endocrine ablation, tumour-free interval, 
menstrual status and distribution of dis­
ease) confirmed that randomization had 
been satisfactory.
The incidence of remission, both clear- 
cut and equivocal, was identical for the 
two procedures (Fig. 3). However, the 
duration of remission in those patients who 
responded to adrenalectomy and oophorec-
Fig. 3.—Incidence of remission (clear-cut and 
equivocal) in patients with advanced cancer of the 
breast selected randomly for treatment by 90Y 
implant of the pituitary, and adrenalectomy and 
oophorectomy.
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Fig. 4.—Duration of remission in responding 
patients.
tomy has now proved significantly longer 
than those responding to 90Y implant (Fig. 
4). As a method of controlling advanced 
cancer of the breast, pituitary ablation by 
screw implant is thus marginally inferior 
to adrenalectomy and oophorectomy.
Extent o f Destruction
It was important to determine the ex­
tent to which pituitary function was 
ablated by this method. This has been 
assessed in two ways: (1) plasma growth- 
hormone response to insulin hypogly­
cemia,5 and (2) postmortem histologic ex­
amination of the gland.
Fig. 5.—Growth-hormone response to insulin 
hypoglycemia (0.15 units/kg.) in 23 patients with 
advanced cancer of the breast.
Growth-hormone response— Hypoglyce­
mia, induced by the intravenous injection 
of insulin, releases growth hormone from 
the pituitary. Such release can be meas­
ured by estimations of the concentration of 
the immunoreactive levels of growth hor­
mone in serial samples of plasma. This 
response has been used to assess the extent 
of pituitary destruction following implant. 
To define the normal response to insulin 
hypoglycemia in patients with advanced 
cancer, we carried out tests in 23 patients 
who had intact pituitary glands. The con­
centration of growth hormone rose from a 
mean fasting value of 7.5 ng. to a mean 
maximum of 34.8 ng./ml. (Fig. 5), a 
response no different from that of normal 
individuals.
Studies were carried out also in 30 pa­
tients following 90Y implant, all but one 
of whom had grossly abnormal responses. 
These fell into three main groups: (1) “ab­
sent”, in which an insignificant rise in 
growth hormone (< 4  ng./ml.) was associ­
ated with low fasting levels (< 4  ng./ml.); 
(2) “unresponsive”, in which there was no 
response to insulin hypoglycemia, although 
fasting levels greater than 4 ng./ml. were 
found, and (3) “responsive”, in which a 
significant rise of growth hormone (> 4  
ng./ml.) followed insulin stimulation (Fig. 
6). An increment of this degree, which 
was taken as unequivocal evidence of 
residual pituitary function, was observed 
in six patients (20%).
Histology.— Postmortem step-sections of 
the pituitary have been examined histo­
logically by Dr. A. T. Sandison of the 
Department of Pathology, Western In­
firmary, Glasgow, Scotland, in 77 patients 
with breast cancer who had been treated 
by yttrium implantation using the screw 
technique. Pituitary remnants of greater 
than 15% of the gland have been observed 
in one-third of the patients.
As a result of these studies we conclude 
that 90Y implant of the pituitary cannot 
consistently achieve complete destruction 
of the gland. This finding adequately ex­
plains its inferiority to adrenalectomy as a 
method of palliation. Nevertheless, because 
it is simple to perform and causes little 
upset to the patient, it has a place in the 
management of those patients who are 
unfit for adrenalectomy.
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Fig. 6.—Growth-hormone response to insulin hypoglycemia (0.10 units/kg.) in 30 patients with 
advanced cancer of the breast treated by  “ Y im­plant of the pituitary.
Tramethmoidal Hypophysectomy
An accurate assessment of morbidity and 
clinical value is not always practised by those who advocate a new method of treat­
ment. Despite scant evidence to support 
their view, many now regard transeth- moidal hypophysectomy as a procedure of 
negligible morbidity which regularly 
achieves complete removal of the gland 
and gives excellent clinical results. For this 
reason, in collaboration with Mr. S. H. 
Richards of the Department of Otolaryn­
gology in Cardiff, we decided on a further 
trial to compare 90Y implantation of the 
pituitary with transethmoidal hypophysec­
tomy in patients with advanced cancer of 
the breast.The design of this trial differed from 
that previously described. Before randomi­zation, patients were carefully matched according to four factors known to in­
fluence prognosis, viz. the presence of the primary tumour, the time from the meno­pause, the tumour-free interval and the distribution of metastatic disease. Ran­domization for either transethmoidal hypo­
physectomy or yttrium implant was carried
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out by a system of sealed envelopes within the 24 subgroups. One hundred and one patients were admitted to the trial, the preliminary results of which have been reported elsewhere.6
Although the immediate postoperative period proved more troublesome for the 
hypophysectomy patients, a slightly higher incidence of complications was observed 
in the yttrium group. More patients treated by yttrium implant also had regression of 
disease, but the difference was not signifi­
cant (Table II). The duration of survival
TABLE I I .— C o m pa r iso n  o f  T r a n seth m o id a l  
H y pophysectom y  and 90Y  I m pl a n t a t io n  o f  t h e
P i t u i t a r y  i n  A d v a n c e d  C a n c e r o f  t h e  B r e a s t
M ethod o f  hypophysectom y
90 y Transethm oidal
T otal number SO 51
Response ra te  (clear- 
cu t and equivocal remission) 32% 18%
Incompletehypophysectomy 13% 24%
of patients in the two treatment groups 
was identical (Fig. 7). Tests for residual 
pituitary function by the growth-hormone response to insulin hypoglycemia indicated 
that the incidence of incomplete hypo­
physectomy following the two methods was the same (Table II).
The findings suggest that 90Y implant of the pituitary and transethmoidal hypo­
physectomy, as performed in our centre, 
are more or less of equal value. Certainly, 
at this point in the trial, we have no 
reason to assume that transethmoidal 
hypophysectomy is superior.
Clinical Investigation
By clinical investigation I mean those 
investigations which, although not per­
formed exclusively in the patients’ own in­terests, are essential for the advancement 
of knowledge of their disease with benefit to patients of the future. Such investiga­tions may be trivial and demand only a chest radiograph or a urine sample; others are more complex. The rule is inflexible- permission must be given freely by the patient in complete understanding of the nature of the studies proposed and with-
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Fig. 7.—Cumulative survival curves of 101 patients with advanced breast cancer allocated ran­
domly for treatment by transethmoidal hypophysectomy and “°Y implant of the pituitary.
out fear that to refuse might prejudice her 
relationship with her doctor.
Some surgeons refuse “on principle” to 
allow investigations of this type on their 
patients. They are hiding from reality be­
cause, without careful studies of this type, 
false premises are accepted and unproved 
methods of treatment used.
Immunity and Cancer
An example of a field of study requiring 
careful clinical investigation is that of im­
munity and cancer. Nowhere in modem 
cancer therapy is there greater danger 
that an uncritical approach may cause ac­
tive harm to the patient.
Evidence that the behaviour of human 
cancer of the breast is affected by the im­
mune system is far from clear and rests 
mainly on the demonstration that certain 
factors, which may indicate an immune 
response, are related to prognosis. Thus, 
tumours of smooth contour,7’ 8 with 
marked lymphocytic infiltration,9 12 and 
those that are associated with enlarge­
ment13, 14 and sinus histiocytosis15 17 of the 
regional lymph nodes, have been reported
to have a better prognosis that those that 
are spiculated, have little lymphocytic re­
action or have failed to evoke a reaction in 
the lymph nodes.
In Cardiff, Dr. H. J. Stewart has carefully 
assessed the contour of 75 tumours by pre­
paring whole breast sections by the tech­
nique described by Gough and Went­
worth.18 The breast, following excision, 
was impregnated with gelatin, frozen and 
cut into 400 //, slices on a sledge micro­
tome. It was then stained with eosin and 
hematoxylin and mounted on filter paper 
between layers of cellophane.
Tumours were classified into four con­
tour types: smooth, spiculated, mixed (tu­
mours with both well-defined, smooth and 
spiculated parts to their outline), and con­
glomerate (tumours with a mulberry-like 
appearance).19
Contrary to the reports of others, tu­
mours of smooth contour not only proved 
to be more extensive at the time of primary 
treatment than those that were spicu­
lated,19 but their mortality, at two years, is 
greater than that of other types (Table III).
Immune responsiveness.—The mechanism
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TABLE III.— R e l a t io n sh ip  of C o n t o u r  of 
T u m o u r  (D e f in e d  b y  W h o le  Sectio n s  of the  
B r e a s t ) to Su r v iv a l  a t  Tw o Y ears in  75 P a t ie n t s  
W ith  P r im a r y  C a n c e r  of the  B r e a s t
Contour
Dead at 2 yrs. 
No. ( % )
Spiculated
Smooth
Conglomerate
Mixed
22 36
10 60
25 36
18 33
by which an immune reaction may keep a 
tumour in check is believed to involve 
predominately the small lymphocyte. Fol­
lowing detection of an abnormal antigen 
in the tumour, messenger lymphocytes in­
duce a change in the regional lymph nodes 
by which large pyroninophilic immuno- 
blasts are formed (Fig. 8). These form a
Fig. 8.—Mechanism of immune response to 
“foreign”  tumour antigen.
new progeny of small lymphocytes which, 
being sensitized against the antigen, can 
react against the tumour. In this reaction 
macrophages also may be concerned.
Some have suggested that failure of this 
“reflex” may promote dissemination of 
cancer. Studies are being carried out in 
Cardiff by Dr. M. M. Roberts with Dr. 
W. Jones Williams to test the integrity 
of this mechanism in patients with cancer 
of the breast.20' 21 In the first study, 
she has assessed the ability of patients to 
react to a previously encountered antigen 
by delayed hypersensitivity, and in the 
second, the capacity of the patient’s 
lymphocytes to react in vitro to phyto- 
bemagglutinin, a non-specific but potent 
mitogenic agent.
For the delayed hypersensitivity reac­
tion, streptococcal antigen (Varidase) was 
used in the belief that a large part of the
25
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Fig. 9.—Delayed hypersensitivity response to 
intradermal streptococcal antigen. Response in 
age-matched normal women, patients with benign 
breast disease and patients with breast cancer.
population would have been sensitized 
previously against it. The test consisted of 
the intradermal injection of five units of 
Varidase, with measurement of the result­
ing reaction 48 hours later. Because the 
response in control women was found to 
be related to age, comparisons have been 
made only between women 40 to 70 years 
of age, the most common decades for 
breast cancer. Seventy-six control normal 
women, 58 patients with primary breast 
cancer and 114 with advanced cancer (of 
whom 36 had localized recurrent disease 
only) were within this age group. A signifi­
cant reduction in the ability to respond to 
the streptococcal antigen was observed 
only in patients with disseminated malig­
nancy (Fig. 9). In these patients the 
presence or absence of this response was 
related to survival, those patients with a 
positive reaction surviving for a signifi­
cantly longer time than those in whom it 
was negative (Table IV).
TABLE IV.— C o m pa riso n  o f  Su r v iv a l  o f  47 A g e -  
M a tc h e d  P a t ie n t s  Un d e r  60 Y e a r s  W it h  A d ­
v a n c e d  C a n c e r  o f  the B r e a s t  of D is s e m in a t e d  
T y p e  in  R e l a t io n  to the  R e sp o n se  t o  D e l a y e d  
H y p e r s e n s it iv it y  (P =  0.02)
Delayed hypersensitivity No. of Survival
reaction to Varidase patients (weeks)
Positive 23 47.4 ± 3 2 .4
Negative 24 28.1 ± 2 3 .7
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The technique for determining the 
ability of peripheral lymphocytes to trans­form with phytohemagglutinin is now well 
established. White cells, obtained from the peripheral blood of normal women and pa­tients with breast cancer, were incubated in tissue culture medium, fetal bovine serum and phytohemagglutinin for three 
days, after which they were harvested, stained with aceto-orcein and examined 
microscopically. The transformation rate 
was established by counting the number 
of immunoblasts in at least 500 cells, and 
subtracting from it the number counted in 
control cultures to which no phytohemag­
glutinin was added. All counts were per­
formed in triplicate.The rate of transformation was identical 
in all groups of patients and no difference 
was observed between control women and 
patients with primary or advanced cancer 
of the breast (Fig. 10).
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Fig. 10.—Lymphocyte transformation following exposure to phytohemagglutinin in normal women, and patients with benign breast disease and breast cancer (all ages).
One hundred and two patients between 
the ages of 40 and 70, included in these 
two studies, had both skin and lymphocyte transformation tests (Fig. 11). Again, the 
only difference observed was a reduced response to Varidase in those patients with 
advanced generalized cancer.These studies indicate that, in carefully staged and age-matched patients, evidence of diminished responsiveness (by failure to react to a previously encountered anti­gen) has been observed only in patients 
with disseminated cancer.
Fig. 11.—Comparison of delayed hypersensi­tivity to intradermal Varidase lymphocyte trans­formation in 140 normal women and patients in whom both tests were performed. All were be­tween the ages of 40 and 70 years.
Such tests are artificial and non-specific 
in that they test the reaction of the patient to a foreign antigen and not to her tumour. 
In additional studies, Dr. Roberts is using homogenates of the patient’s own tumour 
to induce delayed dermal hypersensitivity. 
To date, positive reactions have been ob­served in six of the 21 patients with 
primary cancer of the breast who have 
been tested.
Steroid Hormones
Investigations such as I have described are technically simple and can be carried 
out easily by a clinical research assistant. 
Others, such as the estimation of adreno­
cortical steroids, require complex bio­
chemical techniques. In Cardiff we are 
fortunate to be associated with the Teno- vus Institute for Cancer Research, in which 
Drs. K. Griffiths and E. H. D. Cameron 
direct a steroid hormone group.In common with others, we have been 
interested in the work of Bulbrook and 
his colleagues from the Imperial Cancer Research Fund Laboratories which indi­
cated that a discriminant function, based on the relative excretion of etiocholano- lone and 17-hydroxycorticosteroids in the 
urine, is related to the response of patients with advanced cancer of the breast to endocrine surgery.22 These workers re­ported that those patients whose urinary 
discriminant function was negative (i.e. one in which the contribution made by the excretion of etiocholanolone is low) have 
less chance of benefit than those in whom
January 1971 BRUCE MEMORIAL LECTURE 27
Normal: y = 2-6935 * 0-0244x ~ 0-000595 xa 
U J Benign: y *  2 5693 * 0 0449 » 0 00121 x ;
O  y
20 30 40 50 60 70“  BO '*
AG £
Fig. 12.—Relationship of urinary excretion of 
etiocholanolone (log. ftg./24 hrs.) in 21 normal 
women and 63 women with benign breast disease 
(all ages).
it is positive. Recently Atkins et al.,2S have 
reviewed the results of estimating this 
function in 206 patients and found that its 
prognostic value is strengthened if one also 
takes into account the duration of the “free 
period” and the menstrual status of the 
patient.
Although developed primarily to predict 
the response to endocrine surgery, the Bul- 
brook discriminant and the absolute levels 
of urinary steroids on which it is based, 
have also been found to be abnormal in a 
proportion of women with primary cancer 
of the breast in whom it also is of prog­
nostic value.24 Recently it was reported 
that the eight-year survival rates of 71 
patients treated for primary cancer of the 
breast were three times more favourable in 
those with positive than with negative 
discriminants.25
Because we were interested in this pos­
sibility, we have carried out similar 
analyses in 177 women: 21 normal, 63 with 
benign breast disease, 30 with primary 
cancer of the breast and 63 with advanced 
disease.28 To standardize conditions, pa­
tients were admitted to hospital and two 
consecutive 24-hour specimens of urine 
collected. Etiocholanolone, androsterone 
and dehydroepiandrosterone (DHA) were 
estimated by gas chromatography using 
the method of Thomas and Bulbrook27 
modified by the addition of radioactive 
steroids as markers at several stages in the 
assay. Urinary 17-hydroxycorticosteroids 
were estimated by the method of Few28 
but because these did not vary significantly 
they will not be considered further here.
It had been shown by Bulbrook29 that 
the excretion of etiocholanolone decreases 
with age. To establish this relationship in 
our patients, we calculated the best fit for 
the regression of etiocholanolone against 
age in normal patients and those with be­
nign disease. This was parabolic, the ex­
cretion rising to a peak at the age of 38 
to 40 years and thereafter descending in 
linear fashion (Fig. 12). Provided only 
women of 38 years or more are considered, 
linear regression analysis was a valid 
method of comparison between groups. 
When this was done, the excretion of etio­
cholanolone in patients with primary 
cancer of the breast was identical to that 
of normal women and those with benign 
disease. However, significantly lower levels 
were found in patients with advanced 
cancer (Fig. 13).
For some time we have been impressed 
that advanced cancer of the breast, local­
ized to the chest wall or regional nodes, 
behaves differently from that which is 
widely disseminated. Patients with local­
ized disease tend to respond badly to 
endocrine ablation. Further, in a controlled 
randomized trial to determine whether 
early endocrine ablation (90Y implant of 
the pituitary) carried any advantage over 
delaying it until simpler measures had 
been tried, we found that patients with 
localized disease again behaved differently 
from those in whom dissemination has oc­
curred.30 Twenty-one of our 63 women had 
localized and 42 had generalized disease.
When we further analyzed our steroid 
data according to disease type, the group 
that stood out as different from all others 
was that with localized advanced disease 
in which the levels of etiocholanolone 
were significantly less than those in all 
other groups (Fig. 14).
The excretion of androsterone and de­
hydroepiandrosterone behaved similarly.
These results indicate that an abnor­
mality of 17-oxosteroid excretion is present 
only in patients with advanced cancer of 
the breast. This consists of abnormally low 
levels of etiocholanolone, androsterone and 
possibly dehydroepiandrosterone. This 
change was most pronounced in patients 
with advanced localized disease who have 
been noted previously to respond poorly to
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Fig. 13.—Relationship of urinary excretion of etiocholanolone (log. y .g j24 hrs.) to age in normal 
women, patients with benign breast disease, patients with primary breast cancer and patients with 
advanced cancer over the age of 38 years.
endocrine surgery. Patients with primary 
cancer did not show any abnormality of 
steroid excretion.
Endocrine function of tumour—To some 
it may appear that the surgeon has a re­
mote role in these investigations. This is 
far from the truth. Unless there is a strong 
link between the steroid chemist and the 
clinician (who, being responsible for the 
patient, only can assess the clinical situa-
Fig. 14.—Relationship of urinary excretion of etiocholanolone (log. /tg./24 hrs.) to age in normal 
women and patients with benign breast disease and cancer of the breast over the age of 38 years. 
Patients with advanced cancer of the breast have been subdivided into those with localized and 
generalized disease.
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tion), the validity of the results in terms of 
the patient may be open to question.
In certain allied investigations the sur­
geon has an even more vital part to play, 
such as in those which we are carrying 
out to study the ability of human breast 
cancer to metabolize steroids.31 At opera­
tion radioactive precursors (dehydroepi- 
androsterone sulfate, androstenedione and 
testosterone) have been injected into a 
small artery supplying the tumour before 
its removal. The tumour is then homo­
genized and the steroid metabolites are 
characterized. In vitro studies have also 
been carried out in which preparations of 
breast cancer cells have been incubated 
with radioactive steroids. The results of the 
two types of study are in agreement and 
have shown that human breast cancer pos­
sesses the enzyme systems required for 
steroid biosynthesis (Fig. 15). This finding
- 1  ____________ p e rfu s io n
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Fig. 15.—Pathways of steroid biosynthesis de­
fined by incubation and perfusion of breast cancer 
tissue with steroid substrates. This diagram com­
bines the results of incubation and perfusion ex­
periments.
introduces the exciting concept that hor­
mone dependence may be determined by 
the presence or absence of pathways for 
synthesizing growth-promoting steroids at 
tumour level.
C onclusions
In this lecture I have attempted to show 
the ways in which a surgeon has consider­
able responsibility for the advancement of 
knowledge in the field of cancer research. 
I have used as examples work being car­
ried out in Cardiff, but appreciate that 
similar work is going on in your own
centre in Toronto which, largely through 
the efforts of men like H. A. Bruce, has a 
tradition for the investigation and treat­
ment of cancer of the breast. It is only by 
such research that the ultimate goal can be 
reached—the cure of cancer.
“The magnificent achievements of mod­
em medicine . . . have been achieved by 
patient research, by mastery of every con­
ceivable factor in a given situation, even 
those factors which almost defy visibility, 
and by experimentation after experimenta­
tion until a specific remedy has been 
found.”
So wrote Dr. Herbert Brace.
Cancer research demands co-operation and the 
work reported here is that of the Cardiff Breast 
Group. I would like to thank in particular my 
surgical and radiotherapy colleagues (especially 
Drs. C. A. F. Joslin and Vera Jones) without 
whose help and interest these studies could not 
have been made.
The Tenovus Institute for Cancer Research in 
Cardiff, supervised by Drs. K. Griffiths and 
E. H. D. Cameron, was provided and is main­
tained by Tenovus, Cardiff, to whom all of us owe 
a great debt of gratitude.
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R esume
La presente conference inaugurale du Bruce 
Memorial souligne l’importance d’une etroite col­
laboration entre le clinicien et les scientifiques 
d’autres disciplines, dans le domaine des re- 
cherches sur le cancer. La necessite de cette col­
laboration est illustree par des exemples puises 
dans le service de ehirurgie de l’auteur et dans 
les archives du Tenovus Institute for Cancer Re­
search de Cardiff ( Royaume-Uni). On y donne 
notamment les resultats de 1’implantation 
d’yttrium-90 dans l’hypophyse, de hypophysec- 
tomie transethmoi'dale, de la reaction immuni- 
taire et de l’excretion de stero'fdes chez des 
malades souffrant de cancer mammaire. On y fait 
allusion a des travaux sur les fonctions para- 
endocriniennes du cancer mammaire.
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CYSTOSARCOMA PHYLLOIDES (CELLULAR INTRACANALICULAR 
FIBROADENOMA): CLINICAL-PATHOLOGICAL RELATIONSHIPS*
D. B. RIX, M.D., C .R.C,P.[C],t S. J. TREDW ELL, M.D. and 
A. D. FORWARD, M.D., F.R.C.S.[C], Vancouver, B.C.
The prolonged and interesting clinical 
course of a patient referred to one of our 
colleagues with the diagnosis of cysto- 
sarcoma phylloides stimulated our interest 
in this tumour. Cystosarcoma phylloides, 
first described by Johannes Muller in 
1838,1 is a rare tumour which makes up 
2.5% of all fibroepithelial tumours of the 
breast and only 0.3% of all mammary 
neoplasms found among patients admitted 
to a general hospital.2 To be regarded as 
cystosarcoma phylloides, neoplasms must 
contain fibrous and epithelial tissue, and a 
greater degree of stromal cellularity than 
a fibroadenoma. Histologically the stromal 
cellularity distinguishes it from a fibro­
adenoma. Although the tumour has many 
synonyms, e.g. giant fibroadenoma, Brodie’s 
tumour, cystosarcoma phylloides, the cor­
rect name is that established by the World 
Health Organization, viz. cellular intra- 
canalicular fibroadenoma.3
Material and Methods
Norris and Taylor,4 in an excellent re­
view of 94 cases, correlated the clinical 
course with the tumour’s various patho­
logical characteristics such as size, mitotic 
activity, nuclear atypism and contour. 
Using a similar pathological classification 
on 20 cases of cystosarcoma phylloides 
seen at the Vancouver General Hospital 
between 1954 and 1966, we tabulated the 
clinical data from hospital charts and ana­
lyzed it using the following gross and 
microscopic features:
(1) The contour of the tumour periphery 
was divided into pushing or infiltrating 
types on the basis of multiple random 
sections (Fig. 1).
(2) Nuclear atypism was graded as I 
(minimal) to III (maximal) atypism (Fig. 2).
“Presented at the Annual Meeting of the Royal 
College of Physicians and Surgeons of Canada, 
Vancouver, B.C., Jamiarv 1969.
t  Assistant Professor of Pathology, Faculty of 
Medicine, University of British Columbia, Van­
couver, B.C.
(3) Mitotic activity was graded on the 
number of mitotic figures per 10 high- 
power fields determined in the areas of 
greatest mitotic activity (Fig. 2c).
Each tumour was graded separately by 
Drs. Tredwell and Rix and the results were 
compared. When there was a marked dif­
ference, the opinion of another senior path­
ologist was sought. Initially, standard slides 
showing classes I to III atypia were set up 
so that the slides of individual tumours 
could be compared to them. This was 
done so that accurate uniform results 
could be obtained. Initially all slides of 
the tumour were scanned for areas of 
greatest mitotic activity, then these areas 
were counted and the average was taken. 
Unfortunately tumour size was not re­
corded on each patient and therefore this 
important finding had to be dropped from 
our study. We obtained a follow-up in 
every patient either by contacting the doc­
tor or, in some cases, by telephoning or 
writing to the patient directly.
Pathology
Gross
The cystosarcomas varied greatly in con­
sistency, colour and outline. They ranged 
from a hard gritty consistency to soft 
fleshy areas with localized areas of hemor­
rhagic and cystic change. In size they 
ranged from 1.5 to 30 cm. in diameter.
M icroscopic
All cystosarcomas contained an epi­
thelial element and a stromal hypercellu- 
larity that distinguishes them from a fibro­
adenoma. The epithelial elements ranged 
from normal (15 specimens) through 
hyperplasia (2), in situ adenocarcinoma (1) 
to frank adenocarcinoma (2). Stromal com­
ponents showed marked variation within 
a single tumour, ranging from regular fusi­
form fibroblasts to highly anaplastic 
bizarre cells. Myxoid change was seen in
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Fig. la
Fig. lb
Fig. 1.—A cellular intracanalicular fibroadenoma on the right, and breast stroma on the left; the margin contour of the adenoma is (a) pushing and (b) infiltrating (original magnification X 74).
January 1971 CYSTOSARCOMA PHYLLOIDES 33
Fig. 2c
Fig. 2.—(a) Class 1 nuclear atypism of the stroma. Note also the hyperplasia of the ductal epi­
thelium. (b) Class II nuclear atypism of the stroma, (c) Class III nuclear atypism of the stroma. Note 
also the large number of mitotic figures (x  890).
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TABLE I .—-Su m m a r y  op E x p e r ie n c e  W it h  C e l l u l a r  I n tr a c a n a l ic u l a r  F ib r o a d e n o m a  (C IF )
1954 to  1966
Case
no.
Age at 
diagnosis 
(years)
Pre/post 
menopausal
Margin Mitotic 
contour activity
Nuclear
alypism
Size
(cm.)
Survival
(years)
Cause 
of death
i 35 Pre Pushing 3 I 7 X 7 X 7 7.5 CIF
2 36 Pre Pushing 1 I 4 X 3 X 1.5 6.0 Alive
3 37 Pre Pushing 3 I 2.5 X 2.0 8.0 Alive
4 39 Pre Infiltrating 5 II 1 1 X 7 X 6 4.0 CIF
5 40 Pre Pushing 3 II Unknown 3.5 Adenocarcin­
oma of sigmoid
6 41 Pre Pushing 1 I 30 X 30 X 30 13.5 Alive
7 43 Post Pushing 7 III 5 X 4 2.1 Myocardial
infarction
8 50 Post Pushing 2 II 12 X 8 X 8 2.6 Alive
9 57 Post Pushing 3 III 4 X 4 X 4 4.75 Alive
10 58 Post Pushing 2 I 3 X 2 X 4 8.0 Alive
11 58 Post Pushing 2 II 2 X 2 9.2 Adenocarcin­
oma of breast
12 59 Post Pushing 3 I 24 X 19 1.25 Myocardial 
infarction
13 62 Post Infiltrating 5 III 2.5 X 2.5 2.0 Alive
14 65 Post Infiltrating 1 I 4 X 2 X 1 4.6 CIF
15 69 Post Pushing 1 I 3 X 2 12.6 Hip pneumonia
16 70 Post Infiltrating 7 III 12 X 8 X 6 1.1 CIF
17 73 Post Infiltrating 2 II 5 X 5 X 5 12.0 Alive
18 75 Post Pushing 2 I 1.7 X 1.7 4.75 Alive
19 76 Post Pushing 2 II 6 X 6 X 6 2.75 CIF
20 77 Post Infiltrating 7 III 4 X 3 X 2 1.1 CIF
one tumour and heterotopic ossification in 
one other.
Results
Table I gives a summary of the findings 
in our 20 cases. The patients varied be­
tween 35 and 77 years of age; 14 patients 
were postmenopausal. The average age in 
the premenopausal women was 38 years 
and in the postmenopausal, 64 years. The 
overall average age of our patients was 
56 years. The presenting symptom in 19 of 
the 20 was a lump in the affected breast.
In one patient, the lesion was an incidental 
finding on her hospital physical examina­
tion. Eleven of the 20 tumours were in the 
left breast and nine were in the right. Two 
patients gave a history of recent increase 
in size and complained of significant pain.
Survival D ata
Eleven patients died, six from their dis­
ease (Table II) giving a 30% mortality 
rate. Nine of these patients are alive, five 
having survived five or more years after 
initial treatment.
TABLE I I .—Sum m ary of P a t ie n t s  D y in g  o p  C e l l u l a r  I n tr a c a n a l ic u l a r  F ibr oa de n o m a
Histologic criteria 
at time of diagnosis
Case Age Initial Local Second Size Margin Nuclear Mitotic nival
no. (years) treatment recurrence treatment (cm.) contour alypism activity (years)
i 35 Excision
biopsy
X 3 (1) Radical 
mastectomy
(2) Chemotherapy
7 X 7 X 7 Pushing I 3 7.5
4 39 Excision
biopsy
X 2 (1) Radical 
mastectomy
(2) Chemotherapy
1 1 X 7 X 6 Infiltrating II 5 4.0
14 65 Excision X 2 Extended I 1 4.6biopsy radical
mastectomy
4 X 2 X 1 Infiltrating
III 1.116 70 Simple — (1) Radiation 1 2 X 8 X 6 Infiltrating 7
mastectomy (2) Chemotherapy
II 2.7519 76 Simple
mastectomy
— Radiation 6 X 6 X 6 Pushing
Infiltrating
2
III 1.120 77 Simple X 1 Resection of 4 X 3 X 2 7
mastectomy recurrence
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TABLE I I I .  S ummary op Local R e c u r r e n c e  o f  C e l l u l a r  I ntracanalicular  F ib r o a d en o m a . 
N ote T en d e n c y  T owards I n c rea se  in  H isto lo g ic  A g g r e ssiv e n e ss  o f  R e c u r r e n t  T u m o u rs
Original tumour— Recurrence
Case
no.
Size
{cm.)
Initial
treatment
Second
treatment
i 7 X 7 X 7 Excision biopsy
Excision X 3
Radical
mastectomy
2 4 X 3 X 1.5 Excision biopsy
Excision X 3
Simple
mastectomy
4 11 X 7 X  6 Excision biopsy
Excision X 1
Radical
mastectomy
10 2 X 3 X 4 Excision biopsy
Excision X 1
Simple
mastectomy
14 4 X 2 X 1 Excision biopsy
Excision X 1
Radical
mastectomy
20 4 X 3 X 2 Simple
mastectomy
Excision X 1 
Resection of 
recurrence
Margin
contour
Pushing
Pushing
Infiltrating
Pushing
Infiltrating
Infiltrating
Mitotic activity Nuclear atypism
Re- Re-
Initial currence Initial currence
3
1 ->  3
5------------- >  7
2 -► 3
1-----------------* • I
7
I
I ---------- ► I I I
I I ---------- >  II
I---------- *  II
I---------- >  I I I
I I I
C o rrela tio n  o f  P athological
F ea tu res W it h  Su rvival D ata
Various pathological features such as 
contour of tumour, cellular atypism and 
mitotic activity were correlated with the 
clinical course of the tumour. Although 
the number in this series is too small to 
be statistically significant, it soon became 
apparent that increasing prominence of the 
following features—infiltration, high degree 
of nuclear atypism, or mitotic activity, in­
dicated a poor prognosis. This relationship, 
demonstrated in Table III, parallels the 
results obtained by Norris and Taylor4 in 
their analysis of 94 cases.
One of our patients demonstrates the as­
sociation of pathological changes and 
prognosis clearly.
cision biopsy the mass was 4 x 3 x 1.5 cm. 
and, after pathological examination, was de­
scribed as a “cellular fibroadenoma”, but 
“cystosarcoma phylloides” was offered as an 
alternative diagnosis.
The patient returned again in June 1968 
because she again had a slowly enlarging 
mass in her right breast. The large lobular 
mass was not fixed and we detected no nipple 
discharge and no palpable lymph nodes. On 
June 24, 1968, a simple mastectomy was per­
formed. Microscopically the 6-cm. firm 
pinkish-white nodular mass was described as 
a cellular intracanalicular fibroadenoma (cysto- 
sarcoma phylloides). The patient was dis­
charged on the fifth postoperative day.
Review of all her microscopic slides since 
1962 clearly demonstrates the increasing ag­
gressiveness of this slowly growing tumour.
Mrs. S.S. (Case 2, Table I), a 36-year-old 
woman, was first admitted to the surgical 
service at Vancouver General Hospital in 
September 1965. She had had biopsies of her 
right breast in 1956, 1962 and 1964, the last 
two of which were reported as “fibroadeno- 
mata of a cellular nature”. When seen in 
1965, she gave a nine-month history of a 
slowly enlarging mass in the right breast. She 
had a firm mass in the outer lower quadrant 
of the right breast, which was not fixed to 
the chest wall. There were no palpable nodes 
in the axilla or supraclavicular fossa. On ex­
Year
Margin
contour
Nuclear
atypism
M itotic
activity
1962 Pushing Class I Grade 1
1964 Pushing Class I Grade 1
1965 Pushing Class II Grade 3
1968 Pushing Class III Grade 3
T h er a py
Initially these 20 patients were treated 
by various means—chiefly simple mastec­
tomy, radical mastectomy and simple ex­
cision.
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Table III summarizes the frequency of 
local recurrence of these cellular intra- 
canalicular fibroadenomas. The lesion re­
curred in six patients (30%). Five of the 
six were treated by excision only and in 
four of these five the recurrent tumour 
showed evidence of an increasing aggres­
siveness when examined histologically. 
Even a low-grade cystosarcoma phylloides 
has a tendency to recur until it is com­
pletely removed, as in Cases 2 and 10.
When cystosarcoma phylloides does 
metastasize, it spreads like other sarcomas 
by the blood stream, chiefly to the lung5 
as in the following case.
Mrs. A.B. (Case 20), a 77-year-old woman, 
was admitted to the Vancouver General Hos­
pital in May 1957, because of a swelling in 
the left breast of several months’ duration. 
The breast was enlarged by a diffuse mass 
that showed no fixation, ulceration or nipple 
discharge. On May 2, 1957, after a left simple 
mastectomy, pathological examination re­
vealed a cellular intracanalicular fibroadenoma 
(cystosarcoma phylloides), a scirrhous adeno­
carcinoma and evidence of metastases of the 
adenocarcinoma to three lymph nodes in the 
axillary tail of Spence. After postoperative 
irradiation she was discharged on June 7, 
1957, on her thirty-sixth postoperative day. 
By November 1959, chest films revealed wide­
spread metastatic lesions in both lung fields 
suggestive of sarcoma. She died on November 
28, 1959, three weeks after her final admis­
sion and 30 months after her original opera­
tion.
At autopsy, both lungs contained extensive 
metastases that varied in consistency from soft 
and fleshy to hard and bony. She also had 
metastases over the pleural surface, dia­
phragm, peritoneum, liver and in the left 
humerus. On histologic examination these 
metastatic deposits were cystosarcoma phyl­
loides. We found no evidence of the previ­
ously reported mammary adenocarcinoma.
D iscu ssio n
Our small series of 20 tumours demon­
strates that cystosarcoma phylloides is too 
variable to classify on the basis of one 
histologic feature alone. However, the cri­
teria described in this paper permit us to 
make some prediction of this tumour’s 
tendency to metastasize. All are malignant 
to some degree and hence will recur unless
completely removed. When they do meta­
stasize, they spread by the blood stream 
chiefly to the lung. Generally in our series, 
the survivors were younger women with 
lower grades of mitotic activity. Simple 
mastectomy was the treatment of choice.
In Norris and Taylor’s series only three 
of 94 tumours went to axillary lymph 
nodes and of these, only one was proved 
histologically. In our series of 20 cysto­
sarcoma phylloides, none spread to lymph 
nodes; however, they did spread locally 
and deeply. Our experience suggests that 
the treatment of choice is an adequate 
simple mastectomy, i.e. complete removal 
of breast tissue with or without a skin graft. 
In evaluating the possibility of metastases, 
the most important histologic feature is 
the mitotic activity. Other studies of soft- 
tissue fibrosarcomas and uterine smooth- 
muscle tumours also have demonstrated a 
direct relationship between mitotic activity 
and metastases.
S u m m a r y
Twenty patients with cellular intra­
canalicular fibroadenoma (cystosarcoma 
phylloides) were seen at the Vancouver 
General Hospital and at the British 
Columbia Cancer Institute over a 13-year 
period from 1954 to 1966.
All tumours were graded histologically 
on the basis of contour, cellular atypism 
and mitotic activity, and the results of this 
assessment were compared to the patient’s 
clinical course. These features—contour, 
atypia and mitotic activity—have prog­
nostic value because they indicate the tu­
mour’s potential to metastasize.
All cellular intracanalicular fibroade­
nomas should be treated as sarcomas of 
varying degrees of malignancy. The best 
initial therapy of these patients appears to 
be simple mastectomy with or without skin 
grafting.
The authors wish to express their thanks to 
Dr. F. R. C. Johnstone for his interest which en­
couraged this study.
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R esume
Nous avons etudie, chez 20 femmes souffrant 
de cette tumeur, les constatations cliniques et 
pathologiques dans le but de tenter d’etablir un 
lien entre les constatations pathologiques et le 
comportement clinique. L ’age moyen de nos 
malades etait de 56 ans et le symptome principal 
etait une “bosse” dans le sein affecte. La fre­
quence des recidives etait de 30%. Onze de nos 
malades sont mortes, dont six de leur maladie, ce
qui donne un taux de mortalite de 30%. Neuf 
femmes sont encore vivantes, dont cinq ont 
survecu au moms cinq ans a la premiere opera­
tion.
Les conclusions de notre etude rejoignent celles 
de Norris et Taylor (C an cer , decembre 1967) 
notamment sur le fait qu’aucune caracteristique 
pathologique n’est assez significative pour preciser 
la nature agressive de ces tumeurs. II est cepen- 
dant possible de se faire une idee de leur poten- 
tiel metastatique en leur appliquant divers cri- 
teres pathologiques.
Le traitement ideal est la mammectomie simple, 
parce que la tumeur se propage principalement 
par le courant sanguin. Nous n’avons decouvert 
aucune metastase dans les ganglions lymphatiques. 
Selon la gradation pathologique de la tumeur, 
il peut etre nccessaire de pratiquer une mam­
mectomie plus radicale.
Nous conseillons de proceder precocement a la 
gradation pathologique de tous les cas de cysto- 
sarcome phyllode, de fagon a leur appliquer 
d’emblee le traitement chirurgical convenable.
PERIN EAL WOUND HEALING IN 
ULCERATIVE COLITIS
The perineal part of rectal excision has 
changed little since abdominoperineal excision 
for carcinoma of the rectum and terminal 
portion of the pelvic colon was first per­
formed in 1908. Initially, partial suture with 
open drainage was done, but later (1926) 
the perineum was packed. The authors, and 
others, believe that defective healing of the 
perineal wound is much more common after 
radical operation for ulcerative colitis and 
Crohn’s disease than after abdominoperineal 
resection for cancer of the rectum. This paper 
analyzes the results in 106 patients with ulcer­
ative colitis to assess the factors, both sys­
temic and local, which appear to influence 
healing. The authors arbitrarily defined a 
perineal sinus as a “perineal wound which has 
remained unhealed for more than six months 
after operation”. They noted that only 44% 
were completely healed in less than six 
months, and 7% were still not healed after two 
years.
Age at the time of operation did not appear 
to have a significant influence on healing time. 
Women in whom packing had been used had 
a significantly higher incidence of perineal 
sinus. When the perineum was sutured, there 
was no difference between men and women. 
Healing was delayed in patients who pre­
sented during the first attack of the disease,
that is, within six months of the onset of their 
symptoms. This study failed to confirm the 
findings of others that a long history of the 
disease increased the incidence of perineal 
sinus.
Preoperative complications such as stricture, 
pseudopolyps, or toxic dilatation, did not in­
fluence the healing rate. In this series, pre­
operative steroids did not, to any significant 
extent, affect the incidence of sinus formation. 
Sepsis in the perineal wound, seen as a frank 
purulent discharge in the early postoperative 
period, was associated with defective healing 
and packing appeared to increase wound 
sepsis. Local instillation of antibiotics did not 
affect the occurrence of early postoperative 
sepsis. Recently the perineum has been closed 
with the use of suction drainage led out from 
a sacral hollow via laterally placed stab in­
cisions. This method is an improvement, but 
40% of these wounds still failed to heal com­
pletely within six months.
The recent use of an omental pedicle graft 
to fill the dead space is technically easy and 
may prove a valuable addition to perineal 
suture. Wound healing differs in patients with 
carcinoma (sinus formation is rare). After 
ulcerative colitis, the inflammation may pre­
dispose to defective wound healing. Further 
research into the type of wound healing in 
colitis and the diseases of this nature should 
prove rewarding.—Jalan KN, Smith AN, Ruck- 
ley CV, et al: Perineal wound healing in ulcer­
ative colitis. Brit J  Surg 56: 757, 1969
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BONE AND SKELETAL BLOOD FLOW IN MAN MEASURED 
BY A RADIOISOTOPIC METHOD0
SUN-SHIK SHIM, M.D., M.Sc., Ph.D., F.R.C.S.[C], F.A.C.S.,
S. MOKKHAVESA, M.D., C.M., G. D. McPHERSON, M.D., M.Sc., F.R.C.S.[C] and 
J. F. SCHWEIGEL, M.D., F.R.C.S.fC], Vancouver, B.C.
At  present, no satisfactory method exists 
for measuring the rate (volume/time) of 
bone-blood flow. Consequently little is 
known about the rates of individual bone 
and skeletal blood flow in man. Several 
groups of workers measured the rates of 
bone-blood flow in animals by indirect 
methods using radioisotopes such as 85Sr, 
47Ca and 8GRb. Available data indicate that 
blood flow of various bones in the rat, 
rabbit and dog ranges between 5 and 20 
c.c./min./lOO g. of wet bone. The entire 
skeletal blood flow in these animals is 
about 4%  to 10% of the resting cardiac 
output. Kane,1 Kelly2 and Shim3 recently 
reviewed this subject.
This paper has two aims: (1) to describe 
an indirect method of bone-blood-flow 
measurement in man based on the bone 
clearance from blood of a bone-seeking 
radioisotope; and (2) to report the rates of 
blood flow in various bones including the 
cortical, cancellous, long and short tubular 
bones in man. This appears to be the first 
report of blood-flow measurement of many 
bones in man.
T he Problem
Obviously, we cannot measure directly 
the blood flow of any bone in man and 
animals because this would require the 
cannulation of a vessel, and any one bone 
has many small arteries and veins. Al­
though Shim and Patterson1 have used a 
direct method in animals to evaluate rela­
tive changes in blood flow of bone, it can­
not be applied to many bones and it does 
not give a measure of total blood flow in 
any bone. The direct method is unsuitable
“From the Division of Orthopedic Surgery, Uni­
versity of British Columbia and the Vancouver 
General Hospital, Vancouver, B.C.
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because the cannulation of any vessel of a 
bone requires considerable surgical mani­
pulation in the surrounding soft tissues and 
even then the blood flow through the can- 
nulated vessel is only a small fraction of 
the total blood flow of the bone because 
many other vessels sustain the same bone.
The necessity of an indirect method of 
bone-blood-flow measurement has been 
realized for a long time. Edholm, Howarth 
and McMichael5 in 1945 used venous oc­
clusion plethysmography for this purpose. 
In the light of our knowledge of plethys­
mography and of the circulatory anatomy 
and physiology of bone, it is hard to con­
ceive that plethysmography could give re­
liable bone-blood-flow measurement. Matu- 
moto and Mizuno6 developed an indirect 
method based on clearance of a radiopaque 
dye; the dye is injected into bone and, 
using a theoretical exponential correlative 
curve, the clearance rate is converted to 
blood flow.
A more generally applicable and reliable 
indirect method must be developed if we 
are to measure the total blood flow of 
many individual bones in different species 
under varying conditions. The method 
must be based on sound principles, and 
its validity, general applicability and use­
fulness must be proved. Copp and Shim,7 
and Shim, Copp and Patterson,8 described 
such a method and applied it in a number 
of studies.911 Their method is based on the 
clearance of a circulating bone-seeking 
radioisotope, e.g. 85Sr or 47Ca, and uses an 
adaptation of the Fick principle originally 
proposed by Frederickson, Honour and 
Copp.12 Kelly,2 and Ray, Aouad and 
Galante13 also studied this method.
White, Ter-Pogossian and Stein14 pro­
posed another indirect method based on a 
dilution principle using 51Cr-tagged red 
blood cells. Van Dyke et al.15 showed that 
blood flow of bones could be measured by 
studying the uptake of radiofluorine with 
a positron camera. More recently, Kane1
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proposed another indirect method based 
on bone clearance of circulating 42K and 
86Rb. All of these indirect methods using 
radioisotopes have their advantages and 
limitations. The major advantage all these 
methods have is their general applicability 
to many bones in animals, whereas they 
are all impracticable in man because the 
bone must be removed from the body to 
measure the blood-flow rate. However, 
these methods can be used in man when 
a limb is amputated, a bone biopsied, or 
an operation done on bone.
M aterial and Method
We measured the blood flow of various 
bones in the lower extremity in a 26-year- 
old man just before a high-thigh amputa­
tion for osteogenic sarcoma of the distal 
femoral metaphysis without any known 
metastasis. Under general anesthesia, with 
the patient in a supine position, two 
readily inflatable tourniquets were applied 
above and below the level of amputation 
through the upper thigh. A branch of the 
dorsalis pedis artery was cannulated with 
a fine polyethylene tube to collect the 
dripping blood continuously to determine 
the average isotope concentration in the 
arterial blood. Then, after a percutaneous 
puncture in the femoral triangle, 100 /xc. 
of radioactive strontium (85Sr) was slowly 
injected over 1% minutes into the ipsi- 
lateral femoral artery. After five seconds 
transit time was allowed, the dripping 
arterial blood collection was begun. At the 
end of three minutes the two tourniquets 
were instantaneously inflated and the 
blood collection was stopped. Then a high- 
thigh amputation was done between the 
two tourniquets and all bones below the 
knee of the amputated limb were removed 
and weighed, after the soft tissues were 
completely removed.
The rates of blood flow of these bones 
were calculated as follows: the collected 
blood was mixed well and an average 
radioactivity for 1 c.c. blood was measured 
using a gamma scintillation counter.® The 
background count of the open well was 
70 counts/min. (cpm), and the standard 
error of the count was 1%. The average
0 Auto well II, Picker Nuclear, White Plains, N.Y.
radioactivity of 1 c.c. blood with the back­
ground count correction was 9728 cpm. By 
Using the same equipment and open well, 
radioactivity of each bone for the three- 
minute uptake was measured and this was 
divided by three to give the one-minute 
bone uptake of the isotope by each bone.
Finally, the rate of blood flow of each 
bone, as its 83Sr clearance, was calculated 
by dividing the one-minute bone uptake 
by the 1 c.c. arterial blood radioactivity. In 
the calcaneus, for example, the one-minute 
bone uptake was 16,926 cpm. Dividing this 
by the 1 c.c. arterial blood radioactivity, 
9728 cpm, gives the rate of blood flow of 
the calcaneus as 1.74 c.c./min.
TABLE I .—R ates o f  B lo o d  F l o w  o f  V a r io u s  
B on es  in  a  M a n
Rale of blood flow 
(c.c./min.)
Weight Per 100 g.
Bones (?•) Per bone wet bone
Patella 35 2.44 6.97
Tibia 516 12.33 2.47
Fibula 125 1.75 1.32
Calcaneus 120 1.74 1.40
Talus 65 1.00 1.54
Navicula 20 0.44 2.20
Cuboid 25 0.58 2.32
3 cuneiforms 
Metatarsals:
35 0.92 2.63
First 43 1.28 2.98
Second 30 0.74 2.44
Third 30 0.48 1.58
Fourth 26 0.37 1.50
Fifth 25 0.42 1.68
Great toe 15 1.03 6.87
Other toes 20 1.90 5.45
TOTAL 1130 27.42 2.43
(Average)
Results
The results are summarized in Tables I 
and II. In Table I the rates of blood flow 
of all bones in the limb below the knee, 
including the patella, are shown in two 
ways: that per minute per individual bone 
weight, and that per minute per 100 g. wet 
bone.
T A B L E  II.—E stim a t e d  E n t ir e  S k e l e t a l  B lo o d  
F l o w
Body weight of the man 65 kg.
Skeletal weight (15% of body weight) 9.75 kg. 
Cardiac output 5.0 1.
Rate of blood flow of bone (min./lOO g.) 2.43 c.c.
Rate of skeletal blood flow per minute 237 c.c. 
As of cardiac output 4.74%
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D iscussion
To date we have no satisfactory method 
of measuring bone-blood flow in man and, 
hence, have little information on the rates 
of blood flow of bones and skeleton. Sev­
eral groups of workers have introduced in­
direct methods of bone-blood-flow meas­
urement in animals using radioisotopes, 
and reported reliable and comparable data 
on the blood flow of various bones. The 
radioisotopic method for use in man, de­
scribed in this study, which is a modifica­
tion of a method described earlier by 
Copp and Shim,7 and Shim, Copp and Pat­
terson,8 is based on the bone clearance of 
circulating bone-seeking radioisotopes. 
Used in several studies of bone-blood-flow 
rates in animals, this appears to be the 
first description of its application in man.
Most bones have comparable rates of 
blood flow—between 0.5 and 2.5 c.c./min./ 
actual weight of individual bone—except 
the tibia, the largest and heaviest bone 
studied, whose rate of blood flow was 12.33 
c.c./min. for 516 g. Blood-flow rates calcu­
lated on the basis of 100 g. bone are better 
for comparison because the size and 
weight of bones vary greatly. In this way, 
we found that, regardless of the size and 
weight of the bones, the flow rates are in 
the range of 1.5 and 3.0 c.c./min./100 g. 
wet weight, except for the patella and 
phalanges whose rates are between 5.5 and 
7.0 c.c./min./100 g.
The total weight of the bones in our 
patient’s limb was 1130 g. and the total 
blood flow in these bones was 27.42 c.c./ 
min. The rate of blood flow of the average 
bone was 2.43 c.c./m in./100 g. wet weight.
Taking the blood flow in 1130 g. bone as 
27.42 c.c./min., the skeletal weight as 9.75 
kg. (15%  of the body weight—65 kg.) and 
the cardiac output as 5 l./min., the rate 
of blood flow of the skeleton was estimated 
as 237 c.c./min. or about 4.7% of the 
cardiac output (Table II).
In this study, the rates of blood flow of 
various bones in man are quite comparable 
to each other. However, the average rate, 
2.43 c.c./m in ./100 g. bone, is somewhat 
lower than the rates in the rat, rabbit and 
dog measured by the same method and by 
other methods. Frederickson, Honour and 
Copp12 calculated that the blood flow in
the bones of the rat was 10 to 30 c.c./min./ 
100 g. bone. The values obtained by Shim, 
Copp and Patterson8 in 270 bones of 80 
rabbits were 9.60 ±  3.28 c.c./m in./100 g. 
bone, and the values in 46 bones in 10 
dogs were 10.15 ±  4.12 c.c./min./100 g. 
bone. The value obtained in the dog by 
Ray, Aouad and Galante13 using a similar 
method was about 5.0 c.c./min./lOO g. 
bone, and by Weinman et al.16 in mature 
dogs was 5.6 c.c., and in immature dogs 
was 7.7 c.c./min./lOO g. bone. Kane1 ob­
tained higher values in dogs, 16 c.c./min./ 
100 g. bone, using a different isotopic 
method.
Ray, Aouad and Galante13 and Copp 
and Shim7 found that the bone extraction 
rates of 85Sr and 47Ca (the efficiency with 
which bone took up these isotopes from 
blood passing through it) were 50% to 
75% in the first five to 10-minute period. 
With 86Rb and 42K, Kane1 observed ex­
traction rates in the dog’s tibia as high as 
95% in the first minute. These findings 
indicate that the blood-flow rate measured 
by the bone clearance of 85Sr or 47Ca 
represents only 50% to 75% of the actual 
blood-flow rate. Thus, if the values ob­
tained by Ray, Aouad and Galante,13 
Weinman et al.16 and Shim, Copp and 
Patterson8 are corrected for the extraction 
efficiency of bone, the values compare well 
with those obtained by Kane.1
In this study the average rate of blood 
flow of various bones in a young man was 
2.43 c.c./min./lOO g. bone. Corrected for 
the 85Sr extraction rate of 50% to 75%, the 
true blood-flow rate would become 3.23 
to 4.86 c.c./min./lOO g. bone.
When the estimated skeletal-blood-flow 
rate of 237 c.c./min. or 4.7% of the resting 
cardiac output is corrected for the 85Sr 
extraction rates (75% ), the actual blood- 
flow rate of the skeleton would be 6.25%
TABLE III.— Sk e l e t a l  B lood  F lo w  E stim a t e d  
as  P e r c e n t a g e  op R estin g  C a rd ia c  O u t p u t
% Author
Rat 4.3 Van Dyke et <d.u
Rabbit 7.1 ±2 .3  Shim, Copp and Patterson8
Dog 7.3±3.0 Shim, Copp and Patterson8
3.5— 9.4 Ray, Aouad and Galante13 
Mature 5.0— 7.0 Weinman et al.16
Puppy 8.0— 10.0 Weinman et al.w)
Man 4.7— 6.3 Shim et al. (this paper)
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of the resting cardiac output. As shown 
in Table III, all values agree well with the 
data obtained in the rat, rabbit and dog.
Su m m ar y
A method of radioisotopic measurement 
of blood flow of bones in man is described. 
The method is based on the bone’s clear­
ance of a bone-seeking isotope from blood.
The blood-flow rates of various human 
bones (cortical and cancellous, and long 
and short tubular bones) were measured. 
This appears to be the first report of blood- 
flow measurement of many bones in man.
The total weight of all the bones below 
the knee was 1130 g. and the total blood- 
flow rate in these bones was about 27.5 
c.c./min. The rates of blood flow of various 
individual bones were similar—an average 
of 2.5 c.c./m in./100 g. wet bone. The rate 
of the blood flow of the entire skeleton 
was estimated as about 250 c.c./min.— 
about 5%  of the resting cardiac output.
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R esum e
Le present article decrit une methode de 
mesure indirecte de la circulation sanguine dans 
1’os et indique le debit ( volum e/tem ps) de la 
circulation dans divers os chez Thomme ( os tubu- 
laires, longs et courts, os spongieux, cortex). Ce 
rapport est, semble-t-il, le premier du genre sur 
le sujet. La methode utilisee est basee sur l’epura- 
tion par le sang a partir de 1’os d’une substance 
isotopique osteotrope ( “ Sr). Elle a etc appliquee 
a un jeune homme souffrant d’un sarcome osteo- 
gene et chez lequel on a mesure le debit circula- 
toire dans tous les os de la jarnbe, au moment de 
l’amputation. A cet effet, on a introduit une sonde 
en polyethylene dans l’artere pedieuse. On a place 
deux tourniquets sur la cuisse, mais sans les 
gonfler. On a injecte par ponction porcutanee 
environ 100 microcuries de “ Sr dans l’artere 
femorale homolaterale et on a recueilli le sang 
de l’artere pedieuse pendant les trois premieres 
minutes jusqu’au moment ou les deux tourniquets 
ont etd instantanement gonflds. On a alors ampute 
la cuisse entre les deux tourniquets. Tous les os, 
sous forme de son operation en “ Sr, on a divise 
la captation d’isotope de chaque os par la radio­
activity ernise par 1 c.c. de sang de Tartere 
pedieuse. Le debit circulatoire a etc a peu pres 
semblable dans tous les os. le debit moyen ayant 
etd evalue a 2.5 c.c./min/lOO g  d’os humide. On 
a evalue a environ 250 c.c./m in  le debit de la 
circulation sanguine dans la totalite du squelette, 
ce qui represente 5% du debit du coeur au repos 
chez Thomme.
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RADIOGRAPHIC CONFIRMATION OF SITE OF CENTRAL VENOUS
PRESSURE CATHETERS*
MERVYN DEITEL, M.D., F.R.C.S.[C] and 
J. A. McINTYRE, M.D., F.R.C.S.[C], F.A.C.S., Toronto, Out.
C en tr a l  venous pressure (CVP) is used 
widely to monitor intravenous replacement 
in shock states112 and in the elderly cardiac 
patient.1317 In addition, a central vein 
catheter is being used for long-term intra­
venous hyperalimentation in nutritionally 
depleted patients.18"24 In each of 245 con­
secutive central venous catheter insertions 
at St. Joseph’s Hospital, Toronto, a chest 
radiograph was done to check the location 
of the catheter tip. The study included all 
surgical patients with central venous 
catheters, and patients with these catheters 
from all services in the intensive care and 
shock unit. The catheters were inserted 
by the various doctors on these services. 
Most roentgenograms were done by port­
able anteroposterior technique at the bed­
side. In 71 radiographs (28.98%) the 
catheter tip was found to be in an incorrect 
location.
M a lpo sitio n s
Catheters Introduced Via Arm Veins
Fig. 1 shows the positions where cath­
eters introduced via an arm vein most 
commonly lodge. If the plastic catheter 
has a slight curve, it may drive upwards 
into one of the veins draining the neck, 
and frequently passes into the ipsilateral 
internal jugular vein (Fig. 2). When this 
occurred in our series, the catheter was 
partially withdrawn under sterile condi­
tions, twisted slightly, and on reinsertion 
passed readily into the superior vena 
cava. This malposition could often be 
prevented by turning the patient’s head 
to the side on which the catheter was 
being introduced; this caused the internal
“ From the Department of Surgery, St. Joseph’s 
Hospital and the University of Toronto, Toronto, 
Ont.
Supported by a grant from St. Joseph’s Hospital 
Research Foundation and Abbott Laboratories 
Ltd.
Reprint address: Dr. M. Deitel, St. Joseph’s Hos­
pital, 30 The Queensway, Toronto, Ont.
Fig. 1.—Solid line shows the correct location 
with the catheter tip in the superior vena cava. 
Broken lines show the catheter lodged in the in­
ternal or external jugular veins.
jugular vein to meet the subclavian vein 
at an acute angle.
In one patient, a catheter that had been 
introduced through the cephalic vein just 
above the elbow entered and became 
wedged in veins over the shoulder, an­
terior and superior to the clavicle, where 
it was palpable subcutaneously; this 
catheter gave a falsely elevated reading. 
Catheters introduced via the cephalic vein 
in the arm could rarely be made to tra­
verse the subclavian vein because the tip 
abutted on the inferior wall of the sub­
clavian vein.
In another patient the catheter kinked 
back on itself (Fig. 3) giving a marked 
and falsely elevated CVP. When the 
catheter was withdrawn, slightly twisted 
and reinserted, it readily passed to a satis­
factory location.
In one patient the catheter lodged in the 
right ventricle and gave a high manometer 
reading. In three patients the catheter 
curled up in the right atrium (Fig. 4), a 
position that has produced cardiac 
arrhythmias by contact stimulation in the 
region of the tricuspid valve.25 These 
catheters were withdrawn the proper dis­
tance.
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Fig. 2b
Fig. 2.—The most common malposition, (a) Catheter high up in the neck, associated with an in­
correctly elevated manometer reading, (b) Acute bend taken by a catheter (arrow points to the tip).
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Fig. .3.— Catheter is kinked and has not entered thorax (see inset).
Catheters Introduced Via External 
Jugular Vein
A catheter passed down the external 
jugular vein frequently travels laterally 
through the subclavian vein towards the 
arm (Fig. 5). Whether this happens de­
pends on the angle of entry of the external 
jugular vein into the subclavian vein; this 
is variable and is often in a lateral direc­
tion. Hold-up here can often be corrected 
or prevented by turning the patient’s head 
to the same side as the catheter as it is
being repositioned. When the catheter in­
troduced via the external jugular vein 
enters the thorax, it must bend medially 
(Fig. 6).
In Fig. 7, the catheter inserted into the 
external jugular vein entered the trans­
verse cervical or suprascapular vein 
superior to the clavicle. The catheter may 
occasionally kink back on itself (Fig. 8).
Catheters Introduced Via Subclavian
Puncture
When a catheter has been inserted via 
percutaneous, subclavicular, subclavian 
puncture, one would assume that the 
catheter had passed down into the superior 
vena cava. However, in this series, routine 
films occasionally showed that the catheter 
had entered the internal jugular vein and 
had passed well up into the neck (Fig. 9). 
If the catheter is carefully withdrawn, 
slightly twisted, and reinserted under 
sterile precautions, the tip may still pass 
into the superior vena cava, especially if 
the head is turned towards the same side 
as the puncture. Pressure above the clavicle 
while the catheter is being threaded in, 
will inhibit its passage up into the neck.
Infrequently in this series the catheter
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Fig. 5a
Fig. 5b
Fig. 5.—(a) Catheters introduced into the external jugular vein frequently pass laterally to­
wards the arm. (b) Catheter advancing down the external jugular vein may halt when the tip abuts 
against the inferior rim of the subclavian lumen.
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Fig. 6.—As the external jugular catheter enters the thorax, it bends medially-
had curled in the internal jugular vein 
(Fig. 10) or innominate vein (Fig. 11).
When taking the radiograph after sub­
clavian puncture, we abduct the arm, 
thereby elevating the clavicle so that it 
will not overlie and obscure the catheter 
on the film (Fig. 12).
R esults
D iscussion
Fig. 13 shows the venous system drain­
ing into the upper thoracic area and the 
many abnormal routes these catheters can 
take.
The lumen of a catheter that is wedged 
or kinked may close so that, when filled, 
the manometer column does not fall to its
Table I summarizes our total experience. TABLE I.— C e n t r a l  V en o u s  C a t h e t e r s : 
R e su l ts  o f  245 In se r t io n s
Site of No. of
introduction insertions Malpositions
Arm vein*...........  137 38f
External
jugular vein........  28 14
Subclavian vein
puncture.............. 79 19f
Cephalic vein
cutdown§............  1 0
Total 245 71
‘ Includes seven introductions through the cephalic 
vein, with only one successful. 
fThe malposition occurred twice in four patients. 
fOne patient had three malpositions after sub­
clavian punctures.
§In the deltopectoral groove.
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Fig. 8.—Our routine radiograph showed the external jugular catheter kinked, entering a medial 
branch (see inset).
proper level or fluctuate with respiration. 
When the catheter enters small veins, 
venous resistance, venospasm, the impe­
dance of valves, or external pressure by
skeletal muscle produces an incorrectly 
high CVP. These pressures are often m ore 
than twice the actual value and are as­
sociated with lessened fluctuations with
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Fig. 10b
Fig. 10.—(a) Catheter curled. Hypaque (sodium diatrizoate) injection demonstrates the catheter 
bulging the internal jugular vein, (b) Catheter looped in the internal jugular vein.
respiration. Such venous catheters are less 
sensitive to changes in effective blood 
volume and cardiac function.
To avoid thrombophlebitis in peripheral
veins, these abnormal positions must be 
avoided when hypertonic, high-caloric 
solutions of protein hydrolysates and sugar 
are infused over a long period. In patients
January 1971 SITE OF CVP CATHETERS 49
Fig. 12.—Abducting the arm during roentgenography will raise the clavicle off the catheter for 
better detail. (Vertical opaque line is on a chest-tube.)
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Fig. 13.—Venous system draining into the upper thorax. (CVP catheter is inserted through the 
basilic vein.)
Fig. 14.—Although blood had been aspirated through the syringe during introduction, routine 
radiograph disclosed infusion entering the mediastinum.
January 1971 SITE OF CVP CATHETERS 51
on intravenous hyperalimentation we have 
used central vein catheters inserted via the 
arm for 25 days or, more commonly, via 
subclavian puncture for more than 30 days 
at a time without complications.
In one patient who had a subclavian 
puncture intended for infusion of hyper­
tonic solutions, although blood had been 
aspirated before the catheter was threaded 
in, the radiograph disclosed the infusion 
entering the mediastinum (Fig. 14). No 
problem resulted because, until the radio­
graph had been made, only normal saline 
had been infused: the catheter was re­
moved at once. The next day the width of 
the mediastinum had returned to normal 
on radiography. Serious respiratory com­
plications due to infusion into the medi­
astinum have been reported;20,27 these can 
be avoided through a routine radiograph.
The literature on CVP catheters stresses 
certain problems, such as venous throm­
bosis (especially when the inferior vena 
cava was used) with pulmonary em­
bolism,28 phlebitis,29’ 30 septicemia,20,29 33 
pneumothorax4, n - 16, 27, 32, 34 and atrial 
perforation (if the catheter tip is below the 
superior vena cava).27,35,36 To prevent 
shearing and catheter embolus, the operator 
must never withdraw a plastic catheter 
when the needle is in the skin.4, 16,37,38 
During prolonged use, rigid asepsis and 
meticulous maintenance are manda­
tory.18’20, 22,30, 31 Some have reported that, 
in certain instances, central venous pres­
sure is unreliable as a guide to fluid 
therapy,30-41 but in some of these cases 
the catheter tip may have been in an in­
correct location.
To date, the frequent malpositions of 
these catheters have not been adequately 
stressed. In this study approximately 29% 
of such catheters were positioned in­
correctly. In the one similar series so far 
reported, Gilday and Downs42 had similar 
findings. We have attempted to point out 
techniques that will prevent these mal­
positions.
Many centres use radiolucent catheters. 
Some pride themselves on the threading in 
of sterile infant-feeding tubes, which may 
not be radiopaque. Because we found that, 
in 71 of the last 245 central venous 
catheter insertions, the catheter tips had
assumed abnormal positions, we recom­
mend that: (1) radiopaque catheters be 
employed, and (2) radiologic confirmation 
of the catheter site be obtained whenever 
possible, and the catheter be carefully re­
positioned if necessary.
Summary
Central venous pressure is a valuable 
guide for fluid replacement in shock and 
cardiac patients. Of 245 central venous 
catheter insertions, a routine radiograph 
showed that the catheter tip was in­
correctly located in 71 (29%). These mal­
positions may be prevented or corrected. 
Catheters that come to rest outside the 
thorax can give incorrectly elevated and 
misleading values and, when prolonged 
hyperosmolar infusions are necessary for 
nutrition, may induce phlebitis rapidly. It 
is recommended that radiologic confirma­
tion of the catheter site be obtained when­
ever possible and that, if necessary, the 
catheter be carefully repositioned.
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R esume
L’etude de la pression veineuse centrale est un 
guide precieux de la serotherapie chez les 
cardiaques ou les malades en etat de choc. Or, 
des radiographies courantes ont montre que sur 
245 introductions des sondes intraveineuses, le 
bout du catheter etait mal place dans 71 cas 
(soit 29%). II est possible d’eviter ou de corriger 
ces positions vicieuses. Des catheters qui viennent 
a reposer en dehors du thorax peuvent donner 
des lectures exagerement elevees ou fausses. Dans 
les cas ou il faut donner longtemps des perfusions 
hyperosmolaires, on risque de provoquer rapide- 
ment un phlebite. Les auteurs conseillent done de 
verifier par radiographie la position exacte de la 
sonde et, le cas echeant, de la remettre en bonne 
position.
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COLITIS CYSTICA PROFUNDA: A RARE LESION OF THE COLON*
S. E. O’BRIEN, M.D., F.R.C.S.[C], F.A.C.S., K. J. SHIER, M.D., F.C.A.P., C.R.C.P.[C] 
and R. J. TUTTLE, M.D., F.R.C.P.[C], Hamilton, Ont.
C olitis  cystica profunda, a rare benign 
lesion of the large bowel, was first de­
scribed in the American literature in 1957 
by Goodall and Sinclair.1 Only 36 cases 
have been reported in the surgical litera­
ture to date. The chief importance of this 
condition lies in its differentiation from 
mucus-producing carcinoma of the colon, 
which it mimics very closely.
The purpose of this paper is to report 
an additional case and review the litera­
ture on this most unusual condition.
C ase R eport
A.C., a 65-year-old Italian, was admitted to 
hospital on June 6, 1969. For approximately 
six weeks he had been complaining of vague 
abdominal discomfort associated with loose 
bowel movements. He had also noticed small 
amounts of blood and excessive mucus in his 
stools. He denied weight loss. He had had 
minimal pulmonary tuberculosis as a young 
man and had been followed with regular chest 
films since with no recurrence. He had had 
no previous operations.
He was a stocky well-nourished elderly 
man. Clinical examination of the head and 
neck, chest and heart showed no abnormali­
ties. His blood pressure was 160/85 mm. Hg. 
The abdomen was not distended. There was 
no tenderness and no mass could be palpated. 
The liver and spleen were not palpable. There 
were no hernias. Rectal examination was 
negative.
Urinalysis was normal. His hemoglobin was 
14.7 g./lOO ml. A barium enema revealed a 
grossly redundant sigmoid colon with the apex 
of the sigmoid loop located in the right upper 
quadrant. There was a polypoid lesion in the 
sigmoid loop 5 to 6 cm. long which presented 
several small filling defects. There was no 
evidence of obstruction. No other lesions were 
noted in the colon.
With a preoperative diagnosis of carcinoma 
of the sigmoid colon, a laparotomy was done 
on June 12, 1969, through a right paramedian 
incision. The sigmoid colon was markedly 
redundant and the apex of the sigmoid loop 
was in the right upper quadrant. At this point,
“From the Departments of Surgery, Pathology 
and Radiology, St. Joseph’s Hospital, Hamilton, 
Ont.
there was a well-defined lesion 10 to 12 cm. 
long without evident obstruction. The in­
volved segment was thickened and firm with 
multiple small 1-cm. translucent cysts scat­
tered throughout the serosa. The mesentery 
was normal and there were no enlarged 
mesenteric nodes. The liver was also grossly 
normal.
A segmental resection of the sigmoid colon 
was carried out with a two-layer end-to-end 
anastomosis. The patient made an uneventful 
recovery and was discharged on June 26, 
1969.
The gross specimen consisted of a 19-cm. 
section of large bowel containing a discrete 
9-cm. segment which was abnormally thick­
ened. The overlying mucosa was intact 
throughout and irregularly bosselated. The 
mucosal folds were swollen and in parts raised 
by the submucosal collection of cysts measur­
ing from 2 to 6 mm. in diameter. The cysts 
replaced the entire submucosa and extended 
into the muscularis propria. Their linings were 
smooth, glistening and translucent. In several 
areas the cysts penetrated the entire thickness 
of the bowel wall into the serosa. The cyst 
cavities were filled with clear viscid mucoid 
fluid.
On microscopic examination, some of the 
cysts appeared connected to the bowel lumen 
by narrow-necked channels, and appeared as 
intramural diverticula. These cysts retained 
part of their epithelial linings. In most others 
the lining was reduced to a single layer of 
flattened cells which appeared compressed
T
Fig. I.—Low-power magnification of the wall of 
the involved colon showing large cystic spaces in 
the submucosa extending through the muscularis 
almost to the serosa and completely replacing the 
submucosa.
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and rendered atrophic by accumulated mucus 
(Fig. 1). Some of the cysts contained histio­
cytic foam cells and occasional multinucleated 
giant cells.
Cysts that penetrated through the entire 
wall formed diverticulum-like outpouchings 
with very thin and delicate walls. The latter 
were composed of two layers: the flattened 
atrophic epithelium and peritoneum (Fig. 2). 
Inflammatory changes in the surrounding un­
involved mucosa were scanty.
Fig. 2.—Higher-power view of large submucus 
cyst extending through the serosa resembling a 
typical colonic diverticulum. The cyst wall is 
composed of two layers—a flattened atrophic epi­
thelium and peritoneum.
D iscussio n
Mucous cysts of the colon were first de­
scribed by Stark in 17662 after he encoun­
tered two cases in seven autopsies 
performed on patients with chronic dysen­
tery. Virchow3 described this lesion in 
1863 and gave it the name “colitis cystica 
polyposa”. Subsequently several reports 
mentioned colitis cystica profunda as a 
sequel to bacillary dysentery, rather than 
as a separate entity.
The basic pathological feature of this 
disease is the mucous glands and cysts lying 
deep to the muscularis mucosae. This 
distribution distinguishes it from colitis 
cystica superficialis in which multiple tiny 
mucous cysts are scattered throughout the 
colon but are confined to the mucosa. The 
latter condition is said to be limited to 
patients with pellagra and occasionally 
sprue.
Colitis cystica profunda may present as 
a single lesion usually in the rectum and 
sigmoid, or as a diffuse process involving 
the entire colon. The single lesion, which 
seems to be considerably more common,
is seen more frequently in young adults in 
the fourth and fifth decades, and has no 
specific sex incidence. The chief symptoms 
are diarrhea with excess mucus and oc­
casionally blood in the stool, abdominal 
cramps, and tenesmus. The symptoms may 
be present for a few weeks to several 
years.
Physical findings are usually confined to 
sigmoidoscopy. The lesion usually presents 
as a polypoid or nodular structure varying 
in size to a maximum of 3 cm. in diameter 
and located in the submucosa. The over- 
lying mucosa may be congested and ede­
matous with occasional superficial ulcera­
tion. Biopsy is frequently misinterpreted as 
either chronic inflammation or mucus- 
producing carcinoma. Occasionally, un­
necessary abdominal perineal excisions 
have been carried out for this benign 
lesion. The radiologic picture usually con­
sists of single or multiple polypoid filling 
defects in the colon, most commonly in the 
rectum and sigmoid. The differential diag­
nosis includes multiple polyposis, endo­
metriosis, cystic pneumatosis, granuloma­
tous colitis, mesenteric vascular occlusion 
and carcinoma of the colon. In a few cases 
this lesion has been reported in chronic 
ulcerative colitis.
Grossly in this disease the involved 
bowel is thickened and slightly nodular. 
Excessive viscid mucus is present. Super­
ficial ulceration of the overlying mucosa 
and fibrosis of the submucosa surrounding 
the cysts may occur. This fibrosis may 
result in some degree of obstruction.
Microscopically, the mucosal cysts are 
lined with columnar or cuboidal epi­
thelium although in places the epithelium 
may be flattened or even absent, leaving 
collections of mucoid material free in the 
submucosa. It is this mucoid material 
which may give the false impression of 
mucinous carcinoma. However, the ab­
sence of atypical epithelial cells should 
confirm the benign nature of the lesion.
Frequently, one may see downgrowths 
of epithelium and mucus glands protrud­
ing through defects in the muscularis 
mucosae. There may be areas of ulceration 
of the mucosa and frequently an inflam­
matory infiltration of polymorphs, plasma 
cells, and lymphocytes in the submucosa
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as well as fibrosis surrounding the glandu­
lar structure.
Both congenital and acquired causes 
have been proposed.4’ 5 Ectopic colonic epi­
thelium has been discarded as an explana­
tion because this phenomenon has not 
been seen in a large series of children’s 
autopsies. A congenital defect of the 
muscularis mucosae, allowing submucus 
extension of glandular elements, has also 
been proposed as in diverticulosis. Finally, 
some have postulated that colitis cystica 
profunda represents a sequel to chronic 
inflammatory processes. In the healing of 
follicular abscesses, the down-growing epi­
thelial tracts may penetrate the muscularis 
mucosae, forming new glands in the sub­
mucosa. Such lesions have been demon­
strated histologically. Furthermore, sub­
mucus glands are not infrequently seen in 
association with chronic ulcerative colitis.
The treatment of choice is surgical ex­
cision. If the benign nature of the lesion 
is recognized, local excision may be carried 
out. This is particularly important in the 
rectal lesions where more radical excision 
would require a permanent colostomy. 
Lesions more proximally located in the 
bowel can be treated, as in this patient, 
by segmental resection.
Su m m a r y
A 65-year-old man had colitis cystica 
profunda in a redundant sigmoid colon.
This rare lesion has commonly been mis­
interpreted as carcinoma. The pathology 
and pathogenesis of this interesting condi­
tion have been reviewed.
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R esume
La colitis cystica profunda est une lesion bc- 
nigne, du reste rare, du colon. On ne trouve dans 
la litterature que 36 cas publies. Chez le m alade 
qui fait l’objet du present article, une lesion de 
cette nature siegeait sur le sigmolde et a  p u  etre 
resequee avec succes. Ces lesions, qui sont 
limitees au cdlon et au rectum , peuvent etre 
simples ou multiples. Le malaise habituel est la 
diarrhee, les selles contenant du mucus et du 
sang. Au point de vue pathologique, la lesion se 
compose de petits kystes m uqueux qui surgissent 
dans la  sous-muqueuse et s’etendent souvent vers 
la sereuse. O n suppose que ces lesions sont 
acquises et q u ’elles constituent des sequelles de 
processus inflammatoires chroniques, survenus an- 
terieurement dans la paroi intestinale. Le traite- 
rnent consiste a  les exciser chirurgicalem ent. Le 
degre de gravite de cette pathologie s’evalue par 
sa differentiation de l’adenocarcinome mucineux, 
dont la semeiologie est tres voisine.
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MICROANGIOGRAPHY IN EXPERIMENTAL 
MYOCARDIAL INFARCTION*
C. E. KINLEY, M.D., M.Sc., F.R.C.S.[C], F.A.C.S.f and 
R. L. de C. H. SAUNDERS, M.D., F.R.S.E., F.R.S.A.,1 Halifax, N.S.
Myocardial infarction is the subject of 
clinical and experimental research on a 
widely expanding scale.1 The pathology of 
the infarct itself has not received a great 
deal of attention, although the basic histo­
pathologic changes were described years 
ago.2’ 3 We are now assessing alterations in
the pattern of the microcirculation after 
acute coronary occlusion in dogs. The 
microcirculation patterns are correlated 
with the gross and histopathology in in­
farcts of various ages. The purpose of this 
study was to establish an experimental 
model with which to compare infarcts pro-
Fig. 1.—Microangiogram of a 2-mm.-thick cross-section of ventricles. Micropaque was injected 
into the ADA. The arrow indicates a transmyocardial artery. VS =  ventricular septum (original mag­
nification X 2.5).
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duced in animals receiving various treat­
ments for infarction.
E xperimental Technique
Mongrel dogs are anesthetized with 
thiopental (Pentothal), supplemented by 
nitrous oxide and fluothane. The chest is 
opened by a left fourth interspace incision. 
The anterior descending coronary artery
r *
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Fig. 2.—The inferior surface of (log ventricles 
with the coronary arteries injected. The arrow 
indicates an intercoronary collateral on the left 
ventricle near the apex (original magnification X 
1.5).
Fig. 4.—A front view of a heart with a 4-day- 
old infarct. The arrow indicates the right border 
of the infarct, along the interventricular groove. Fig. 4
Fig. 3.—Microangiogram of a heart injected two hours after ligation of the ADA. Arrows indi­
cate the borders of unfilled (ischemic) myocardium (x  2).
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Fig. 5.—Histology of a 4-day-old infarct. The arrow indicates the posterior extent of the infarct, 
in the ventricular septum (original magnification X 4).
(ADA) is tied off, just below the first major 
branch passing to the left over the front 
of the left ventricle; this site is distal to the 
origin of the major septal artery.
Within a minute of ligation of the ADA, 
the anterolateral surface of the left ventricle 
assumes a deeply cyanotic hue. The area 
of colour change is roughly pear-shaped; 
its right border is the interventricular 
groove and the left border, which is clearly 
demarcated, runs several millimetres below 
and parallel to the oblique branch of the 
ADA proximal to the point of ligation. In 
another few minutes the ischemic area 
usually stops moving and may show some 
degree of paradoxical systolic expansion. 
The chest is either closed and the animal 
studied again days or weeks later, or 
microangiograms are prepared immedi­
ately. For coronary injection a cannula 
passed into the ascending aorta enters the 
left coronary artery and is secured by a 
ligature outside the artery. Intravenous 
heparin is administered before eannulation. 
Micropaque* is then injected at a pressure 
not exceeding 150 mm. Hg. The heart is
“A barium sulfate compound, supplied by 
Damancy and Co. Ltd., Slough, Bucks., England. 
The manufacturers emphasize that Micropaque is 
not suitable for angiography in humans.
cooled, removed, and fixed in formalin for 
24 hours. The fixed specimen is sliced from 
base to apex into 2-mm. sections, contact 
microangiograms are made,4 and standard 
histologic sections are prepared.
R esu l t s  o f Acute  E x p e r im e n t
This acute experiment has been com­
pleted in 60 dogs. The acute mortality of 
ADA ligation at this level was 15%, similar 
to other studies.5- 6 Fig. 1, a microangio-
Fig. 6.—Microangiogram of a 2-mm.-thick cross- 
section of the ventricles in a 4-day-old infarct. 
Arrows indicate the borders of unfilled ischemic 
myocardium (original magnification X 2).
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Fig. 7.—Cross-sections of ventricles with a 2- 
week-old infarct. The top section is taken from 
near the apex, and the infarct occupies about 
50% of the circumference of the left ventricle.
gram prepared after injection of the ADA 
at the site chosen for ligation, shows that 
this vessel supplies mainly the front wall 
of the left ventricle and the adjacent an­
terior one-third of the ventricular septum. 
In addition, a fringe of anterior right 
ventricle bordering the septum has filled 
and, via connections with the posterior 
descending artery, a portion of the 
posterior wall of right ventricle has filled.
Fig. 8.—Microangiogram of the top section in 
Fig. 7 showing that the microcirculation is not 
filled in the area of the infarct (arrows), although 
some injectant has entered the epicardial vessels 
on the surface of the infarct (original magnifica­
tion X 2).
This figure also shows the distinctive 
“transmyocardial” arteries passing verti­
cally through the heart from epicardial to 
endocardial surfaces. These arteries, which 
are 200 to 300 n  in diameter at their ori­
gins, give off side branches at all levels of 
their course, but significant collateral 
communications between transmyocardial 
arteries are not apparent. There are, how­
ever, consistent grossly visible collateral 
channels on the epicardial surface, be­
tween branches of the ADA and branches 
of the left circumflex coronary artery. Some 
of these surface collaterals are shown in 
Fig. 2, the smallest being about 100 n  in 
diameter.
In animals whose left coronary artery 
was injected within two hours of ADA 
ligation (Fig. 3), the anterior wall of the 
left ventricle and adjacent portion of ven­
tricular septum showed no microcircula­
tion filling at the injection pressures used. 
There is no filling despite the normal inter­
coronary collateral channels on the heart 
surface, connecting branches of the ADA 
and the left circumflex coronary artery.
The lack of significant intramyocardial 
collateral arteries, combined with the 
functional inadequacy of the epicardial 
collateral channels, results in a sharp de­
marcation between injected and uninjected 
microcirculation. This means that the
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Fig. 9.—Histology of a 2-week-old infarct shows muscle necrosis with a rim of leukocytes and 
granulation tissue (arrows) (original magnification X 3.5).
acutely ischemic and cyanotic area seen 
on the surface of the left ventricle in vivo, 
reflects similar ischemia throughout the 
ventricular wall underneath. Standard 
histology of these acutely ischemic speci­
mens in the first few hours shows no 
visible alteration.
R esults in  Sxjbacute or C h ronic
E x per im en ts
The surface appearance of a 4-day-old 
infarct is shown in Fig. 4. The infarct is 
pear-shaped, the narrow superior border 
situated a small distance below the site of 
ADA ligation. In vivo this area was 
akinetic. On histologic examination (Fig. 5) 
there was extensive muscle necrosis and a 
surrounding border of neutrophil infiltra­
tion. On microangiography (Fig. 6) the 
microcirculation did not fill in the area of 
infarction. Myocardial veins accompany 
many arteries, and such venous filling was 
found in all hearts that were not injected 
immediately after ADA ligation.
Three sections from a heart with a 2- 
week-old infarct are shown in Fig. 7. The
top section is near the apex, and the in­
farct at that level occupies about 50% of 
the circumference of the left ventricle. A 
microangiogram of this section (Fig. 8) 
shows that the swollen infarct area is not 
filled by the Micropaque. Histologically 
(Fig. 9) there is massive muscle necrosis 
with a rim of leukocytes and granulation 
tissue.
Fig. 10 shows a 3y2-week-old infarct in 
cross-section. In vivo the anterior wall of 
the left ventricle (arrow) was aneurysmal. 
A microangiogram (Fig. 11) shows that the 
microcirculation in the centre of the swol­
len infarct area contains no Micropaque, 
but vessels in the surrounding developing 
granulation tissue have filled. Some col­
lateral channels are visible in the septum.
The microangiogram in Fig. 12 shows 
thinning of the anterior wall of the left 
ventricle at the site of a 5x/2-week-old 
infarct. Note the transversely oriented col­
lateral channels situated deep in the ven­
tricular wall. The infarct was akinetic in 
vivo.
Microangiograms of an 8-week-old in­
farct are shown in Figs. 13 and 14. In Fig.
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Fig. I I .—Microangiograms of two sections from 
a heart with a 3%-week-old infarct. The micro­
circulation of the infarct area is unfilled, but ves­
sels in the surrounding granulation tissue area are 
well injected (original magnification X 2).
L°____t!°,------ -------- L3. — ------150
Millimetres _ _
Fig. 10.—Cross-sections of ventricles with a 3%- 
week-old infarct (arrows).
13 note the tortuous vessels, tending to a 
transverse arrangement in the infarct area. 
Fig. 14 shows collateral channels appear­
ing in the ventricular septum, particularly 
in the anterior third.
In cross-sections of a 22-week-old infarct 
(Fig. 15), arrows indicate scarring in the 
anterior left ventricle and adjacent sep­
tum. Histologic appearances are shown in 
Fig. 16 and a microangiogram in Fig. 17. 
The latter shows that the scarred infarct 
area is relatively avascular and contains 
numerous transversely oriented vessels, 
supplied by tortuous collaterals at the 
margins and outer surface of the infarct.
D iscu ssio n
Research on myocardial infarction is 
often hampered by unsatisfactory experi­
mental models. To assess the effect of as­
sisted circulation on acute infarction, 
workers have used staining techniques to 
quantitate reduction of infarct size in 
treated animals, after only a few hours or 
days of infarction.7 9
We have constructed a model of acute 
myocardial ischemia which shows consis­
tent changes in gross and microscopic 
pathology, and similarly predictable 
changes in the structural pattern of the 
microcirculation. The model allows objec­
tive assessment of various treatment pro­
grams, not only immediately after the 
onset of ischemia, but also at subsequent 
intervals of weeks or months.
We feel that the microangiograms pre­
pared in the first hours after coronary
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occlusion are significant. The injectant has 
a viscosity similar to blood. The mean in­
jection pressure of 150 mm. Hg is higher
than that seen after acute coronary liga­
tion. The absence of filling of the micro- 
circulation in the infarct was seen in all
Fig. 13.—Microangiogram of a 2-mm.-thick cross-section of ventricles with an 8-week-old infarct. 
Note the collaterals, tending to a transverse lie, in the area of the infarct (arrow) (X 2).
Fig. 12.—Microangiogram of a cross-section of a ventricle with a 514-week-old infarct (arrow). 
Note the transversely oriented collaterals in the infarct area (X 2.5).
January 1971 MICROANGIOGRAPHY 63
Fig. 14.—Microangiogram of a heart with an 8-week-old infarct, at a higher level than Fig. 13. 
Note the extensive development of collaterals in the ventricular septum (arrow) (original magnifica­
tion X 2).
Millimetres
Fig. 15.—Cross-sections from a heart with a 22- 
week-old infarct. Arrows indicate scarring in the 
anterior left ventricle and adjacent septum.
stages of this study and correlated well 
with the areas of muscle necrosis histo­
logically. We therefore assume that our 
patterns of microcirculation, shown by in­
jections at various stages of infarction, 
reflect similar functional patterns of flow 
in the areas of, and adjacent to, infarction.
Grossly visible collateral channels are 
regularly seen on the epicardial surface of 
the normal dog heart. However, in our ex­
periments, these could not prevent exten­
sive myocardial necrosis. Counterpulsation 
may achieve improved myocardial per­
formance by allowing effective perfusion 
of these surface collateral channels.10 Simi­
lar improvement has been noted in experi­
mental infarction after the use of vaso­
pressors.11
Intramyocardial collateral channels have 
not been seen in the ventricles of normal 
dog hearts including the subendocardial 
area. There are communications between 
adjacent transmyocardial arteries of 30 to 
40 /x in size. Significant intramyocardial 
collaterals, 100 to 150 ix in size, are ap­
parent by two weeks, but by then myo­
cardial necrosis has already occurred.
S u m m a r y
The authors have devised an experimen­
tal model of myocardial infarction. The 
model shows consistent correlation be-
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Fig. 16.—Histology of the infarct shown in Fig. 15. Scar tissue occupies the full thickness of 
the ventricular wall (original magnification X 4.5).
tween alterations in angiographic patterns model will prove useful in assessing 
of microcirculation and standard patho- various treatment methods for myocardial
logical preparations. It is expected that the infarction.
Fig. 17.—Microangiogram of a 2-mm.-thick cross-section of ventricles with a 22-week-old infarct 
(arrows). The infarct area is relatively avascular, despite collateral vessels adjacent to the arrow on the 
left (original magnification X 2).
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R e s u m e
Les auteurs ont congu un modele experimental 
d’infarctus du myocarde. Ce modele a permis aux 
auteurs de mettre en evidence une etroite corre­
lation entre les modifications des traces angio- 
graphiques de la microcirculation et les prepara­
tions pathologiques classiques. Les auteurs esti- 
ment que ce modele pourra etre utile pour 
evaluer diverses methodes therapeutiques de l’in- 
farctus du myocarde.
TRANSPOSITION OF TH E GREAT 
ARTERIES
Transposition of the great arteries is one 
of the commonest forms of congenital heart 
disease and, unfortunately, is one of the most 
lethal. Initial palliation achieved by Rash- 
kind’s balloon septostomy, followed later by 
total surgical correction by atrial septopexy. 
has stimulated interest anew.
Twelve patients were seen since December 
1967. Their age ranged from 1 day to 20 
months—10 patients were less than 6 weeks 
of age when first seen. Seven patients had 
associated defects including ventricular septal 
defect alone in three, patent ductus arteriosus 
in three, and both ventricular septal defect 
and patent ductus arteriosus in one. The re­
maining five patients had no associated defects 
other than the essential atrial shunt.
Cardiac catheterization was performed 
under local anesthesia through a femoral vein, 
and balloon atrial septostomy was performed 
at the conclusion in nine patients. Five pa­
tients died. Of these, two were moribund 
when first examined. No deaths or serious 
complications were attributed to the balloon 
septostomy, although in four of nine patients 
the results were unsatisfactory. In three of
these four, the balloon septostomy was re­
peated after three to four weeks because of 
the unsatisfactory initial result, but no further 
significant improvement was achieved. Two of 
these patients were then treated by a Blalock- 
Hanlon atrial septectomy. One had moderate 
improvement but died at home three months 
later. The other had good results. The third 
child died after pulmonary banding.
For reasons not yet understood, pulmonary 
vascular resistance rises in these patients at 
an accelerated rate compared with similar size 
ventricular septal defects, but with normally 
placed arteries. Three of four patients with 
ventricular septal defect had high pulmonary 
vascular resistance. In one patient, it was 
equal to the systemic resistance when first 
measured at 3 years of age. In two patients, 
increases have been documented by serial 
catheterizations between 18 and 34 months, 
and between three and 13 months. Pulmonary 
artery banding was successfully performed in 
these instances. The authors perform pulmo­
nary banding in all such patients as early as 
possible to protect the pulmonary vascular 
bed, so that total repair may be subsequently 
performed.—McCredie RM, Wright JS: Man­
agement of transposition of great arteries. 
M ed J  Aust 1: 202, 1970
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EMERGENCY TRANSUMBILICAL PORTAL DECOMPRESSION FOR 
BLEEDING ESOPHAGEAL VARICES*
YVAN J. SILVA, M.D., F.R.C.S.fC], F.A.C.S. and 
ALEXANDER J. WALT, M.D., F.R.C.S.fC], F.A.C.S., Detroit, Mich., U.S.A.
Massive hemorrhage from esophageal 
varices in patients with cirrhosis of the 
liver presents several frustrating problems 
in control and management. The North 
American literature over the past 20 years 
indicates that only one in three cirrhotic 
patients hospitalized with their first epi­
sode of bleeding leaves the hospital alive.1 
Control of hemorrhage is usually accom­
plished by balloon tamponade and man­
agement includes treatment of hypo­
volemia, correction of electrolyte and 
acid-base imbalance and prevention of 
liver failure by catharsis, protein restric­
tion and control of ammonia production 
by bacteria in the alimentary tract using 
antibiotics. Pitressin has been used to 
lower portal pressure but has little benefi­
cial effect.2 The surgeon may intervene by 
directly oversewing or resecting the 
varices, constructing a portosystemic shunt, 
or by cannulating the thoracic duct to 
decompress indirectly the portal venous 
system but, in the face of deteriorating 
liver function, results are poor.
In recent years at the Detroit General 
Hospital, using both conservative and 
operative approaches, the mortality rate in 
these patients has been greater than 70%. 
Balloon tamponade has been used rou­
tinely to control bleeding, but complica­
tions such as gastroesophageal ulceration, 
esophageal perforation, atelectasis, pneu­
monia and massive aspiration occasionally 
follow its use. Any method of portal de­
compression that will buy time and allow 
liver function to recover before major 
surgery is worth exploring.
“From the Robert S. Marx Surgical Laboratories 
and the Department of Surgery, Wayne State 
University School of Medicine, Detroit, Mich.
Presented at the Annual Meeting of the Royal 
College of Physicians and Surgeons of Canada, 
Montreal, Que., January 24, 1970.
Supported by a grant from the Detroit General 
Hospital Research Corporation.
Reprint address: Dr. Y. J. Silva, 1400 Chrysler 
Freeway, Detroit, Mich. 48207.
Since umbilical vein cannulation in the 
adult was described in 19593 this method 
of gaining access to the portal venous 
system has become well established.* Since 
1966 several authors5'7 have described 
portal decompression by umbilicosystemic 
shunting. We use an extracorporeal Silas­
tic-tube shunt between the reopened um­
bilical vein and the systemic circulation. 
Before being used in patients, we tested 
these shunts in laboratory animals to en­
sure that they could produce adequate 
portal decompression8 and, in 1969, re­
ported its successful use in three patients.2
The objectives of the present study 
were: (a) to assess the feasibility of using 
a wide-bore extracorporeal umbilico­
systemic shunt; (b) to observe its efficacy 
in attaining and maintaining portal de­
compression; (c) to determine the duration 
of patency and occurrence of thrombosis; 
and (d) to determine its value as an alter­
native to balloon tamponade in the 
primary control of variceal hemorrhage.
The Shunt
The shunt, made of Silastic tubing with 
an incorporated side-arm, is fabricated to 
our specifications.® The umbilical limb has 
a flange at its tip and the systemic limb 
has an impregnated barium-sulfate radio­
paque marker at its distal end. The shunt 
is approximately 36 inches long—the um­
bilical limb is six inches and the systemic 
limb 30 inches (Fig. 1). It is available in 
two sizes: large—OD 7.5 mm. (0.295 inches) 
and ID 4.8 mm. (0.188 inches), and small— 
OD 6.4 mm. (0.250 inches) and ID 4.3 mm. 
(0.170 inches).
M aterial and M ethod
We selected nine patients who had 
severe hepatic decompensation and had 
recently had massive variceal hemorrhage.
“Aid to Medical Research, Dow Corning Corpora­
tion, Midland, Mich.
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Fig. I.—Extracorporeal umbilicosystemic shunt: 
the flange-tipped umbilical limb is six inches long; 
the systemic limb, with a radiopaque marker tip, 
is 30 inches long; at the point marking the divi­
sion between the two limbs, a side-arm is in­
corporated.
Diagnosis was confirmed by the onset and 
type of bleeding, stigmas of liver failure, 
barium swallow and/or esophagoscopy, 
control of bleeding by balloon tamponade 
and portal pressure greater than 30 cm. 
H20  demonstrated at umbilical vein can- 
nulation. In all patients, portal cirrhosis 
was confirmed by liver biopsy at the time 
of operation. After the insertion of a 
Sengstaken-Blakemore tube, ice-saline gas­
tric lavage and correction of hypovolemia, 
the patients were taken to the operating 
room and the umbilical vein was can- 
nulated using an extraperitoneal tech­
nique.9 The umbilicoportal junction was 
dilated to 7 or 8 mm. with Bakes’ dilators 
and a No. 14 F. polyethylene catheter in­
serted into the left portal vein to measure 
pressure (zero point mid-axillary line). 
After portal hypertension was confirmed, 
the umbilical limb of the shunt was in­
serted in the umbilical vein and the flange 
impacted in the left portal vein. The shunt 
was filled with heparinized Ringer’s solu­
tion (10 mg. heparin/1000 c.c.) and, under
local anesthesia, the skin over the right 
groin was incised and the saphenofemoral 
junction identified. The junction was dilated 
with Bakes’ dilators to 6 or 7 mm., the 
systemic limb of the shunt introduced into 
the inferior vena cava through an incision 
in the saphenous vein and threaded up so 
that the tip was in the supradiaphragmatic 
vena cava; this was confirmed by fluoro­
scopy.3 A three-way stopcock attached to 
the side-arm was used (a) to monitor 
pressures intermittently and (b) for con­
tinuous infusion of heparinized Ringer’s 
solution at the rate of 25 c.c./hr. through 
a Harvard peristaltic pump.
Thirty minutes after the shunt was 
established the gastric and esophageal bal­
loons were deflated. Further bleeding was 
monitored by irrigation of the stomach 
with ice-saline. Every two to four hours 
the systemic limb was clamped and the 
portal pressure was measured with the tip 
of the side-arm at the mid-axillary line. 
The portosystemic shunt pressure at the 
level of the side-arm was recorded inter­
mittently. Side portal flow was measured 
by clamping the systemic limb and bleed­
ing the side-arm into a cylinder, the tip of 
the side-arm being elevated to the height 
of the central venous pressure to compen­
sate for the resistance offered by this pres­
sure. This flow was measured every 12 
hours and the blood thus acquired was 
submitted for laboratory examination of 
various biochemical and coagulation para­
meters.
Results
We could not insert the shunt in three 
of the nine patients for technical reasons. 
Six patients were decompressed immedi­
ately; their portal pressures ranged from 35 
to 90 cm. H20  and the shunt pressures 
from 10 to 47 cm. HaO (Table I). Bleeding
T A B L E  I .—R esu lts  of Umbilicosystemic Sh u n tin g  in  S ix  P a t ien ts  W ith  B l e ed in g  E so ph a g ea l
V ARICES
N am e S ex
Age
(years)
Portal pressure 
(cm. H ,0 )
Immediate shunt 
pressure 
(cm. H ,0 )
Flow
(c .c ./m in .)
A.J. M 50 90 47 80
C.H. F 41 35 20 110
C.B. M 48 48 36 120
— J J.McC. M 38 40 22 108
F.J. M 40 37 10 100
J.B. M 56 51 30 600
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Cirrhosis of liver
Fig. 2.—Hemodynamic profile during 23 days of extracorporeal umbilicosystemic 
shunting.
stopped two to seven hours after the shunt 
was inserted and the shunts were left in 
place from one to 23 days.
Of the six shunts, one had to be re­
moved within 36 hours because of clotting 
attributed to portal thrombosis. In this 
patient an umbilical vein catheter had 
been left in place for seven days before 
the shunt was set up. The catheter was in­
serted initially to measure portal pressure 
and was left in place in anticipation of re­
current bleeding. When this did occur on 
the seventh day, we introduced the shunt 
but flow ceased after 36 hours. At autopsy 
this patient had portal vein thrombosis. 
The other five patients had no clotting 
and, in four, the shunts were removed at 
time of death, one, four, nine and 12 days 
after insertion. The sixth patient in whom 
the shunt was maintained for 23 days, was 
discharged because he refused definitive 
shunt surgery. This 48-year-old white man 
was admitted with a second episode of 
massive bleeding from esophageal varices.
His portal pressure was 48 cm. H20  when 
the shunt was set up; the portosystemic 
shunt pressure on the first day was 35 cm. 
H20  and decreased on continued shunting. 
His portal pressure showed a steady de­
cline over the 23 days (Fig. 2). On the 
eighteenth day during transfer to an x-ray 
table, he suddenly bled from his varices 
during a Valsalva maneuver. At that time, 
the systemic limb was clamped and we 
found that the portal pressure was greater 
than 100 cm. H20 . Shunting was reinsti­
tuted immediately and bleeding stopped 
within 30 minutes. Nine months later he 
was readmitted after another bout of 
bleeding for definitive shunt surgery and, 
at operation, had portal vein thrombosis.
In one of these patients, a 41-year-old 
woman, the umbilical vein was cannulated 
three times on separate hospital admis­
sions; first, during the investigation of 
upper gastrointestinal bleeding; second, 
approximately three months later, during
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Fig. 3.—Portal pressure profile in a patient (A.J.) who died of hepatic failure nine days after shunt­ing was begun.
an episode of bleeding which subsided 
spontaneously; and, finally, nine months later to insert an umbilicosystemic shunt 
which functioned for four days before she 
died from hepatic failure.
In one patient we could not establish 
a shunt because of a technical failure, but 
he is included in this report because of an 
important observation. During dissection 
we noted that the umbilical vein contained 
blood; this was confirmed by venotomy. During dilatation, the umbilicoportal junc­
tion could not be entered and a false pas­sage was created. We opened the peri­
toneum and found approximately 500 c.c. 
of blood. This blood had accumulated from back bleeding from the left portal vein 
into the peritoneum and then had escaped 
from a rent in the posterior wall of the 
umbilical vein. The falciform ligament was 
ligated at the hepatic hilus and the opera­tion was terminated.
D iscussion
Liebowitz10 believes that a precipitous upheaval of circulatory dynamics within the splanchnic and portal venous systems initiates varix wall rupture. In all six pa­tients, true portal pressures were lowered 
by shunting and, unless bleeding recurred, remained at levels lower than those re­corded when bleeding began (Figs. 2 and
3).
Shunt thrombosis remains a significant problem in these patients. Primarily shunt patency depends on the size and type of tubing used, the pressure gradient between the high portal pressure and the intra- 
thoracic negative pressure in the supra­diaphragmatic vena cava, and also the 
sucking action of the chest. While we can­not correlate the side portal flow in these 
patients with the efficacy of decompres­sion or maintenance of patency, these 
measurements are reproducible and can be 
used for comparison, especially when 
studying the action of drugs on the portal 
system.2
If a surgeon is to use this method of 
portal decompression he must first cathe- 
terize the umbilical vein. This may be 
impossible with a small or friable umbilical 
vein or if bosselations of cirrhotic liver encroach upon the umbilicoportal junc­
tion.9 Unless blood flows freely from the left portal vein, catheter clotting results. Previous catheterization of the umbilical 
vein is not a contraindication and re­catheterization is frequently technically 
easier because the lumen is easy to identify and reopen. In one of these patients (C.H.) 
the umbilical vein was reopened three times. Furthermore, this method of portal 
decompression lends itself well to the 
study of portal hemodynamics.2
Summary
Six patients had extracorporeal umbilico­
systemic portal decompression using a 
Silastic tube with an incorporated side- 
arm. These patients had effective decom­
pression lasting one to 23 days; esophageal 
bleeding stopped two to seven hours after 
insertion of the shunts. The portal vein 
thrombosed in two patients in whom the 
umbilical vein had been catheterized for 
eight and 23 days.
We recommend this method for selected 
patients in whom the procedure is techni­cally feasible, either as an alternative to balloon tamponade or to assess temporary portal decompression during preparation 
for emergency or definitive shunt surgery. Shunting should probably not be continued longer than seven days because portal 
thrombosis can occur.
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R esu m e
Chez neuf cirrhotiques qui avaient ete choisis 
parce qu’ils presentaient une hemorragie massive 
et une decompensation hepatique, les auteurs ont 
precede, sous anesthesie locale, a un catheterisme 
ombilical extraperitoneal. Leur traitement a ete 
couronne de succes chez six malades. Ils ont 
utilise a cette fin un tube de Silastic de fort 
calibre pourvu d’un embranchement lateral. L’ex- 
tremite a bout renfle du tube ombilical a ete 
introduite dans la veine porte gauche et l’extre- 
mite de la portion du tube destine a la grande 
circulation ( introduite par une incision de la veine 
saphene) a ete mise place sous observation 
fluoroscopique jusque dans la portion supra- 
diaphragmatique de la veine cave inferieure. La 
pression de la circulation porte, la pression dans 
le shunt au niveau de la branche laterale et le 
debit de la circulation porte derivee ont ete sur- 
veilles continuellement. Chez les six malades, on 
a pu realiser une decompression efficace de la 
pression porte qui est tombee de 35 a 90 cm de 
HlO a des pressions de derivation variant de 10 a 
47 cm de FLO. L’hemorragie a ete enrayee dans 
un delai variant de deux a sept heures apres la 
creation des shunts: 1’arret de l’hemorragie a ete 
confirme par lavage gastrique. Les derivations ont 
fonctionne pendant une periode variant de un 
jour a 23 jours. Le debit de la circulation porte 
dans la derivation a ete de 80 a 600 c.c./mn. 
Chez deux malades dont la veine ombilicale avait 
ete sondee pendant une periode de huit a 23 
jours, s’est developpee une thrombose porte.
Chez des malades ou cette methode peut etre 
appliquee du point de vue technique, la deriva­
tion ombilico-svstemique enraye temporairement 
l’hemorragie. Cette methode constitue du reste 
un excellent moyen d’etude de Themodvnamique 
de la circulation porte. L ’intubation prolongee de 
la veine ombilicale risque de se compliquer de 
thrombose porte.
CANCER OF THORACIC ESOPHAGUS 
AND CARDIA
Tlie authors explored 51 of 66 patients 
(77%) reviewed between 1959 and 1966. 
Major resection was performed in 37 (75%). 
The overall operative mortality rate was 40% 
and the five-year survival rate was 10%. 
Laparotomy was performed first to exclude 
intra-abdominal metastases. The chest was 
then opened, and the lesion was resected if at 
least 5 cm. of proximal clearance could be 
obtained. Partial esophagectomy, total gastrec­
tomy with splenectomy, and excision of the 
tail of the pancreas were done in 15 patients: 
10 had colonic replacement of their esophagus 
and stomach, while five had a Roux-en-Y eso- 
phagojejunal anastomosis. Partial esophago-
gastrectomy with an esophagogastric anas­
tomosis was done in the remaining 22 patients.
Of the 10 patients with the colonic replace­
ment after total esophagogastrectomy, six died 
in the immediate postoperative period, and 
three died within the first year. Death was 
most commonly due to infarction of the inter­
posed colon. One patient was alive and well 
nine years after operation. Five patients lived 
more than four years without late morbidity. 
Three of four patients who were long-term 
survivors had squamous carcinoma; one had 
an adenocarcinoma of the gastric fundus. In 
view of the results of the alternative methods 
of treatment, the authors believe that an ag­
gressive surgical approach is still justified.— 
Wosornu JL, Fraser K: Carcinoma of thoracic 
oesophagus and cardia. Brit J  Surg 57: 42. 
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PATHOLOGIC CHANGES WITH INTERVERTEBRAL 
JOINT ROTATIONAL INSTABILITY IN THE RABBIT0
JAMES D. SULLIVAN, M.D., C.M., F.R.C.S.JC],
H. F. FARFAN, M.D., C.M., F.R.C.S.fC] and DAVID S. KAHN, M.D., Montreal, Que.
In the whole intervertebral joint in the 
rabbit we studied the pathologic changes 
that accompany the instability created by 
removing a single posterior facet process.
Since the studies of Schmorl1 in 1927, 
disc degeneration has been attributed to 
vertical compression forces acting on an 
incompressible nucleus pulposus.2'7 This 
force transmitted to the annulus fibrosus, 
ruptures it and allows nuclear material to 
escape through the rent in the annulus. 
This theory, however, is inconsistent with 
certain facts about the physical properties 
of the intervertebral disc. In degenerated 
discs, the nucleus itself is not less com­
pressible than the annulus8'10 especially 
when the nucleus is fibrotic1, 9 or if it is 
calcified5 or contains air.2’ 11 The central 
portion of the vertebral plate is permeable 
and tissue fluid moves easily in and out of 
the nucleus, as can be demonstrated in 
discograms,12-14 and under mechanical 
stress.15 The vertebral end-plate is 
strengthened for the sake of the annulus 
rather than the nucleus; the greater bulk 
of the disc is annulus and its weight-bear­
ing capacity cannot be ignored.12'14’ 16 
Finally, the compression strength of the 
intervertebral disc is more than twice that 
of the vertebral body.17 These facts sug­
gest strongly that, in degenerated discs, 
the nucleus pulposus does not act as an 
incompressible body, and hence Schmorl’s 
theory cannot account for disc protrusion. 
Neither can compression force alone ex­
plain the damage seen in disc degenera­
tion.
Studying cadaver spines subjected to a 
rotation force (torque), we demonstrated 
that intact intervertebral joints could be 
ruptured by a torque of 500 to 1000 in.- 
lbs.18 Of this value, 40% of the torque was 
attributable to the facet joints. Because
“From the Division of Orthopedic Surgery and 
the Department of Pathology, St. Mary’s Hospital, 
Montreal, Que.
Supported in part by Medical Research Council 
of Canada Grant MA-2125.
the facet joint provided much of the rota­
tional stability of the whole joint, we con­
cluded that intervertebral joint instability 
was related to improperly aligned facet 
joints. Should one or the other of the facet 
joints be improperly aligned (obliquely 
placed), repetitive or sustained rotatory 
force to that side could eventually rupture 
the disc. This conclusion was supported by 
our clinical study of back pain in which 
we found that disc prolapse was associated 
with facet joint asymmetry and sciatica.19
To test this hypothesis in the rabbit, we 
created rotational instability by removing 
a single facet process of the posterior 
intervertebral facet joint complex and 
studied the pathologic changes that de­
veloped subsequently in the contralateral 
facet joint and intervertebral disc.
Material and Methods
We used 39 white male domestic im­
mature rabbits averaging 2.5 kg. in weight. 
Under general anesthesia, an incision was 
made over the lower lumbar region ex­
posing four intervertebral joint levels. The 
paravertebral muscles were retracted. In 
25 rabbits at each of the two middle joints 
but on opposite sides, the inferior articular 
facet process was resected with a small 
bone-cutting forceps (Fig. 1). The exposed 
joints above and below the joints with 
partial facetectomy served as controls. The 
fascia and skin were closed in separate 
layers.
In 14 rabbits before closure and under 
direct vision, we rotated the spine force­
fully at the operated level to study the 
healing process in the disc subjected to 
rotation.
After they recovered from the anes­
thesia, the rabbits were allowed full ac­
tivity. All the animals used in the study 
were fully ambulatory one week after 
operation and showed no signs of neuro­
logic deficit.
The rabbits were killed at intervals of 
two weeks, one, two, four, six, nine and
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12 months. The segment of spine contain­
ing the two operated joint levels and the 
normal joints above and below was re­
moved en bloc  and cleared of muscle. The 
intervertebral disc at each level was in­
jected with contrast material (Lipiodol) 
through a 25-gauge needle inserted antero- 
laterally into the disc. Radiographs in the 
anteroposterior and lateral projections pro­
vided discograms of the control vertebra 
as well as the joints with partial facetec­
tomy (Fig. 2).
The radiologic criteria for a degenerated 
intervertebral disc were: (a) disc space 
(height) of less than 1 mm. by direct 
measurement (normal value 1 mm. to 1.4 
mm.), or (b) acceptance of sufficient dye,
Fig. 2.—Discogram showing dye within the disc 
at all four levels. The intervertebral joint is nar­
rowed at the lower of the two operated levels 
(arrow).
or (c) extravasation of dye into the epi­
dural space (Fig. 3).
From each of the four discs, transverse 
histologic sections were obtained at three 
levels: (1) near the superior end-plate, (2) 
mid-disc and (3) near the inferior end- 
plate (Fig. 4). The sections were mounted 
and stained with hematoxylin and eosin 
(Fig. 5).
Radiologic D iscographic Studies
Discography
These studies were inconclusive. Gen­
erally an unoperated rabbit disc accepted 
less than 0.1 ml. of contrast (Lipiodol), in­
sufficient to be visible on radiographs, 
although, in 10 rabbits, apparently normal
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Fig. 3.—Discogram showing intervertebral joint 
narrowing at operated levels as compared to con­
trol levels (arrows). Note the dye within the 
epidural space.
discs accepted as much as 0.5 ml. How­
ever, in rabbits killed between six and 12 
months, the operated joints accepted more 
dye than control joints and, in 10, the dye 
escaped into the epidural space (Fig. 3).
Disc Narrowing
The unoperated lumbar discs had an 
average height of 1.0 to 1.5 mm. Using the
Fig. 4.—Levels for histologic sections at control 
and operated levels.
Fig. 5.—Section taken at a control level to show 
the normal appearance of the posterior facet 
joints and intervertebral disc. Part of the outer 
annulus on one side was lost in processing (origi­
nal magnification X 40).
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Fig. 6a Fig. 6b
Fig. 6.—(a) Radiograph showing fracture involving a vertebral end-plate, (b) Specimen cut 
longitudinally through the lumbar spine of the rabbit seen in (a) killed at 12 months. The upper disc is 
at an operated level and shows a fracture of the end-plate with an attempt at healing. The lower disc 
is at a control level and shows an intact end-plate (original magnification X 40).
arbitrary lower limit of 1.0 mm., we found 
that the vertical height of the disc in the 
operated joints was reduced in 50% of the 
rabbits at six months. In rabbits killed at 
nine to 12 months, 74% of the operated 
joints had narrowed discs (Fig. 3).
It is interesting to note that in rabbits 
killed early 12% of control joints showed 
observable disc narrowing; this figure in­
creased to 46% in those killed at nine to 
12 months.
One of the animals had a fracture of the 
end-plate (Fig. 6). Three others had con­
trast medium in the vertebral body, sug­
gesting that the end-plates were fractured 
or fissured (Fig. 7). The radiographs did 
not show osteophyte formation or help us 
to follow changes in the facet joints.
The 14 rabbits subjected to forced rota­
tion of the spine at operation showed no 
evidence of injury to bone. The radio­
graphs of these rabbits were indistinguish­
able from those of the remainder.
Microscopic F indings
Disc
The earliest changes were seen in the 
periannular areolar tissue at the postero­
lateral angles of the disc and were particu­
larly marked on the operated side. This 
reaction did not seem to be due entirely to 
the recent injury because it persisted and 
even increased up to the time fibrous scar 
formed.
Some of the rabbits killed at four
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Fig. 7.—Discogram showing contrast material 
within a vertebral body which presumably en­
tered through a fissured end-plate (arrows).
months showed fresh polymorph exudate 
in the same location (Fig. 8) suggesting 
that recent new injury may have occurred 
to the annulus at this point.
One disc showed a small chondrophyte 
at the posterolateral angles of the disc and 
three rabbits killed at 12 months had well- 
formed small osteophytes there (Fig. 9).
In the 14 rabbits subjected to forced 
rotation at operation, the changes in the 
disc were identical in all respects with the 
others.
Five rabbits had extruded nuclear mate­
rial through the posterior annulus into the 
epidural space (Fig. 10). In all of these we 
believe the extrusion was a postmortem 
accident because there was no tissue reac­
tion in the vicinity of the extrusion. Never­
theless, it is reasonable to conclude that 
the annulus had been weakened—a con­
clusion supported by the fact that one of 
the protrusions occurred in a joint sub­
jected to forced rotation in a rabbit killed 
at two weeks. The other four rabbits (Nos. 
7, 14, 15, and 23) were not subjected to 
torsion and were sacrificed at nine and 12 
months.
Other changes in the disc involved both 
nucleus and annulus and, though not so 
apparent in the first six months, are clearly 
demonstrated in those killed at nine to 12 
months. The posterior annulus thins in the 
midline and the slightly rounded postero­
lateral angle seems to bulge much more 
prominently (Figs. 11 and 12).
The area occupied by the nucleus seems 
to have increased and the nucleus appears 
to be edematous and to have lost some of 
its normal organization.
We observed peripheral circumferential 
slits in the annulus particularly at the 
posterolateral angle, although these may 
be artefacts.
Facet Joints
The partial facetectomy healed in one of 
several ways. At four months, these joints 
showed either a fibrous non-union or a 
complete bony ankylosis (Fig. 13). Rabbits 
killed at two weeks, one month, and two 
months showed abundant fibrous-tissue 
proliferation.
In the first four months, the contralateral 
facet joints showed no changes; the carti­
lage maintained its normal thickness com­
pared to controls above and below the site 
of operation. In the two rabbits killed at 
six months, and in later groups, the non- 
operated facet joint showed signs of early 
degeneration. At first there was fibrillation 
followed by thinning of the articular carti­
lage (Fig. 14). This progressed to almost 
complete loss of articular cartilage with 
eburnation of the underlying bone (Fig. 
15).
D iscussion
The changes observed in this study sug­
gest that resection of one articular process 
of one posterior facet at the intervertebral
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Fig. 8.—Focal acute inflammation with fibrin and polymorphs within the epidural space at an operated level in a rabbit killed at four months (arrows) (original magnification X 80).
Fig. 9.—Early posterolateral osteophyte forma­tion at an operated level. Note Assuring of the posterior annulus (original magnification X 80).
Fig. 10.—Annular and nuclear disc protrusion into the epidural space and substance of the spinal cord (arrows indicate tear and nuclear pro­trusion) (original magnification X 80).
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Fig. 13.—Bony ankylosis of one facet joint at 
an operated level in a rabbit killed at four months 
(original magnification X 40).
Fig. 12.—Section showing extreme posterolateral 
bulging of the annulus with nuclear disorganiza­
tion (original magnification X 40).
Fig. 14.—Fibrillation of the articular cartilage 
of the non-resected facet joint at an operated 
level (original magnification X 80).
Fig. 11.—Annular thinning posteriorly and bulg­
ing posterolaterally in a rabbit killed at 12 
months. Note the nuclear disorganization, and 
compare with Fig. 5 (original magnification X 40).
joint level altered the mechanics of the 
whole joint and precipitated a progressive 
change in the disc and also in the contra­
lateral facet joint. The appearance of the
i '
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Fig. 15.—Extensive degenerative changes of the 
hyaline cartilage involving the contralateral facet 
joint at an operated level (original magnification 
X 80).
experimental joint is quite distinct from 
that of the controls. The developing patho­
logic processes are reflected in changes in 
the radiologic appearances of the joints.
The facet joint changes observed here 
are typical of advancing osteoarthritis and 
resemble the changes described by other 
authors6 in human facet joints. The patho­
logic changes in the disc are less dramatic. 
Although the experiment did not produce 
disc degeneration in all respects typical of 
that described in human lumbar joints, 
several features in the experimental joints 
at least suggest a similar degenerative 
process.20 Thus, radiologic evidence of disc 
thinning and fracturing of the end-plate 
are both constant findings in human disc 
degeneration. The spill of radiologic con­
trast into the spinal theca is also typical 
of disc degeneration with annular rupture.
In these intervertebral joints the annulus 
seems to thin with eventual weakening. 
These changes, although not dramatic, are 
clearly discernible and increase with the 
passage of time.
When these disc changes are compared 
with those observed by workers21'25 who 
made a direct surgical assault on the disc
itself, it is apparent that the response of 
the disc to direct injury does not resemble 
natural disc degeneration. In these experi­
mental joints, the periannular tissue reac­
tion was related to injury to the annulus 
and not to the operation on the facet joint.
One of the principal roles of the lumbar 
posterior facet joints is to protect the disc 
against rotational stresses. In this experi­
ment, the facet joint instability probably 
allowed abnormal rotation stresses to act 
on the disc, producing the observed 
changes. These changes resemble those 
noted in humans at disc operation—a find­
ing that corroborates our earlier work on 
the effect of torque on whole intervertebral 
joints in the cadaver and our clinical study 
correlating disc prolapse and sciatica with 
facet joint asymmetry.
Su m m a r y
In the rabbit a single posterior facet 
process was removed to study the patho­
logic changes so produced in the whole 
intervertebral joint. The changes in the 
disc and posterior facet joints at the 
operated levels differed significantly from 
those observed at control levels. The de­
generative changes in the disc and 
posterior facet joints were caused by an 
indirect surgical assault on the disc and 
were similar to the changes seen in human 
disc disease. We believe that the main role 
of the posterior facet joint is to protect the 
disc against rotational stresses and that the 
removal of one facet produces rotational 
instability and subsequent degeneration of 
the whole joint. These findings appear to 
support this hypothesis and to corroborate 
an earlier experimental and clinical work 
on this subject.
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R e s u m e
Sur la colonne lombaire du lapin, nous avons 
excise une seule facette articulaire posterieure en 
vue detudier quelle en serait la repercussion sur 
l’ensemble de l’articulation intervertebrale. Aux 
niveaux operes, les changements constates sur le 
disque et sur les facettes articulaires posterieures 
differaient sensiblement de ceux qui s’observaient 
sur des articulations-temoins. Les changements 
degeneratifs ont ete causes par une agression 
chirurgicale sur le disque (le disque lui-meme 
n’etant pas touche). Ces changements etaient 
semblables a ceux qui s’observent dans la maladie 
discale chez 1’homme. Les auteurs estiment que 
le role principal de la facette articulaire poste­
rieure est de proteger le disque contre une in­
stability rotative et d’eviter que l’ensemble de 
l’articulation ne degenere. Les presentes constata- 
tions confirment cette vue et corroborent les 
premiers travaux experimentaux et cliniques des 
auteurs sur le sujet.
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SUCCESSFUL SKIN GRAFT ON RENAL ALLOGRAFT: 
REPORT OF A CASE*
K. T. WU, M.D., F.R.C.S.[C], M. H. GAULT, M.D., M.Sc., F.A.C.P. and 
L. D. MacLEAN, M.D., Ph.D., F.R.C.S.[C], Montreal, Que.
W hen a transplanted kidney is placed in 
the pelvic cavity, it is usually covered by 
layers of fascia, subcutaneous tissue and 
skin. An unusual case was recently ob­
served at the Royal Victoria Hospital, 
Montreal, in which a patients transplanted 
kidney remained externally exposed for six 
months and skin was successfully grafted 
onto the exposed surface.
Case Report
The patient, an 11-year-old girl, was first 
admitted to the Royal Victoria Hospital in 
December 1967 because of uremia. Dialysis 
was instituted and she had a renal biopsy 
which showed severe diffuse interstitial fibro­
sis. In February 1969 she received a cadaver 
renal allograft, but rejection during the fourth 
week led to transplant nephrectomy and a 
return to hemodialysis. She received a second 
renal allograft in August 1969. The donor 
was a 27-year-old man who had died of sub­
arachnoid hemorrhage. Tissue typing showed 
a B match, according to the criteria of Lee 
et al.1 Prednisone and azathioprine, anti­
lymphocyte globulin, and local irradiation 
were used as immunosuppressive agents. The 
transplant graft functioned well initially, but 
a major rejection episode occurred six weeks 
later, which responded to increased dosages of 
prednisone. The kidney was explored in No­
vember 1969 because of perinephric abscess 
associated with ureteral obstruction. Frozen 
section showed healthy cortical tissues with­
out evidence of serious rejection and a 
nephrostomy was performed. The grossly in­
fected wound was left open and the large 
transplanted kidney was thereby exposed ex­
ternally. The renal function improved and the 
exposed surface of the allograft continued to 
ooze clear yellowish lymph-like material. Four 
weeks after the kidney was exposed, a split­
thickness skin graft obtained from the pa­
tient’s right thigh was placed over the kidney. 
Thereafter the oozing from the surface of the 
renal allograft markedly diminished. The skin 
graft was accepted and there has been no
"From the Transplant Service, Royal Victoria 
Hospital, and the Department of Experimental 
Surgery, McGill University, Montreal, Que.
evidence of its rejection over a period of more 
than six months, despite repeated evidences 
of minor rejection of the renal allograft. A 
plastic protective shield was designed and 
used to cover and support the allograft. In 
February 1970 the patient developed viral 
hepatitis with jaundice, but this subsided dur­
ing the next month.
In April 1970, four months after skin graft­
ing, the transplanted kidney was well covered 
with skin (Fig. 1). No sensation to pain or
Fig. 1.—Four months after transplantation, the 
externally exposed renal allograft is well covered 
with skin. A nephrostomy tube enters the upper 
pole of the kidney.
touch was present over the skin graft. A 
biopsy of kidney with overlying skin revealed 
that the skin graft blended imperceptibly 
with the kidney (Fig. 2). There was a thick 
layer of connective tissue, with marked neo­
vascularization between the dermal layer and 
kidney cortex. The renal tissue showed fea­
tures consistent with moderate cellular rejec­
tion. Immunofluorescent studies of both skin 
and renal grafts were done for immunoglobu­
lins IgG, IgM and |8lG. No staining was seen 
in the kidney or skin.
In April 1970 she was discharged from the 
hospital with a nephrostomy tube in place.
D iscussion
The patient demonstrates that a trans­
planted kidney can be exposed externally, 
can maintain good function, and that the 
recipient’s skin can be grafted successfully 
onto this renal allograft.
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Fig. 2.—The recipient’s skin has been success­
fully grafted onto the transplanted kidney (x  30).
The indication for the skin graft in an 
externally exposed kidney is not yet de­
fined. In this patient, it was done to reduce 
the amount of lymph drainage from the 
denuded surface of the kidney and to close 
the space between the kidney and the ab­
dominal wall. Initially the kidney was held 
in place only by the vascular pedicle, 
ureter and dressings. Because of the possi­
bility of distortion of the vessels and ob­
struction of blood flow, especially if she 
stood up, the patient was kept in bed for 
approximately one month until it became 
clear that adhesions between the kidney 
and underlying tissue had developed. 
When she was ambulatory, we designed a 
plastic shield to conform with the shape 
of the renal allograft and the abdominal 
wall; this has been both effective and com­
fortable.
Wheeler, Corson and Dammin2 have 
grafted tissue slices from various organs 
onto kidney cortex in isogeneic mice, but 
have not grafted skin. The unique feature 
in this patient—that there was no evidence 
of alteration of the skin graft even though 
there were episodes of minor rejection of 
renal transplant—can be explained by the 
fact that the immunologic properties of the 
blood supplying the skin graft are not 
significantly altered by its passage through 
the renal allograft.
Summary
We have described an 11-year-old girl 
whose skin was successfully grafted onto 
an externally exposed cadaver renal allo­
graft. No evidence of rejection of the skin 
has been observed for more than six 
months although she has had several epi­
sodes of minor rejection of the trans­
planted kidney.
Addendum
Follow-up examination in October 1970 re­
vealed that the skin graft was still intact and 
the exposed renal allograft was functioning.
Re f e r e n c e s
1. L e e  HM, H ume DM, V red ev o e  DL, et al:
Serotyping for homotransplantation. IX.
Evaluation of leukocyte antigen matching
with clinical course and rejection types.
Transplantation 5 : 1040, 1967
2. W h e e l e r  HB, C o r so n  JM, D a m m in  GJ:
Transplantation of tissue slices in mice.
Ann NY Acad Sci 129: 118, 1966
Resum e
En aout 1969, une jeune fille de 11 ans 
subissait sa deuxieme transplantation d’un rein de 
cadavre, deux mois apres l’echec de la premiere. 
Trois mois apres cette intervention, il fallut ex­
plorer l’organe transplante, en raison de la per­
foration du bassinet, de la formation d’un abces 
perinephrique et de l’obstruction de l’uretere. Les 
coupes congelees n’ayant revele aucun signe de 
rejet, on proceda au drainage de l’abces, le rein 
etant laisse en place et expose exterieurement, 
puis on pratiqua une nephrostomie.
Un mois plus tard, on tentait une greffe cutanee 
sur le rein transplante a partir de peau prelevee 
chez le receveur. Une biopsie prise quatre mois 
apres cette greffe montrait que la peau s’etait 
unie imperceptiblement au rein transplante. 
L’autogreffe cutanee est restee saine pendant plus 
de cinq mois, malgre plusieurs episodes de rejet 
mineur de 1’homogreffe renale.
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THE CANADIAN JOURNAL OF SURGERY
All communications concerning this journal 
should be marked “The Canadian Journal of 
Surgery” and addressed to the Editor, C.M.A. 
Publications, 129 Adelaide Street West, Toronto.
The Journal is published bi-monthly. Sub­
scription is $15 per year ($7.50 per year for 
trainees in surgery), and starts with the Janu­
ary issue of each year. Single copies are $2.50  
each, payable in advance. ( It would be greatly 
appreciated if subscribers would add bank ex­
change to their cheques.)
INSTRUCTIONS TO CONTRIBUTORS  
Manuscripts
Manuscripts in duplicate of original articles, 
case reports, and other contributions should 
be forwarded with a covering letter re­
questing consideration for publication in T he  
Canadian Journal o f Surgery. Acceptance 
is subject to the understanding that they 
are submitted solely to this Journal, and 
will not be reprinted without the consent 
of the author and the publishers. Accept­
ance or rejection of contributions will be 
determined by the Editorial Board. As 
space is available, a limited number of 
case reports will be published. Articles 
should be typed on one side only of un­
ruled paper, double-spaced, and with wide 
margins. The author should always retain a 
carbon copy of material submitted. Every 
article should contain a summary of the 
contents. The Concise Oxford Dictionary 
will be followed for spelling. Dorland’s 
Illustrated Medical Dictionary will be fol­
lowed for scientific terminology. The Edi­
torial Board reserves the right to make the 
usual editorial changes in manuscripts, in­
cluding such changes as are necessary to en­
sure correctness of grammar and spelling, 
clarification of obscurities or conformity 
with the style of T he Canadian Journal of 
Surgery. In no case will major changes be 
made without prior consultation with the 
author. Authors will receive galley proofs 
of articles before publication, and are asked 
to confine alterations of such proofs to a 
minimum.
Reprints
Reprints may be ordered on a form which 
will be supplied with galley proofs. It is 
important to order these before publication 
of the article, otherwise an extra charge 
for additional type-setting will be made,
References
References should be referred to by numer­
als in the text. They should include in 
order: the author’s name and initials in capi­
tals, title of the article, abbreviated journal 
name, volume number, page number and 
year. The abbreviations of journal names 
should be those used in Index M edicus. 
References to books should include in order: 
author’s name and initials, title of book, 
number of edition (e.g. second ed .), city 
of publication, title of publishing house, 
year of publication, page number if a 
specific reference. For examples, see this 
journal January 1971 issue onwards.
Illustrations
A reasonable number of black-and-white 
illustrations will be reproduced free with 
the articles. Colour work can be published 
only at the author’s expense. Photographs 
should be glossy prints, unmounted and 
untrimmed, preferably not larger than 8" 
x 6". Prints of radiographs are required 
and not the originals. The magnification of 
photomicrographs must always be given. 
Photographs must not be written on or 
typed on. An identifying legend may be 
attached to the back. Patients must not be 
recognizable in illustrations, unless the 
written consent of the subject for publica­
tion has been obtained. Graphs and dia­
grams should be drawn in India ink on 
suitable white paper. Lettering should be 
sufficiently large that after reduction to 
fit the size of the Journal page it can still 
be read. Legends to all illustrations should 
be typed separately from the text and sub­
mitted on a separate sheet of paper. Illustra­
tions should not be rolled or folded.
Language
It should be clearly understood that con­
tributors are at full liberty to submit 
articles in either English or French, as they 
please. Acceptance will be quite independ­
ent of the language of submission. If the 
contributor wishes, he may submit an in­
formative summary of not more than 300 
words in the language other than that in 
which he has submitted the article. For 
example, an article in English must carry 
an English summary and may, if the author 
wishes, carry a more detailed summary in 
French.
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devra porter la mention “Le journal eanadien de 
chirurgie” et etre adressee a l’Editeur, Publica­
tions de 1’A.M.C., 129 Adelaide Street West, 
Toronto.
Le journal est publie a tous les deux mois. Le 
prix de l’abonnement est de $15. par an ($7.50 
par an pour les medecins qui sont residents en 
chirurgie) et commence avec le numero de 
janvier de chaque annee. Un exemplaire isole 
coute $2.50 et est payable d’avance. (Nous 
serions reconnaissants aux souscripteurs de vou- 
loir bien ajouter a leur cheque le montant des 
frais bancaires eventuels).
INSTRUCTIONS A NOS
COLLABORATEURS
Manuscrits
Les manuscrits d’articles originaux, de rap­
ports cliniques etc. seront envoyes en deux 
exemplaires, accompagnes d’une lettre deman­
dant qu’on veuille bien considerer leur publica­
tion dans L e  journal eanadien de chirurgie. Us 
ne seront acceptes qu’a la condition qu’ils 
n’aient ete soumis qu’a notre Journal et qu’ils 
ne soient pas reimprimes sans le consentement 
expres de l’editeur et l’auteur. L’acceptation 
ou le refus des articles soumis releve du Con- 
seil de la publication. Si la place est disponihle, 
un nombre limite d’histoires cliniques pourront 
etre publies. Les articles seront dactylographies 
sur un seul cote d’un papier non ligne, a double 
espace et avec une large marge. L ’auteur devra 
toujours conserver une copie au papier carbone 
du texte soumis. Tout article devra etre ac- 
compagne d’un resume. L ’orthographe sera 
celle adoptee par le dictionnaire Larousse. 
Quant a la terminologie scientifique, elle sera 
basee sur le Dictionnaire des termes techniques 
de medecine ou tout autre ouvrage de refe­
rence serieux. Le Conseil de la publication se 
reserve le droit d’apporter au texte les change- 
ments qu’il jugerait a propos pour assurer la 
correction grammaticale et l’orthographe, pour 
eliminer d’dventuelles obscurites ou pour ren- 
dre la presentation conforme au style du Jour­
nal eanadien de chirurgie. Aucun changement 
important ne sera apporte au texte sans que 
l’auteur art ete prealablement consulte. Les 
auteurs recevront avant la publication des 
epreuves d’imprimerie de leur texte, auxquelles 
ils sont pries d’apporter le minimum de correc­
tions.
Tires-a-part
On pourra commander des tires-a-part sur 
une formule qui est envoyee avec les epreuves. 
II est important de les commander avant la 
publication de l’article, sous peine de devoir 
payer un supplement pour une nouvelle com­
position.
Bibliographie
Les references bibliographiques seront indi- 
quees par des numeros dans le corps du texte. 
Elies comprendront dans l’ordre: le nom de 
l’auteur et ses initiales, en majuscules, le titre 
abrege du Journal, le numero du volume, le 
numero de la page et l’annee. Les abreviations 
admises pour les noms de revues sont celles qui 
figurent dans I’lndex Medicus. Les renvois aux 
livres comprendront dans l’ordre: le nom de 
l’auteur, ses initiales, le titre de l’ouvrage, le 
numero de l’edition (p. ex. deuxieme ed.), la 
ville et le nom de la maison d’edition, et 
l’annee de la publication; enfin, le numero de 
la page s’il s’agit d’un renvoi precis. Pour 
examples, voye, Tissue de janvier 1971 et ceux 
a venir.
Illustrations
Le journal accepte de publier gratuitement 
un nombre raisonnable d’illustrations en noir 
et blanc. Les reproductions de cliches en cou- 
leurs seront publiees aux frais de Tauteur. Les 
photographies seront imprimees sur papier bril- 
lant, ne seront ni montees ni calibrees et d’un 
format maximum de 6" x 8". En ce qui con- 
ceme les radiographies, nous demandons des 
copies et non pas Voriginal. On devra toujours 
foumir un agrandissement de microphoto­
graphies. 11 ne faut jamais ecrire ou dabtylo- 
graphier un texte quelconque sur les photo­
graphies. Une legende les identifiant pourra 
etre jointe au dos. Dans les illustrations mont- 
rant des malades, ceux-ci ne pourront etre 
reconnus, a moins qu’ils n’en aient donne le 
consentement ecrit prealablement a la publica­
tion. Les graphiques et diagrammes seront des- 
sines a Tencre de Chine sur un bon papier a 
dessin blanc. Le lettrage devra etre ecrit en 
caracteres assez grands pour que, apre reduc­
tion proportionnelle au format du Journal, ils 
soient encore lisibles. Les legendes devant 
accompagner les illustrations seront dactylo- 
graphiees sur une feuille independante du 
texte. Les illustrations ne seront ni roulees ni 
pliees.
Langue vehiculaire
II doit etre clairement etabli que les colla- 
borateurs ont pleine liberte de soumettre leurs 
articles en frangais ou en anglais, a leur choix. 
L ’acceptation de l’article sera entierement inde­
pendante de la langue choisie par Tauteur. Si 
le collaborateur le desire, il peut d6crire le 
contenu de l’article en un sommaire ne depas- 
sant pas 300 mots et dans une langue differente 
de la langue choisie pour Tarticle lui-meme. 
Par exemple, un article ecrit en frangais doit 
comporter un resume en frangais et peut, si 
Tauteur le desire, etre accompagne d’un som­
maire plus detaille en anglais.
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CORTICOSTEROIDS IN TH E TREATMENT
OF SHOCK. Edited by William Schumer and
Lloyd M. Nyhus. 163 pp. Illust. University of
Illinois Press, Urbana, 1970. $10.00.
This short monograph contains the published 
proceedings of a symposium conducted by the 
University of Illinois College of Medicine on 
the important but confused subject of cortico­
steroids in shock. While not unanimous, most 
of the distinguished participants believed that I 
“pharmacological doses” of corticosteroids 
should be used in septic shock—usually as 50 
to 150 mg./kg. of hydrocortisone in a single 
bolus, which might be repeated during the 
subsequent 24 hours. One reason given for 
this recommendation is that the distribution of 
cardiac output is improved, even though the 
total output is not increased. An improvement 
in urine flow is the evidence for this. More 
convincing is the concept that corticoids j 
promote the normal respiratory cycle in the 
cell and protect lysosomal membranes against 
pH changes. It was shown in man in shock j 
that corticoids: (1) decrease serum in­
organic phosphate by incorporation into ATP; 
(2) decrease lacticacidemia; and (3) decrease 
aminoacidemia. All of the above suggest en­
hancement of normal aerobic oxidation within 
the cell.
This text assembles a large volume of in­
teresting clinical and research data, and the 
overall clarity is enhanced by three workshop J 
discussions which are reproduced verbatim, j 
Anyone treating patients with septic shock will 
find the book of considerable interest.
FACIAL INJURIES. Richard Carlton Schultz.
264 pp. Illust. Year Book Medical Publishers,
Inc., Chicago, 1970. $15.00.
Dr. Schultz has written an authentic and well- 
conceived monograph. By his own admission, | 
this book was “conceived as a sort of primer [ 
for other physicians who, by choice or singu­
lar circumstance, provide a great portion of 
this care”. The text is brief and extremely 
well documented with step-by-step illustra­
tions. The philosophy of the book is excellent, 
but does contradict the purpose of the text, 
viz. the author suggests that open reduction 
and interosseus fixation is the method of choice 
in most facial fractures. This approach re­
quires more than preliminary training.
His concept of wound management is excel­
lent and up to date, and should provide the I 
attending surgeon with many helpful hints. 
Basic concepts are well demonstrated by J 
sketches, drawings and photographs. The 1 
chapter on personal injury litigation is unique 
and certainly will help those surgeons in- I
"In abdominal surgery, 
constipation caused by 
hard, dry stools 
frequently complicates 
the postoperative course. 
This hazardous 
postoperative straining 
can cause tissue trauma 
or suture damage. 
Straining should 
obviously be avoided, but 
we don’t want the 
stimulated mobility of a 
laxative either. So I rely 
on Surfak from Hoechst. 
It's a fecal softener but 
not a laxative".
"Doctor, those 
loudmouths behind us 
are yelling again".
when laxatives are unw ise
SU R FA K
For prescribing information see page 91
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volved in the treatment of facial injuries, most 
of which terminate in the courts of law.
Dr. Schultz does not include any formal 
bibliography which is unusual and somewhat 
disappointing. The book falls short o f the two 
intensive texts now available on the treat­
ment of facial injuries but Dr. Schultz has 
accomplished his original aim. This is a worth­
while text for every surgeon’s consulting or 
operating room.
CARDIOVASCULAR PATHOLOGY. Vol. 3. 
Suppl. to vols. 1 and 2. Reginald E. B. Hudson. 
1166 pp. Illust. Edward Arnold (Publishers) 
Ltd., London; The Macmillan Company of 
Canada Limited, Toronto, 1970. $78.50.
Doctor Hudson’s original two-volume mono­
graph, published in 1965, is recognized as a 
most comprehensive and accurate treatise on 
the whole field of cardiovascular pathology. 
This new volume 3, supplements and updates 
the information found in the original books. 
It is divided into 43 supplementary chapters, 
each corresponding to a chapter in the original 
books and incorporating all relevant new 
knowledge. No group or department con­
cerned with cardiovascular disease and already 
having copies o f the two previous volumes can 
afford to be without this supplementary vol­
ume. The three volumes form a most impor­
tant reference work and should be available 
in all hospital libraries.
GASTREKTOMIE UND KARDIARESEKTION 
BEIM MAGENKARZINOM. Pathologie-Klinik 
—Operationstechnik Folgeerscheinungen und 
Ergebnisse. Rudolf Haring and Herman Franke. 
210 pp. Illust. Intercontinental Medical Book 
Corp., New York; Georg Thieme Verlag, Stutt­
gart, Germany, 1970. DM 88,00. $24.80 (ap­
prox.).
The surgical treatment of carcinoma of the 
stomach is thoroughly reviewed in this mono­
graph. The anatomy, pathology and surgical 
technique are described in detail and are well 
illustrated. Less emphasis is placed on physio­
logic considerations. In particular the descrip­
tions o f esophageal motility studies, the 
cardiac sphincter mechanism and some aspects 
of the postoperative disturbances of the gastro­
intestinal canal are incomplete. An interesting 
detail is the report on cholinesterase determi­
nations preoperatively. The authors carried out 
this determination in 3000 patients and sub­
divided them in three groups as follows: 
Group 1—low values, corresponding to de­
creased energy stores; Group 2—average 
values, suggesting a good general condition of 
the patient; Group 3—increased values, sug­
gesting lability and irritability. The prognosis 
was found to be better in Group 2 than in 
Groups 1 and 3. For the gastrointestinal sur­
geon this book is a useful review of the 
present state of the art. For others, it may 
emphasize the extremely grave prognosis of 
carcinoma of the stomach.
INAKTIVITATSOSTEOPOROSE. Klinische und 
experimentelle Studie zum Knochenumbau 
durch Inaktivitat. Joachim Eichler. Aktuelle 
Orthopadie Heft 3. 90 pp. Illust. Intercontinen­
tal Medical Book Corp., New York; Georg 
Thieme Verlag, Stuttgart, Germany, 1970. DM 
36,00. $10.15 (approx.).
This monograph deals with the problems en­
countered when an extremity of a growing 
organism is immobilized in a plaster cast. After 
reviewing the literature related to the prob­
lem, the author states that little is known 
about the effect of immobilizing a child’s ex­
tremity in a plaster cast. Immobilization of a 
hind leg in a growing guinea pig has the fol­
lowing effects: reduction of bone growth, re­
duction in bone weight and density, as shown 
on radiographs, reduction o f the hydroxyl apa­
tite and collagen content resulting in changes 
in mechanical properties. The author suggests 
that in children it might be advisable to avoid 
prolonged immobilization in plaster by using 
surgical fixation. The experimental methods are 
described in detail and include quantitative 
histology, interferometry and metabolic bal­
ance studies. Although the conclusions are of 
interest to the clinician, this book is recom­
mended primarily for the experimental sur­
geon.
INSTRUCTIONAL COURSE LECTURES. Vol­
ume XIX. American Academy of Orthopaedic 
Surgeons. 236 pp. Illust. The C. V. Mosby 
Company, St. Louis, 1970. $21.45.
This volume deals with 10 important subjects 
in the field of basic sciences and clinical ortho­
pedics. The clarity o f the text and the illustra­
tions throughout are o f the highest possible 
standards. This reviewer found these instruc­
tional course lectures were of very high 
calibre when he heard them delivered at meet­
ings of the Academy, and their reproduction 
in this volume should make them of great 
value to the reader. The lectures will be of 
considerable value to the practising as well 
as to the academic surgeon, helping him to 
keep up to date with modem trends, and they 
will be of great assistance to teachers of 
orthopedic surgery and residents during their 
training. Certainly all those engaged in teach­
ing and in learning orthopedic surgery should 
be thoroughly conversant with the material 
presented in this book.
The subjects dealt with are the surgical 
anatomy and exposures o f the foot and ankle, 
clinical and pathological studies of fat em­
bolism, the incidence and prevention of 
thromboembolic disease, clinical applications 
of electrodiagnostic studies, bracing for pa­
tients with acquired spasticity, diagnosis and 
management of internal derangements of the 
knee joint, orthopedic management of muscu­
lar dystrophy and related disorders, unstable 
intertrochanteric fractures, troublesome frac­
tures and dislocations o f the hand, fractures
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in children, analysis and treatment of ankle I 
injuries produced by rotatory, abduction and | 
adduction forces, early care of severe ex­
tremity wounds, a review of the Vietnam ex- | 
perience and its civilian applications, and the 
articular cartilages: a review.
Many readers will look forward with great J 
anticipation to the publication of future vol- I 
umes of this outstanding work.
NOUVELLE PRATIQUE CHIRURGICALE IL- 
LUSTREE. 2e Serie. Fascicule III. Jean Quenu. 
269 pp. Illust. Editions Doin, Deren & Cie, | 
Paris, 1969. 82 F. $15.58 (approx.). Paperbound.
This book is part of a series covering subjects 
such as bronchial anastomosis, pancreatectomy 
and adrenalectomy. As a whole, the book is 
well presented and the illustrations are good. 
The indications for each operation are well 
detailed and the text is sober. It is certainly a | 
good reference book for operations that are 
not currently practised.
On the other hand, the book has absolutely 
no order. Being part of a series, we would 
expect one volume to include thoracic sur­
gery and another abdominal surgery etc., but 
this is not the case. This presents a serious 
problem to the reader if he wants to find a 
particular operation. However, there is a good 
table of contents at the end of the book.
The incision for resection of pheochromo- 
cytoma, which can be extended into the 
thorax, has a great deal of logic to it. For the 
hemicolectomy procedure, many surgeons will 
approve the early ligature of the inferior 
mesenteric vein. On the whole, each technique 
is well illustrated and described, but the 
lack of order in the chapters themselves is a 
serious disadvantage.
OPERATIVE TREATMENT OF BONE 
TUMORS. 3rd International Symposium Janu­
ary 24th-26th, 1969 in Basle, Switzerland.
Edited by George Chapchal. 182 pp. Illust. 
Intercontinental Medical Book Corp., New York; 
Georg Thieme Verlag, Stuttgart, Germany, 
1970. DM 49,00. $13.50 (approx.). Paperbound.
This volume consists of a collection of papers 
presented by an international group of ortho­
pedic specialists meeting in Basle, Switzerland. | 
The papers are arranged in four groups: 
Part I covers pathology, use of angiography 
and lymphangiography in diagnosis, and the 
difficulties encountered in making accurate 
diagnoses. Part II is concerned with the man­
agement of juxta-articular tumours and in­
cludes discussions of homotransplantation as | 
well as the use of prosthetic devices. One 
paper discusses research in the biochemistry J 
of plastic materials. Part III deals with the I 
continuing problems of resection in primary 
and metastatic tumours. The final section 
emphasizes case studies and follow-up over 
varying periods of time and discusses the use j 
of chemotherapeutic agents in tumour therapy.
After anorectal surgery a 
good many patients 
develop constipation, 
and occasionally  fecal 
impaction, because of 
the fear of pain. Surfak 
from Hoechst promotes 
the formation of soft, 
formed stools, avo id ing 
abrasions or further 
irritation of inflamed 
structures, and so  acts to 
prevent trauma and 
constipation due to fear 
of evacuation. Surfak is 
a fecal softener, not a 
laxative".
"That's a bon sp ie l, 
doctor".
w h e n  laxatives  a re  u n w is e
SURFAK
Fo r p re sc r ib in g  in fo rm a tion  see page  91
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One gains the impression that, as in all 
tumour therapy, there is little standardization 
in approach and much inconsistency in results. 
However, the search continues for proper 
combinations of surgical extirpation and 
chemotherapy.
This collection of papers would probably 
be of most interest to practising orthopedic 
surgeons and is of little value to under­
graduate students.
DER RETROMAXILLARE RAUM. Eine Darstel- 
lung aus klinischer, rontgenologischer und 
chirurgischer Sicht. Siegfried Zehm. Aktuelle 
Oto-Rhino-Laryngologie Heft 3. 53 pp. Must. 
Intercontinental Medical Book Corp., New York; 
Georg Thieme Verlag, Stuttgart, Germany; 
1970. DM 28,00. $7.90 (approx.). Paperbound.
This short but complex monograph deals with 
the surgical treatment of benign and malig­
nant retromaxillary tumours, appearing prim­
arily in that region or secondarily invading 
the retromaxillary space.
More than one-half of its pages deals with 
anatomy, and tomograms of the retromaxillary 
region in normal individuals and in those with 
retromaxillary tumours. They also describe the 
symptomatology, pathology and differential 
diagnosis of lesions in this area.
The author discusses the three main 
methods of surgical treatment—the oral, mid­
face and retromaxillary methods of tumour 
removal, giving the indications for each ana­
tomical approach. He discusses in detail the 
operative technique and the complications that 
can arise. In the malignant group, operation 
should be completed by block resection o f the 
cervical lymphatic glands. The author con­
cludes that the benign tumour heals without 
recurrence if it is totally removed. The prog­
nosis o f the malignant tumour is poor; none 
o f the author’s four patients with primary 
retromaxillary tumour survived two years after 
a radical operation and irradiation therapy. 
Only five of 18 patients operated on for 
secondary retromaxillary tumours survived for 
five years without any sign of recurrence.
Although radical surgery often produces 
striking deformation of the face and some 
temporary functional disturbances, the relief 
o f the constant pain that was present before 
treatment is certainly an improvement.
THE ROLE OF THE SURGEON IN MEDICAL 
SCHOOL EDUCATION. Transactions of the 
11th Annual Meeting of the Allen O. Whipple 
Surgical Society. Edited by Harold G. Barker. 
155 pp. Charles C Thomas, Publisher, Spring- 
field, 111.; The Ryerson Press, Toronto, 1970. 
$7.50.
The Allen O. Whipple Society was originally 
formed to honour Dr. Whipple. Its member­
ship now exceeds those who were trained by 
this man and the Society proposes to address 
itself to medical education, with particular 
reference to the role of surgery and surgeons 
in that process. This book, which reports the
eleventh meeting of the Society, is a compila­
tion of papers presented by invited guests and 
members. It begins with a view of hospitals, 
medical schools and curriculum innovation, 
and notes the continuing difficulty created by 
the need for constant change. Most recently 
this change has been occasioned by an expan­
sion of our biological knowledge and our 
abandonment of the concept that each student 
should learn something of everything. Chap­
ter II by Dr. Raymond Allen contains a par­
ticularly refreshing view of current ideas in 
curriculum change and emphasizes that this 
change is attitudinal rather than a shifting of 
hours or courses.
The mid section of the book—views of sur­
geons presented by our non-surgical col­
leagues, allows them to comment upon us as 
they see us. This section examines our hal­
lowed and traditional views of the value of a 
surgical experience for all students, and we 
may be left a little breathless and over­
whelmed by these critical and careful observa­
tions. The vantage point from which dean, 
internist, social scientist, psychologist and 
pathologist view the surgeon makes this essen­
tial reading for all surgical educators.
The concluding section attempts to justify 
the surgeon’s role in medical education. This 
section proposes tactics, methods, assignments 
and areas of interest rather than analyzing the 
traditional patient-doctor-student relationship. 
An excellent chapter by Lawrence A. Fisher 
describes methodology of curriculum construc­
tion, objective formulation and examination of 
the process of learning. However, this entire 
section fails to grapple with the interrelation­
ship of patient-doctor-student, and does not 
define the relevant components of that experi­
ence which the student must extract in pre­
paration for his future specialty. Despite this, 
this perceptive and worthwhile book belongs 
on the library shelf o f all those involved in the 
surgical education of the medical student.
UROLOGISCHE OPERATIONSLEHRE. Number
4. Abdominale Komplikationen bei und nach
urologischen Eingriffen. Operationen an der
Harnblase. Edited by G. W. Heise and E.
Hienzsch. 159 pp. Must. VEB Georg Thieme,
Leipzig, 1970. DM  50,00. $14.00 (approx.).
Paperbound.
This volume is one of a set of 10 which will 
cover the whole field of urologic surgery. It 
consists of two parts: (1) abdominal complica­
tions after urologic surgery and (2) bladder 
operations. The first part is a brief survey of 
the anatomy of the abdominal cavity and of 
the most common procedures of abdominal 
surgery including the treatment of ileus and 
peritonitis. In the second part, the surgical 
anatomy of the urinary bladder is reviewed 
and the various surgical procedures are de­
scribed. The book is well illustrated and in­
cludes a selected bibliography. It appears to 
be written primarily for the urologist in train­
ing.
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Books Received
Books are acknowledged as received, but 
in some cases reviews will also be made 
in later issues.
Atlas of Extraocular Muscle Surgery. John A. 
Dyer. 180 pp. Illust. W. B. Saunders Company, 
Philadelphia; W. B. Saunders Company Canada 
Limited, Toronto, 1970. $12.45.
Basic Immunology. E. R. Gold and D. B. Pea­
cock. 416 pp. Illust. John Wright & Sons Ltd., 
Bristol; The Macmillan Company of Canada 
Limited, Toronto, 1970. $14.50.
Body Fluid Replacement in the Surgical Patient.
An International Symposium, 1969 Sponsored by 
the Departments of Surgery and Anaesthesiology 
of the College of Physicians and Surgeons, Colum­
bia University in Association With the Division 
of Medical Sciences National Research Council. 
Edited by Charles L. Fox, Jr. and Gabriel G. 
Nahas. Grune & Stratton, Inc., New York; Long­
mans Canada Limited, Toronto, 1970. $28.75.
Clinical Paediatric Surgery. Diagnosis and Man­
agement. Edited by Peter G. Jones. 511 pp. Illust. 
John Wright & Sons Ltd., Bristol; The Macmillan 
Company of Canada Limited, Toronto, 1970. 
$19.50.
Les Entretiens de Bichat 1970. Chirurgie et 
Specialities. P.-L. Chigot and A. Beilin. 378 pp. 
Expansion Scientific Franpaise, Paris, 1970. Price 
not stated.
Epithelial Tumours of the Salivary Glands. R.
Winston Evans and Alan H. Cruickshank. Volume 
1 in the Series Major Problems in Pathology. 
Consulting Editor: James L. Bennington. 299 pp. 
Illust. W. B. Saunders Company, Philadelphia; 
W. B. Saunders Company Canada Limited, To­
ronto, 1970. $15.70.
Extracranial Occlusive Cerebrovascular Disease.
Diagnosis and Management. Edwin J. Wylie and 
William K. Ehrenfeld. 231 pp. Illust. W. B. Saun­
ders Company, Philadelphia; W. B. Saunders 
Company Canada Limited, Toronto, 1970. $14.05.
Gastro-Intestinal X-Ray Diagnosis. A Descrip­
tive Atlas. D. H. Cummack. 351 pp. Illust. E. & 
S. Livingstone Ltd., Edinburgh; The Macmillan 
Company of Canada Limited, Toronto, 1970. 
$27.50.
Hematologic Problems in Surgery. Harold Lauf- 
man and Robert B. Erichson. 249 pp. W. B. 
Saunders Company, Philadelphia; W. B. Saunders 
Company Canada Limited, Toronto, 1970. $10.80.
Hepatic Failure. Henry Brown. 137 pp. Illust. 
Charles C Thomas, Publisher, Springfield, 111.; 
The Ryerson Press, Toronto, 1970. $10.50.
The Intervertebral Disc. Anthony F. DePalma 
and Richard H. Rothman. 373 pp. Illust. W. B. 
Saunders Company, Philadelphia; W. B. Saunders 
Company Canada Limited, Toronto, 1970. $17.85.
Laparoscopy, Culdoscopy and Gynecography. 
Technique and Atlas. Melvin R. Cohen. Volume I
w h e n  la x a t iv e s  a r e  u n w i s e
SURFAK
S urfak is a safe, effective fecal 
softener which prevents the for­
mation of hard, dry stools thus 
reducing pain and discomfort, 
undue straining and irritation. 
Surfak is not a laxative. . .  it 
acts solely to permit normal bowel 
function by preventing the for­
mation of hard, dry stools. 
Com position: Each capsule con­
tains 50 mg. or 240 mg. of dioctyl 
calcium sulfosuccinate. Ind ica­
tions: Prevention and treatment 
of constipation, especially in he­
morrhoids, anal fissures, geriatrics, 
pediatrics, immobilized patients, 
pregnancy, following anorectal 
surgery, ulcerative colitis, divert­
iculitis, and to avert straining after 
abdominal surgery, in cardiac 
patients and hypertensive patients. 
Contraindications: None known. 
Precautions: None known. A d­
verse effects: Mild, transitory
cramping pains may rarely occur. 
Dosage: Usual adult dose is 240 
mg. daily; children and adults with 
minimal needs, 50 to 1 50 mg. daily. 
Supply: Red, soft gelatin 240 mg. 
capsules in bottles of 100; orange, 
soft gelatin 50 mg. capsules in 
bottles of 100.
H O E C H S T
P H A R M A C E U T I C A L S
3400 JEAN T AL ON W M O N T R E A L  301 
D I V I S I O N  OF C A N A O I A N  H O E C H S T  L I M I T E D
IPMAC)
ER ey Hoechsi TM 760/730/H
92
in tile Series Major Problems in Obstetrics and 
Gynecology. Consulting Editor; Emanuel A. 
Friedman. 171 pp. lllust. W. B. Saunders Com­
pany, Philadelpma; W. B. Saunders Company 
Canada Limited, Toronto, 1970. $11.90.
Leber- und Pankreas-Schiiden durch Schock 
und Narkose. Symposion auf der Insel Helogland 
am 4./5.10.1909. Edited by Karl Horatz. 114 pp. 
lllust. Intercontinental Medical Book Corp., New 
York; Ceorg Thieme Verlag, Stuttgart, Germany, 
19 iO. DM 22,00. $6.20 (approx.). Paperbound.
Normale und Pathologische Anatomie. Mono- 
graphien in zwangloser Folge. Edited by Woli- 
gang Bargmann and Wilhelm Doerr. Heft 23. Syn- 
daktylien. Anatomie, Entwicklung, therapeutische 
Aspekte. Giinter M. Losch. 58 pp. lllust. Inter­
continental Medical Book Corp., New York; 
Ceorg Thieme Verlag, Stuttgart, Germany, 1970. 
DM 38,00. $10.70 (approx.). Paperbound.
Organ Transplantation. 2nd ed. Edited by Felix 
Largiader. 398 pp. lllust. Intercontinental Medical 
Book Corp., New York; George Thieme Verlag, 
Stuttgart, Germany, 1970. DM 98,00. $27.60 
(approx.).
Penetrating Wounds of the Abdomen. Edited 
by James E. Pridgen, J. Bradley Aust and George 
W. Fisher. 126 pp. lllust. Charles C Thomas, 
Publisher, Springiield, 111.; The Ryerson Press, 
Toronto, 1970. $9.75.
Reconstructive Surgery of the Middle Ear.
Adolph Wolferman. 184 pp. lllust. Grune & 
Stratton, Inc., New York; Longmans Canada 
Limited, Toronto, 1970. $28.75.
Rypins’ Medical Licensure Examinations. Topi­
cal Summaries and Questions. 11th ed. Edited by 
Arthur W. Wright. 825 pp. J. B. Lippincott Com­
pany, Philadelphia; J. B. Lippincott Company of 
Canada Ltd., Toronto, 1970. $17.50.
Surgery and Biology of Wound Repair. Erie E. 
Peacock, Jr. and Walton Van Winkle, Jr. 630 pp. 
lllust. W. B. Saunders Company, Philadelphia; 
W. B. Saunders Company Canada Limited, To­
ronto, 1970. $23.25.
Surgery of the Chest. A Handbook of Operative 
Surgery. 4th ed. Julian Johnson, Horace Mac- 
Vaugh III and John A. Waldhausen. 428 pp. 
lllust. Year Book Medical Publishers, Inc., Chi­
cago, 1970. $15.40.
Urologische Operationslehre. Number 4. Ab- 
dominale Komplikationen bei und nach urolo- 
gischen Eingriffen. Operationen an der Harnblase. 
Edited by G. W. Heise and E. Hienzsch. 159 pp. 
lllust. VEB Georg Thieme, Leipzig, 1970. DM 
50,00. $14.00 (approx.). Paperbound.
Visual Anatomy. Volume One. Head and Neck. 
Sydney M. Friedman. 227 pp. lllust. Harper & 
Row Publishers, New York, 1970. $11.50.
Die Wiindheilung. Theoretische und praktische 
Grundlagen. H. J. Hemandez-Richter and H. 
Struck. 197 pp. lllust. Intercontinental Medical 
Book Corp., New York; Georg Thieme Verlag, 
Stuttgart, Germany, 1970. DM 39,00. $10.90 
(approx.). Paperbound.
Tandearil Geigy
For symptomatic 
treatment of
sprains 
strains 
contusions 
muscular lesions 
dislocations 
fractures
Dosage — In trauma and its sequelae — 
400-600 mg (4-6 tablets) daily in divided 
doses for 4 days to a week.
In arthritis, extra articular rheumatism 
and other medical indications — 400-600 
mg per day (4-6 tablets). When improve­
ment is obtained (generally two or three 
days), the dose should be reduced to 
the lowest effective level which gives 
relief. It is suggested that the mainte­
nance level not exceed 400 mg per day. 
Tandearil should be taken at meal time or 
with a glass of milk. In the absence of a 
favourable response after a one week trial 
period, it is recommended that adminis­
tration of Tandearil be discontinued.
For indications in surgery — 400-600 mg 
(4-6 tablets) daily in divided doses dur­
ing the 24 hours prior to surgery. As 
soon as oral medication can be resumed 
after surgery, maintenance is 300-400 mg 
daily for 3-4 days.
Contraindications — Tandearil is contra­
indicated in patients with a history of 
blood dyscrasia or drug allergy, or in 
patients with severe renal, hepatic or 
cardiac disease. It should not be given 
to patients with clinical edema, to senile 
patients or to patients with a history or 
symptoms of peptic ulcer.
Precautions — A careful history, phys­
ical examination and complete blood 
count should be done before initiating 
therapy. Patients receiving this drug 
should be followed closely and should 
be warned to discontinue Tandearil and 
contact their physician immediately 
should any of the following signs or 
symptoms appear: fever, sore throat, 
lesions in the mouth, black or tarry 
stools, skin reactions or a sudden gain in 
weight. Patients undergoing long term 
therapy should have blood counts done 
at monthly intervals. Care should betaken 
in prescribing Tandearil to the elderly. 
Side Effects — Nausea, vomiting, ab­
dominal discomfort, rash, formation or 
activation of peptic ulcer and sodium re­
tention with edema are known to occur. 
Availability — Tandearil tablets. Each 
light brown coated tablet, imprinted 
with fesy contains 100 mg oxyphenbuta- 
zone Geigy. Supplied in bottles of 50 
and 500.
Full information is available on request.
Geigy Pharmaceuticals
Montreal 308, P.Q. G-
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NOTICES
HADEN MEMORIAL CONFERENCE 
“DISORDERS OF THE RED C E LL” 
The Cleveland Clinic Educational Foun­
dation will hold a postgraduate course in 
hematology (Haden Memorial Conference 
“Disorders of the Red Cell”) on February 
10 and 11, 1971, in the Bunts Auditorium 
of the Education Building. The course will 
be presented by the Staff members of the 
Foundation. The guest speakers will be: 
William B. Castle, Professor of Medicine, 
Harvard University, Emeritus Director of 
the Thorndike Laboratory, Boston City 
Hospital; Lemuel W. Diggs, Emeritus 
Goodman Professor of Medicine, Uni­
versity of Tennessee College of Medicine, 
Section of Hematology, Memphis, Ten­
nessee; Clement A. Finch, Professor of 
Medicine, University of Washington, 
Seattle, Washington; T. Hale Ham, Pro­
fessor of Medicine and Director, Divi­
sion of Research in Medical Education, 
Case Western Reserve University, Cleve­
land; John W. Harris, Professor of Medi­
cine, Metropolitan General Hospital, Case 
Western Reserve University; Robert W. 
Kellermeyer, Associate Professor of Medi­
cine, Case Western Reserve University; 
and Anita M. Klein, Staff, Euclid Clinic 
Foundation, Euclid, Ohio.
The registration fee for the course is 
$45.00. Acceptances will be made in order 
of application.
Accommodation may be obtained at The 
Bolton Square Hotel, 8907 Carnegie 
Avenue, and the Clinic Inn, 8945 Carnegie 
Avenue (adjacent to the Cleveland Clinic 
Education Building).
For further information write to: Edu­
cation Secretary, The Cleveland Clinic 
Educational Foundation, 2020 East 93rd 
Street, Cleveland, Ohio 44106.
POSTGRADUATE COURSE IN 
RHEUMATIC DISEASE
The Cleveland Clinic Educational Foun­
dation will hold a course in rheumatic 
disease on February 24 and 25, 1971, in the 
Bunts Auditorium, Education Building. 
The participating faculty will be members 
of the Staff of the Foundation. Subjects 
covered will be: manifestations of the con­
nective tissue diseases by systems; immu­
nologic aspects of connective tissue dis­
eases; and immunofluorescent studies, 
electron microscopy and a review of drugs 
used in the management of connective 
tissue diseases.
The registration fee is $45.00, accept­
ances made in order of application.
For further information write to: Edu­
cation Secretary, The Cleveland Clinic 
Educational Foundation, 2020 East 93rd 
Street, Cleveland, Ohio 44106.
POSTGRADUATE COURSE 
IN UROLOGY
The Cleveland Clinic Educational Foun­
dation will hold a postgraduate course 
“Advances in Urology” on March 10 and 
11, 1971, in the Bunts Auditorium of the 
Education Building. The course will be 
presented by Staff members of the Foun­
dation, and guest speakers will include: 
Malcolm A. Bagshaw, Professor and Di­
rector of Radiation Therapy, Stanford Uni­
versity Medical Center; Joseph J. Kauf­
man, Professor and Chairman, Department 
of Urology, University of California at Los 
Angeles School of Medicine; Lester Persky, 
Professor and Chairman, Department of 
Urology, Case Western Reserve School of 
Medicine; and David C. Utz, Department 
of Urology, Mayo Clinic Foundation.
The registration fee for the course is 
$60.00 and acceptances will be made in 
order of application.
Accommodation may be obtained at The 
Bolton Square Hotel, and the Clinic Inn 
(adjacent to the Cleveland Clinic Educa­
tion Building).
For further information write to: Educa­
tion Secretary, The Cleveland Clinic Edu­
cational Foundation, 2020 East 93rd Street, 
Cleveland, Ohio 44106.
FIRST WORLD CONGRESS OF THE 
COLLEGIUM INTERNATIONALE 
CHIRURGIAE DIGESTIVAE
The 1st World Congress of the Collegi­
um Internationale Chirurgiae Digestivae 
will be held May 20 to 23, 1971, in San- 
remo, Italy. The following subjects have 
been chosen for the symposia, round table 
discussions and lectures: esophagoplasty;
(Continued on page 96)
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We coat our silk with silicone. Not wax. This lets you tie a 
firm knot that won't slip. You can even snip knot ends short 
without fear of their slipping. But that's not the only reason 
for the silicone. It protects the suture against enzymatic 
or body fluid invasion. You get a strand of physiologically 
inert suture material. And, our silk has ex-
One that's firm and I  I  l i  111 L J J  ce p tion a l te n s ile  
uniform, too. And pli- strength. Try Davis &
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surgical treatment of precancerous lesions 
of the rectum and colon; chronic vascular 
mesenteric insufficiency; emergency surgi­
cal treatment of acute pancreatitis; surgical 
treatment of primary and secondary liver 
tumours; clinical experience of liver trans­
plantation; and teaching of digestive sur­
gery in universities and hospitals. During 
sessions simultaneous translations will be 
provided in English, French, German and 
Italian. Registration fees are $45.00 for 
active members and $20.00 for accom­
panying persons.
For further information write to: Secre­
tariat of 1st World Congress of Collegium 
Internationale Chirurgiae Digestivae, II 
Divisione Chirurgica, Ospedale S. Giovanni, 
00184 Rome, Italy.
12TH SICOT CONGRESS 
FELLOWSHIPS
The Israel Section of SICOT, in con­
junction with the Orthopedic Association 
of Israel, is offering 15 travel fellowships 
to the 12th SICOT CONGRESS to be held 
in Israel from October 9 to 13, 1972.
The fellowships include free air travel 
and seven days full board in Israel during 
the Congress.
These 12th SICOT Congress fellowships 
will be awarded for the best original and 
unpublished papers on an orthopedic sub­
ject or any basic scientific subject con­
nected with orthopedic surgery.
The competition is open to those up to 
40 years of age. Papers should be sub­
mitted in four copies. The final date for 
submission of papers is January 31, 1972 
and papers should be submitted to: Societe 
Internationale de Chirurgie, Orthopedique 
et de Traumatologie, 43, rue des Champs- 
Elysees, Bruxelles 5, Belgium.
ABSTRACTS
MULTIPLE FOCI EPILEPSY
For successful surgical treatment of 
multifocal epilepsy the dominant focus 
must be accurately determined because 
only this focus needs to be removed. The 
authors define multifocal epilepsy. In con­
ditions such as bitemporal epilepsy, in 
which there are several independent foci, 
removal of one focus not only fails to pro­
duce improvement but may activate other 
foci, thus aggravating the condition.
In the authors’ hands, removal of the 
dominant focus and stereotaxic destruction 
of secondary foci has produced good re­
sults in isolated cases. Only prolonged ob­
servation and more experience will permit 
a final evaluation of this method.—Shefer 
DP, Ivanov EV, Bein BN: Multiple foci 
epilepsy: approach to surgical treatment. 
Voprosyi Neirokhirurgii 3:1, 1969
LATE IRRADIATION NECROSIS 
OF BRAIN
The author describes the late effects on 
the brain of radiotherapy of brain tumours 
and differentiates the effects from con­
tinued growth of the treated tumour. He 
studied 19 patients who had mega volt ir­
radiation of a brain tumour. The late 
effects of cerebral necrosis due to radio­
therapy manifest themselves by a slowly 
developing syndrome of focal lesions re­
lated to the irradiated area. They are not 
attended by any signs of increased intra­
cranial pressure, characteristically there is 
no radiographic evidence of a shift of the 
midline and there are no changes in the 
appearance of the ventricles in the pneu­
moencephalogram.—Samoilov VI: Clinical 
picture and diagnosis of late irradiation 
necrosis of brain. Voprosyi Neirokhirurgii 
6: 10, 1969
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Bridine
POVIDONE-IODINE
Originally introduced by B.D.H. in 1962
Kills bacteria, viruses, fungi, tricho- 
monads,yeasts,sporesand protozoa.
BRIDINE PREPARATIONS
b r id in e — The topical 
germicide whose colour 
indicates a germ-free environment.
b r id in e — Rapid and dependable 
microbicidal action even in the 
presence of blood, pusor necrotic tissue.
b r id in e — Non-injurious to skin, 
mucous membranes or exposed tissue.
Bridine Solution • Bridine Surgical 
S crub  • B rid in e  Aeroso l Spray 
Bridine Douche • Bridine Vaginal Gel 
Bridine Shampoo
Literature available on request
BRITISH DRUG HOUSES LTD.
TORONTO • CANADA
UNDER LICENCE NO. 615726
The Canadian Journal of Surgery
UNIVERSITY OF TORONTO 
Faculty of Medicine
DEPARTMENT OF OTOLARYNGOLOGY
SEPTO REHINOPLASTIC COURSE
February 8th-12th, 1971 
FEE -  $200.00
Limited to 30 students. The course is designed 
for those who have some knowledge but not 
necessarily expert in the field of septorhino- 
plasty and mentoplasty. The course will in­
clude preoperative assessment, photography, 
surgical techniques, postoperative care and 
complications, of septoplasty, rhinoplasty and 
mentoplasty.
Enquiries invited:
Departm ent o f Postgraduate M edica l Education, 
Faculty o f Medicine,
University of Toronto,
Toronto, Ontario.
ROYAL VICTORIA HOSPITAL
PROBLEMS IN 
GENERAL SURGERY
MARCH 31, APRIL 1 & 2, 1971
This C ou rse  is d e s ign e d  fo r the su r­
ge o n  in active  practice. Se ssio n s  w ill 
inc lude  g e n e ra l su rge ry , com m on  
p e rip he ra l v a sc u la r  su rg e ry  a n d  co v ­
e ra g e  o f p re  a n d  post-ope rative  care. 
T each in g  m ethod s to be  utilized are  
op e ra t ive  clinics, se m in a rs  a n d  lec­
tures. Recent a d v a n c e s  w ill be em ­
phasized . Enro lm ent is lim ited to 
forty-five.
FEE: $ 100 .00
For further inform ation, write to:
The Secretary, 
Post-Graduate Board,
Royal Victoria Hospital, 
Montreal 112, Quebec.
N EW  C.M.A. H EA D Q U A R TERS  B U ILD IN G  
O T T A W A
OFFICE SPACE FOR 
RENT
Tw o Sm a ll O ffice s A v a ila b le  for rental 
to A ssoc ia te d  o r A ff ilia te d  M ed ica l 
O rg an iza t io n s.
A lso , O ffice  A v a i la b le  on  a Sha red  
D a ily  o r  M o n th ly  basis.
Secretaria l se rvice s can  be p rov ided  if 
desired.
S ituated  in re sidentia l section o f n a ­
tion 's  cap ita l.
Free Pa rk in g .
For further inform ation, p lease  contact:
Mr. W. G. G ow ling, C.A.,
C.M.A. Headquarters,
1867 A lta  V ista  Drive,
O ttaw a 8, Ontario,
Telephone: (613) 731-9331.
U N IVERS ITY  OF TO RO N TO  
Faculty of Medicine 
D IV IS IO N  OF
PO STG RAD UATE M E D IC A L  ED U CA T IO N
The O rthopaedic D iv ision  of the 
Departm ent of Surgery 
and
The W orkm en 's  Com pensation  Board Ontario 
offer
FRACTURES
AND ASSOCIATED TRAUMA
April 15th, 16th, 17th, 1971 
Theme:
COMPLICATIONS OF 
MUSCULO SKELETAL TRAUMA
Am ong the Guest Faculty will be:
Dr. Paul Brown, Denver, Colorado, U.S.A. 
Professor Merle D 'A ub igne, Paris, France 
Professor H. W illenegger, Switzerland 
For further inform ation  contact:
The Director,
D iv ision  of Postgraduate  Medical Education, 
Medical Sciences Building,
Toronto 5, Ontario.
INSIDE THE SYSTEM IS STILL STERILE
Even if you do the procedure in 
the basement. Because only 
UROMATIC plastic containers give 
you a completely closed irrigation 
system. Since there are no vents, 
no room air can enter the system. 
So airborne contaminants are 
locked out. Even when the spike 
of the set is inserted, no air can 
get in— because the spike com­
pletely occludes the port opening
before it punctures the internal 
safety seal. A self-sealing latex 
cap on the second port is pro­
vided for adding supplemental 
solutions; it is easily removed for 
series hookups. The third port 
can be clipped for use as a con­
venient pouring spout. An exter­
nal wrap protects sterility before 
use. If it has been opened or 
removed, you can immediately
B A X TE R  LABO RATORIES O F C A N A D A
DIVISION OF TRAVENOl LABORATORIES. INC.
6405 Northam Drive, Malton, Ontario
see that the container has been 
tampered with. UROMATIC is the 
first and only plastic container 
forTUR, cysto and irrigation solu­
tions. For the patient safety of 
a completely  closed system—  
and the convenience of easier, 
faster procedures— 
the UROMATIC way is ■  
the first and only one 
you should consider.
uromcftc
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( Please forward two months prior to 
effective date)
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d’entree en vigueur)
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Nom .......... ......................................
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(en caracteres d’imprimerie)
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Ancienne adresse ..........................
(Please print)
(en caracteres d’imprimerie)
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(en caracteres d’imprimerie)
Date effective 
A partir du
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